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Glutathione (GSH) is a well-known anti-oxidant that prevents cellular damage caused by 
oxidative stress. It is synthesized by most eukaryotes but not by actinomycetes amongst 
which mycobacteria. However, mycobacteria synthesize two other thiols namely Mycothiol 
(MSH) and Ergothioneine (ERG). The role of MSH has been extensively investigated in 
mycobacteria and it has been shown that it protects mycobacteria from oxidative stress. 
However, MSH-deficient M. tuberculosis mutants have no growth defect ex vivo neither in 
vivo which indicates that MSH deficiency is compensated for. On the other hand, many 
studies have demonstrated the anti-oxidative role of ERG in eukaryotes but little is known of 
the role of ERG in mycobacteria. Recently, the enzymes involved in ERG biosynthesis have 
been identified. This enabled us to investigate the role of ERG in mycobacteria specifically 
M. tuberculosis. To achieve that we first generated an ERG deficient single mutant and an 
ERG/MSH deficient double mutant in M. smegmatis, a non-pathogenic fast growing 
mycobacteria used as a surrogate for M. tuberculosis. This was achieved by deleting the gene 
coding for the first enzyme involved in ERG biosynthesis (EgtD) in a wild type strain of M. 
smegmatis and a related MSH-deficient strain of M. smegmatis. Then we tested the 
susceptibility of the resulting mutants to oxidative stress, nitrosative stress and anti-
tuberculosis drugs. We could show that ERG protects M. smegmatis from oxidative stress and 
that it compensates for MSH-deficiency in M. smegmatis. Then we investigated the role of 
ERG in M. tuberculosis. To achieve that, we generated mutants deficient in ERG biosynthetic 
enzymes, namely EgtA, EgtB, EgtC, EgtD and EgtE, a MSH-deficient single mutant and a 
MSH/ERG-deficient double mutant. Ergothioneine quantification in these mutants revealed 
that EgtE is not essential for ERG biosynthesis and may not be the only enzyme that catalyses 
the last step of ERG biosynthesis. On the other hand, though EgtB is essential for ERG 
biosynthesis, it may not be an ideal drug target since the loss of EgtB caused the 
accumulation of gamma glutamyl cysteine which potentially protected the mycobacteria from 
oxidative and nitrosative stress. The enzyme EgtC as well may not be an ideal drug target 
since the mutant deficient in this grew slightly better than the wild type during the 
exponential phase. The enzymes EgtA and EgtD could be the ideal drug targets since deleting 
the gene coding for these enzymes did not favour the survival of the resulting mutants under 
stress conditions. In addition, we were able to show that every CDC1551 ERG-deficient 
mutant generated in this study grew poorly during stationary phase. This indicates the 





potential protective role of ERG in dormant mycobacteria during latent tuberculosis.In 
addition; we have shown that ERG is secreted by mycobacteria (M.smegmatis, M.bovis and 
M.tuberculosis). This finding is an indication of the imperative role of ERG during infection. 
Taking into account the ability of ERG to modulate immune responses, it is possible that 
M.tuberculosis secretes it during infection to suits its survival and proliferation within the 
host. 
Opsomming 
Glutatioon (GSH) is ‘n welbekende antioksidant en beskerm teen radikaal selskade as gevolg 
van oksidatiewe stres. Dit word in die meeste eukariote vervaardig maar nie deur 
aktinomycetes nie en waaronder mycobakterieë ook resorteer. Mycobakterieë vervaardig 
egter twee ander tiole naamlik mycothiol (MSH) en ergothioneine (ERG). Die rol wat MSH 
in mycobakterieë speel is reeds goed bestudeer waar dit bewys is dat MSH mycobakterieë 
beskerm teen oksidatiewe stres. MSH tekort M.tuberculosis (M. tuberculosis) mutante toon 
geen groeiafwykings ex vivo of in vivo nie wat daarop dui dat die MSH tekort op ‘n ander 
manier voor gekompenseer word. In vele studies is dit reeds aangetoon dat ERG ‘n anti-
oksidatiewe rol speel in eukariote maar baie min is bekend omtrent ERG se rol in 
mycobakterieë. Onlangs is die ensiemsisteme betrokke by die biosintese van ERG 
geïdentifiseer wat ons in staat gestel het om die rol van ERG in mycobakterieë en spesifiek 
M. tuberculosis te ondersoek. Om dit te kon bereik is eerstens ‘n ERG enkelmutant in 
M.smegmatis geskep, gevolg deur ‘n ERG/MSH dubbelmutant. Mutante is eers in 
M.smegmatis geskep en daarna in M. tuberculosis om tegnieke te standardiseer en ook omdat 
M.smegmatis ‘n nie-patogeniese model is vir M.tuberculosis studies. Mutante is geskep deur 
die uitskakeling van die geen wat vir die eerste stap van ERG biosintese verantwoordelik is 
(EgtD) in M.smegmatis en ook in ‘n MSH tekort mutant van M.smegmatis. Hierna is die 
mutante geëvalueer vir vatbaarheid vir oksidatiewe stres, stikstofradikaal stres en anti-
tuberkulose middels. Ons kon aantoon dat ERG in M.smegmatis ‘n beskermingsfunksie het 
teen oksidatiewe stres en dat ERG kompenseer vir MSH tekort in M.smegmatis. Om die rol 
van ERG in M.tuberculosis te bestudeer is mutante geskep wat ‘n tekort het aan ensieme in 
die ERG biosintese pad nl. EgtA, EgtB, EgtC, EgtD, EgtE, ‘n MSH tekort en ‘n MSH/ERG 
dubbelmutant. Kwantifisering van ERG in hierdie mutante het getoon dat EgtE nie belangrik 





is vir ERG biosintese nie en is moontlik dat dit deur n ander ensiem vervang word vir die 
finale stap in ERG biosintese in M. tuberculosis. Alhoewel EtgB essensieël is vir ERG 
biosintese sal dit nie ‘n goeie middelteiken wees nie aangesien die verlies aan EgtB die 
akkumulasie van gamma-glutamiel sisteïen tot gevolg het wat op sy beurt weer 
mycobakterieë teen oksidatiewe stres beskerm. Die ensiem EgtC is moontlik ook nie ‘n goeie 
middelteiken nie omdat M. tuberculosis mutante van EgtC effens beter gegroei het in die 
eksponensiële fase in vergelyking met die intakte kontrolestam. Daarteenoor sal EgtA en 
EgtD beter middelteikens wees omdat M. tuberculosis mutante wat tekorte het aan hierdie 
ensieme baie sensitief was vir en moeilik oorleef het onder oksidatiewe toestande. Ons kon 
ook aantoon dat elke CDC1551 ERG mutant, wat in hierdie studie gegenereer is, baie swak 
groei getoon het in die stasionêre groeifase. Dit is ‘n sterk aanduiding van die potensiële 
beskermings rol wat ERG kan speel in dormante M. tuberculosis gedurende sluimerende 
tuberkulose. 
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CHAPTER 1: INTRODUCTION 
(LITERATURE REVIEW) 
1.1 Tuberculosis infection and transmission 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (M. 
tuberculosis) that was discovered in 1882 by Robert Koch. Around 460 BC, this disease was 
described by Hippocrates as the most common of the time [1]. M.tuberulosis, M. bovis, M. 
Africanum, M. macroti, M. pinnipedii, M. caprae and M. canetti are members of the M. 
tuberculosis complex and are all pathogenic [2]. Active TB is primarily manifested by a 
cough, loss of appetite, fever and chest abnormalities (observed by X-ray) in case of 
pulmonary TB. Extra-pulmonary TB develops when mycobacteria spread to other parts of the 
body such as the abdominal cavity, bladder, bones, pericardium, kidneys, brain, lymph nodes, 
spine, joints and reproductive system [3]. This may lead to fatigue, swelling, painful 
urination, brain damage, sterility etc. TB is transmitted either through inhalation of the bacilli 
from cough aerosols, ingestion of bacilli from milk of diseased cows, inoculation through the 
skin (very rare) or through the placenta from a diseased pregnant woman to the foetus. Some 
studies indicate that TB transmission is more likely to occur after a prolonged repeated 
exposure. Using a model they indicated that constant travelling in minibuses (usually poorly 
ventilated), or long flights contribute enormously to the spread of pulmonary TB [4-6].But 
this remains to be shown in other settings. It has been speculated using a model that 
transmission may also depend on the environment, type of activity (usually the commuter 
population), and also on the size of the household [7]. Approximately 30% of individuals get 
infected after exposure (depending on the inhaled bacillary load, the competency of the 
immune system, the state of the inhaled mycobacteria) [8], then 5 to 10 % of these develop 
disease (primary TB). In the remaining 90%, in 10% the immune system eradicates the 
mycobacteria, and the remaining 90% of cases, the mycobacteria may escape the host 
defence activities and remain dormant in old lesions. In this latter case, some develop disease 
after 5 years, some during their life time (HIV co-infection) and others when they age (≥65), 
this is known as post-primary TB (latent TB) and occurs in low endemic countries (figure 
1.1). Post primary TB is usually caused by re-infection of individuals by a new strain or 
reactivation of the dormant bacilli due to immune suppression [9, 10]. Primary TB occurs as 







a result of either HIV co-infection or immune suppression by medications, other diseases, 
renal dysfunction, stress, malnutrition or cancer. 
 
Figure 1.1. Tuberculosis disease progression upon exposure 
Seventy percent of individuals are usually not infected upon exposure 
1.2 Tuberculosis currently and treatment  
Today, TB cases are increasing, with an average of 2 million deaths annually. The current 
drug regimen consists of combination of Isoniazid and Rifampicin which last to 6 months. In 
2010, the highest rate of multidrug-resistant tuberculosis (MDR-TB, resistance to at least 2 
first line drugs namely rifampicin and isoniazid) was recorded and extensive drug resistant 
tuberculosis (XDR-TB, which are MDR that are resistant to the most effective second line 
drugs (fluoroquinolones) and at least one injectable second line drug (capreomycin , amikacin 
or kanamycin, [11] ) cases were detected in 58 countries [12]. There are 27 high burden 
countries for MDR-TB. These are countries with at least 4000 MDR cases a year and/or 
where MDR constitute at least 10% of newly registered TB cases. In 2011, there was an 
estimate of 10085 notified cases of MDR TB in South Africa.  In 2012, there was an estimate 
of about 170000 deaths from MDR TB and 450000 new cases of MDR-TB worldwide. More 
than 10 million children were orphaned due to TB. In 2013, there were an estimated 9 million 
new cases of TB and 1.5 million deaths amongst which 1.14 million were HIV negative while 
360 000 were HIV positive people. Most of the new cases occurred in Asia (56%) and the 
African Region (29%) amongst which 0.55 million were children and 3.3 million women, 
while 1million were co-infected with HIV. An estimated 480 000 people had developed 
MDR-TB while an estimated 9% of these had XDR-TB. South Africa is amongst the six 
countries with the largest numbers of newly reported TB cases in 2013 (~0.45 million) and is 
the country with the largest numbers of new TB cases per 100 000 population (860) [13].   
Amongst children there were an estimated 550 000 cases and 80 000 deaths of HIV negative 
children. An estimate of TB deaths in HIV positive children is not yet available [14]. Totally 
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drug resistant tuberculosis (TDR) for which no effective treatments are available is becoming 
a major threat [15]. 
1.3 Basic factors of tuberculosis control and eradication  
HIV co-infection, the rapid emergence of MDR-TB, overcrowded hospitals in the third 
world, rapid increase of population density, drug abuse, destructive life styles, inaccurate or 
delayed diagnoses are the main hindrances of TB control. A few of these factors are 
discussed below. 
 Diagnostic factors 
Diagnosis of TB plays an essential role in its transmission and spread [7]. An inappropriate 
diagnosis of tuberculosis, will lead to a wrong prescription of the drug combination regimen 
and consequently acquisition of drug resistance. A diagnostic test that will be very quick (to 
minimize transmission, disease spread), determine the type of infection (active or latent), the 
drug resistance pattern of the patient strain (to enable the right drug regimen) will be ideal. 
The current diagnostic tools are: microscopy detection of the mycobacteria in sputum 
samples, solid culture of the specimen, tuberculin skin test (TST), molecular based 
techniques and interferon gamma release assays.                                                                  
There are two main microscopy tools that enable detection of acid fast bacilli such as M. 
tuberculosis in sputum. These are based on two staining methods: the ziehl-neelsen (ZN) 
method and the auramine-rhodamine (AR) method. 
The ziehl-Neelsen principle is based on counter staining the sample with carbol fuchsin and 
methylene blue. This will enable distinction between the pink acid fast bacilli from the blue 
non-acid fast bacilli under the microscope. Because of the low sensitivity of the ZN based 
microscopy, it was subsequently replaced by the AR based fluorescence microscopy. AR was 
shown to be less specific than ZN, however it is more sensitive. Acid fast bacilli fluoresce 
red-yellow under microscopy. However, microscopy based diagnosis is less sensitive in case 
of HIV co-infection, and is not appropriate in paediatric diagnosis due to the fact that children 
can’t expel sputum [16, 17].  
The original culture based diagnosis  involves plating the samples on solid media containing 
selective reagents such as malachite green and antibiotics such as ampicillin and nalixidic 
acid that prevent the growth of  bacteria other than M. tuberculosis. It is a slow technique as it 
takes 8 weeks for visible growth of the bacteria [18, 19]. However, faster technologies have 







been developed. These include the BATEC system (quick automated radiometric detection of 
M. tuberculosis in a liquid medium) [20] and the MGIT system (quick automated 
fluorescence based detection of M. tuberculosis) [21]. However, the equipment used in these 
techniques is very expensive and therefore not readily available in developing countries. 
The tuberculin skin test (TST) (Mantoux test, heaf test, tine test) involves injecting 
intradermaly a purified protein derivative tuberculin (glycerol extract of tubercle bacillus) 
that will cause an immune reaction displayed as an induration on the site of injection of the 
skin of the patient. Diagnosis is based on the size and diameter of the induration. TST 
reliability is affected by infection by other mycobacteria or by calmette Guerin vaccine with 
Mycobacterium bovis, (in this case, false TB positive results are predominant) [22-24]. 
Radiographic examinations of the chest to detect visible lesions are used for the diagnosis of 
TB as well. However, diseases such as sacoidosis that affect lungs and HIV co-infection 
make chest radiography not reliable [25]. Interferon gamma release assay (IGRA) 
(QuantiFERON-TB Gold, T-SPOT.TB and ELISPOT (Immunotec, UK)) measures the 
quantity of interferon gamma produced in the serum of the patient as a result of stimulation 
with ESAT 6 and CFP 10 antigens. However, members of the M. tuberculosis complex such 
as Mycobacterium marinum, or Mycobacterium szulgai, or Mycobacterium kansasii share 3 
common proteins: CFP10, TB7 and ESAT6. Therefore the specificity of IGRA is 
questionable.  
Molecular based diagnoses involve the detection the M. tuberculosis DNA molecule in the 
patient sample. There are several molecular based diagnostic methods available currently 
with the new rapid fully automated test known as GeneXpert MTB/RIF which enable the 
detection of  rifampicin resistant strains [26, 27]. However, no molecular tests are able to 
differentiate DNA molecules from dead mycobacteria (or from latent mycobacteria) from 
DNA of actively growing mycobacteria. Therefore they are usually performed only on TST 
positive patient samples [28, 29].  
 Therapeutic factors 
A combination of isoniazid (INH), rifampicin (RIF), pyrazinamide (PZN), streptomycin, and 
ethambutol (ETB) is the current standard regimen  for active cases of drug susceptible TB 
[30]. This treatment is cumbersome and lengthy (6 to 9 months) increasing the probability of 
poor compliance and consequently, rapid emergence of drug resistant TB cases. Therefore, 
there is a need for drugs that could be taken in lower quantities and which can efficiently 







achieve TB treatment within a shorter period. This could be preferably drugs that can destroy 
latent bacilli since it was shown that dormant bacilli were less sensitive to some drugs like 
isoniazid [31, 32]. 
On the other hand, toxicity of the second line drugs considerably impedes the eradication of 
MDR and XDR TB, Aminoglycosides are nephrotoxics and ototoxics, while ethionamide is 
hepatotoxic and gatifloxacin may cause dysglycemia [11, 33]. 
HIV co-infection is another factor. In this case, the patient’s immune system is not only 
compromised and therefore favours the spread of the infection throughout the body, but also 
the TB therapy may interfere with the antiretroviral therapy. One common case is the 
decrease of therapeutic concentration in the body of any drugs (including HIV protease 
inhibitors) co-medicated with Rifampicin. This is because Rifampicin causes an up-
regulation of hepatic cytochrome (CYP) p450 oxidase system expression which as a result 
induces a higher metabolism  [34]. On the other hand, retonavir is usually administered to 
inhibit CYP450, in order to increase the intracellular level of the antiretroviral drug to meet 
the therapeutic dose. However, when taken with rifampicin in case of TB co-infection, it 
would favour the increase of Rifampicin beyond the therapeutic dose and therefore expose 
the patient to Rifampicin toxicity [35]. Diabetes has become another major factor. Diabetes 
does not only promote the development of active TB [36], but also increases the risk of MDR 
development because it slows the response to TB treatments [37, 38]. Though it is well 
known that diabetes suppresses the cell-mediated immunity, no biological link has been 
established between diabetes and TB. It was proposed that this results from the effect 
hyperglycaemia and cellular insulinopenia on macrophages; leading to a diminish capacity of 
containing mycobacteria. This speculation was supported by the finding showing that 90% 
diabetic’s mice relatively to 10% of normal mice died after challenging with tuberculosis. To 
support this finding, it was shown that aveolar macrophage of diabetic patient were less 
activated and produced less hydrogen peoxide [39]. Therefore further investigation into this 
peculiar effect of diabetes on TB disease progression is required, and in so doing enabling the 
development of new drugs for these cases.  
In view of all these, there is an urgent need for the development of new anti-TB drugs. An 
ideal regimen would enable a brief therapy, decreased dosage, would target dormant bacilli, 
and would be effective in TB in diabetic patient cases and in HIV-co-infected individuals 
without interfering with their HIV regimen. But since RIF was approved, only 2 anti-TB 







drugs (Rifanbutin and Rifapentine) were approved in the USA and other countries 38 years 
later [40, 41]. The inability to find a suitable inhibitor once a target has been validated; to 
convert any target inhibitor into a stable derivative able to cross the complex mycobacterial 
cell wall is one of the many obstacles in drug development. 
1.4 The survival of Mycobacterium tuberculosis  in adverse conditions 
As mycobacteria enter the alveolar space, the immune system reacts through two main 
defensive mechanisms. In an oxygen dependent mechanism, upon phagocytosis of 
mycobacteria by macrophages, the oxygen intake of macrophages generate a respiratory burst 
leading to the formation of oxidants (superoxide, hydrogen peroxide, free radicals) toxic to 
both the macrophages and the mycobacteria [42, 43]. In addition, Interferon gamma induces 
the production of nitric oxide by macrophages which is highly toxic to the mycobacteria [44]. 
In an oxygen-independent mechanism, lysozymes breakdown the cell wall, lactoferin 
removes essential iron or charged proteins from the bacteria to damage it and hydrolytic 
enzymes and proteases digest the proteins [45, 46]. The myeloperoxidase enzyme secreted by 
neutrophil granules in the phagolysozome catalyses the reaction between chlorine and 
hydrogen peroxide (from the respiratory burst) to form hypochlorite, a very toxic compound 
to the cell [42, 47, 48] 
In spite of the harsh conditions generated by the host immune system to kill invading 
mycobacteria, some do survive and multiply causing active disease (primary TB) or become 
dormant for several years (latent TB) in lesions known as granulomas [31, 49, 50]. However, 
these granulomas are composed of dead macrophages surrounded by fibroblasts. The dormant 
mycobacteria reside at the centre of the granuloma which is known to be hypoxic, containing 
nitric oxide, carbon monoxide and other toxic substances [51]. On the other hand, it was 
shown that the intracellular ATP levels were 5-6 times lower in dormant bacilli than in 
actively growing bacilli. In addition, these bacilli can use the anaerobic electron transport 
chain to generate proton motive force while ndh-2 is responsible for the turnover of NAD
+ 
[52]. 
The host susceptibility to TB depends largely on its ability to destroy invading mycobacteria 
with ROS and RNS. This was proven when it was observed that NADPH oxidase deficient 
(NOX2) mice and iNOS (nitric oxide synthase) deficient mice were more susceptible to 
invading mycobacteria [53, 54]. Furthermore, children with chronic granulomatous disease (a 
disorder characterized by phagocytic oxidative bursts causing recurrent pyogenic infections) 







are highly susceptible to TB and present complications during BCG vaccination [55] which 
further support the imperative role of ROS released by phagocytes to destroy M. tuberculosis. 
Therefore, investigating the mechanisms that enable M. tuberculosis to survive in harsh, 
adverse host conditions has been important.  A clear understanding of the physiological 
elements that enable M. tuberculosis survival will be an avenue for the development of new 
drug targets against tuberculosis. Few studies have identified enzymes that may enable the 
mycobacteria to resist the oxidative burst generated by the macrophages during their first 
encounter. There are two families of enzymes associated with the detoxification of ROS in 
bacteria; the peroxiredoxin family and the Ohr/OsmC superfamily. Alkyl hydroperoxide 
reductase AhpC belongs to the peroxiredoxin family. It exists as two subunits AhpC and 
AhpF that are co-transcribed in some bacterial species[56]. While AhpC metabolises 
peroxynitrite, reduces hydrogen peroxide, alkyl hydroperoxides and organic peroxides into 
their corresponding alcohol, AhpF is a flavoprotein that reduces the oxidized AhpC at its 
NH2-terminal cysteine residue using NADPH or preferably NADH [56, 57]. However, 
thioredoxin, or thioredoxin reductase/tryparedoxin, or trypanothione/trypanothione reductase 
or cyclophilin reduce the oxidized AhpC in bacteria lacking AhpF [58]. M. tuberculosis does 
not have any AhpF-like proteins[59] and neither does it use its thioredoxin/thioredoxin 
reductase to support the activity of AhpC. Instead, AhpD, coded by ahpD which is located 11 
base pairs downstream of ahpC and contributes to the reduction of the oxidized AhpC in M. 
tuberculosis. Oxidized AhpD in turn reduced by SucB (dihydrolipoamide 
succinyltransferase) that is in turn reduced by Lpd (dihydrolipoamide dehydrogenase) using 
NADH [57] (Figure 1.2). There are three main classes of peroxide-sensing regulators, OxyR, 
PerR and Ohr. AhpC are regulated by a member of the LysR family of the OxyR sensing 
regulators [60]. The OxyR gene is inactivated in M. tuberculosis by multiple lesions 











Figure 1.2 AhpC enzymatic detoxification of ROS and RNS in M. tuberculosis [57] 
The ROS detoxifying enzyme AhpC can be reduced by AhpD which is dependent on SucB and NADH 
The second ROS detoxification enzyme family Ohr/OsmC, constitute of organic 
hydroperoxide reductase (Ohr) first identified in Xanthomas campestris [62] and the 
osmotically inducible protein (OsmC) first identified in E.coli [63]. OsmC and Ohr are 
structurally and functionally similar [64-66]. They both are implicated in the protection of 
bacteria against organic peroxides [67-70]. However, OsmC is induced by ethanol and 
sodium chloride while Ohr is induced by organic peroxides [64, 71]. Ohr expression is 
regulated by the ohr regulator OhrR (suppressor) [60, 71]. M. tuberculosis on the other hand 
does not have Ohr but OsmC. The regulator of OsmC is not known and OsmC deficient M. 
tuberculosis mutants have not yet been characterized [67].  
On the other hand, few proteins have been speculated to play a protective role in the dormant 
mycobacteria that reside in the hypoxic granuloma causing latent TB. Rv3133 (devR) was 
shown to be up-regulated in dormant mycobacteria and this gene is implicated in the 
induction of three other dormancy proteins namely, α-crystallin, Rv2626c (hrp1) and Rv2623 
(TB31.7) known as the dosR (dormancy survival and regulation) which are able to regulate 
the expression of many other dormancy proteins in latent bacilli [72-77]. There are ten 
proteins shown to be up-regulated during dormancy known as the universal stress proteins 
(USP). Three are regulated by the dosR. However, mutants deficient in most of these proteins 
present no growth defect under in vitro stress conditions representing the macrophage 
environment, neither in mouse nor in human derived macrophage cell lines [78]. This is an 
indication that M. tuberculosis acquires a wide range of compensatory mechanisms in 
response to the host defence conditions.  
1.5 The protective role of thiols  
Thiols are compounds with a sulfhydryl group and their function is to maintain the redox 
balance of biological systems. There are two main types of thiols: Thiols with cysteine as 
their core amino acid and thiols with histidine as their core amino acid. However, it is worth 
mentioning the intracellular thiol 2-mercapto-ethanesulfonate (Coenzyme M). 
 Thiols with cysteine as their core amino acid   
Thiols with cysteine as their core amino acid are: the tripeptide glutathione (γ-L-Glutamyl-L-
cysteinylglycine), the pseudoglucosaminedisaccharide mycothiol (1-D-myo-inosityl-2-(N-
acetyl-L-cysteinyl) amino-2-deoxy- R -D-glucopyranoside) and the bis-glutathionyl 
conjugate of spermidine trypanothione (Figure 1.3). 





























































Glutathione (GSH) is found in eukaryotes, gram negative bacteria, but not in gram positive 
bacteria [79, 80]. Elaborate studies of the role of glutathione have demonstrated the anti-
oxidative role of GSH, its ability to function as a cofactor, and its involvement in the cellular 
maintenance of the redox system [81]. Trypanothione (TSH) is predominantly found in 
protozoa of the genera Trypanosoma and Leishmania the causative agents of trypanomiasis 
[82] and leishmaniasis respectively [83]. The inhibition of the biosynthesis of TSH or the 
reduction of the intracellular level of TSH affects the viability, virulence and the 
susceptibility to oxidative stress of protozoa, making trypanothione biosynthesis a potent 
drug target against Trypanomiasis and Leshmianiasis [84, 85]. On the other hand, mycothiol 
(MSH) is synthesized and abundant in streptomycetes and mycobacteria [80]. Glucose-6-
phosphate (Glc-6-p) is the precursor of MSH biosynthesis. It is generated by myo-Inositol-1-
phosphate synthase (Ino1). Then four other enzymes are involved in MSH biosynthesis:  N-
acetylglucosamine transferase (MshA) transfers N-acetylglucosamine (GlcNAc) from uridine 
diphosphate (UDP)-GlcNAc to myo-inositol to form GlcNAc-inositol [86], which is 
deacetylated by deacetylase (MshB) [87] and the resulting GlcN-inositol (GlcN-INS) is 
ligated by a ligase (MshC) [88] to cysteine and then acetylated by acetylase (MshD) [89] to 
form MSH (Figure 1.4). 
 
Figure1.4 Mycothiol biosynthesis [90] 
Glucose-6-phosphate (Glc-6-p) is the precursor of MSH biosynthesis. It is generated by myo-Inositol-1-
phosphate synthase (Ino1). The enzyme MshA catalyses the transfer of GlcNAc and the dephosphorylation of 
GlcNAc-Ins-P 
Then, in the presence of NAD/mycothiol-dependent formaldehyde dehydrogenase, MSH will 
detoxify formaldehyde resulting in an oxidized MSH known as mycothioldisulfide (MSSM) 







which can be reduced by MSSM reductase (MTR) to MSH. Mycothiol can also form a 
conjugate (MSX) with toxic substances which will be degraded by MSH conjugate amidase 
(Mca) to glucosamine-myo-inositol (GlcN-Ins) and mercapturic acid derivatives (AcCysSR) 
which are excreted from the cell [91, 92]. In addition it was shown that MSH is involved in 
the biosynthesis of the antibiotic lincomycin A by Streptomyces lincolnensis where it serves 
as the sulphur donor involving the Mca-homologs LmbT, LmbV and LmbE [93]. In the 
detoxification of arsenate, MSH forms an arseno-MSH conjugate by the MSH-dependent 
arsenate reductase (ArsC1/C2) reduced in the mycoredoxin -1 (Mrx-1) /MSH/Mtr pathway 
[94]. In contrast, it can use another arsenate reductase (Cg_ArsC1) to detoxify arsenate 
through the thioredoxin (Trx) [95] pathway. Mycothiol can form a conjugate with 
monochlorobimane catalysed by MSH S-transferase (Mst) in M. smegmatis[96]. Mycothiol 
serves as a cofactor of enzymes involved in the detoxification of peroxides, electrophiles, 
nitric oxide and aromatic compounds (maleylpyruvate) such as MSH peroxidase (MpX), thiol 
peroxidase (Tpx) and one-cyst peroxidoxin (AhpE) [97]. It was shown that the formaldehyde 
dehydrogenase AdhE/FadH depends on MSH to detoxify formaldehyde. The mycothiol-
dependent alcohol dehydrogenase (MscR), catalyses the detoxification of S-nitrosyl-
mycothiol (MSNO) and formaldehyde as well [90]. Protein S-mycothiolation (of Tpx and 
Mpx) is induced under hypochlorite NaOCl stress [98]. The S-mycothiolated proteins are 
involved in carbohydrate metabolism, amino acid biosynthesis and nucleotides biosynthesis 
[97] ( Figure 1.5). 
 
Figure1.5 Mycothiol metabolism [97] 







Mycothiol is involved in protein S-mycothiolation, in ROS and electrophile detoxification, in lincomycin 
biosynthesis, in maleylpyruvate isomerization and in arsenate reduction. 
It has been shown that MSH-deficient M. smegmatis mutants produce a high level of Ohr [99, 
100] indicating the role of Ohr in the protection of M. smegmatis from organic peroxides, this 
finding was supported when OhR (Ohr supressor) deficient M. smegmatis were shown to be 
very sensitive to oxidative stress generated by organic peroxides [67]. Since M. tuberculosis 
does not have any homolog of Ohr, it is not known if MSH-deficient M. tuberculosis mutants 
produce a high level of OsmC, however studies indicate that mycobacteria acquire a wide 
range of compensatory protective mechanisms against oxidative stress in-vivo. An example is 
the Ohr-deficient M. smegmatis mutants which are highly susceptible to oxidative stress in 
vitro but had no growth defect ex-vivo [67]. While it was shown that mshC is essential in M. 
tuberculosis [101], mshA, mshB, mshD have been successfully deleted in M. tuberculosis 
[102, 103]. M. tuberculosis ∆mshA mutants are MSH-deficient [102]  while ∆mshB and 
mshD  M. tuberculosis mutants produce a low but detectable level of MSH which indicates 
the possibility of compensatory enzymes with low activities [103, 104]. On the other hand, 
M. bovis ∆mshC and ∆mshA mutants produce no detectable level of MSH [105]. Mycothiol 
protects mycobacteria from oxidative stress and acidic stress making it a potent drug target 
against tuberculosis [104, 106, 107]. Though it was previously shown that ∆mshD Erdman 
mutant strain grew poorly within macrophages [103], it was however reported that H37Rv 
mutants ∆mshA mutants had no growth defect in immuno-competent mice neither in 
immuno-deficient [102] mice. M. smegmatis ∆mshA and ∆mshD mutants are sensitive to RIF 
but resistant to INH and ETH (Table 1.1).  The M. smegmatis ∆mshC is susceptibible to RIF, 
INH and ETH. The M. smegmatis ∆mshB  is resistant to ETH and susceptibility to INH and 
RIF [108]. The ∆mshA and ∆mshC M. bovis mutants are resistant to INH and ETH [105] . 
The H37Rv frame shift spontaneous ∆mshA mutants are ETH and INH resistant. The 
CDC1551 ∆mshA deletion mutants are ETH and INH resistant. The H37Rv and Erdman 
strain  ∆mshA deletion mutants are ETH resistant only [102].  The H37Rv ∆mshB mutants are 
sensitive to RIF and resistant to INH but their susceptibility to ETH has not been determined 
[104] (summary in Table 1.1). Therefore drugs targeting mycothiol may not be used in 
combination with INH. 
 
Table 1.1 First line drug resistance profile of MSH-deficient mutants 
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ND ND ND ND 
*S: sensitive, R: resistant 
 
 In contrast, it was shown that ETH hypersensitivity results from a gain of function mutation 
of the mono-oxygenase gene (etaA) (coding for an antioxidant) while ethionamide resistance 
resulted from an overproduction of the regulatory protein EtaR (which affects EtaA by down 
regulating it’s expression) [109]. But the level of EtaR has not been investigated in MSH 
deficient mutants, so it is not sure if MSH deficiency affects the production of EtaR. On the 
other hand it was shown that a mutation in the catalase-peroxidase gene (KatG) is associated 
with INH resistance [110]. The drugs INH and ETH are activated by KatG and EthA 
respectively but they both target the NADH-dependent enoyl-ACP reductase InhA [111]. 
Therefore it is expected that mycobacterial strains that are co-resistant to INH and ETH 
should harbour mutations in inh and or ndh (NADH dehydrogenase that indirectly affects 
InhA since it is NADH-dependent). On the contrary, it was shown that INH and ETH co-
resistance could be associated with a mutation in mshA or mshC in M. bovis, M. tuberculosis 
and M. smegmatis [102, 105, 108]. In vitro experiments showed that MSH is involved in the 
activation of ETH by EthA but the exact mechanism is still unclear [102]. On the other hand, 
it was proven that INH resistance is observed in MSH-deficient mutants because of the 
increased production of Ohr since the ohrR-deficient M. smegmatis mutants are resistant to 
INH as well. Therefore INH resistance is observed in M. smegmatis because of the absence of 
the antioxidant that causes an increase of intracellular organic peroxides leading to an 
overproduction of Ohr which in turn inhibits INH activity [67]. It is not known if Ohr is 







directly involved in the INH mode of action or if INH action is dependent on the regulation 
of enzymes that can reduce ROS. Because it was also observed that M. smegmatis ahpC 
mutants were sensitive to INH which may be due to an elevated expression of KatG in these 
strains [112]. This is an indication that drugs targeting MSH biosynthesis should not be used 
in combination with ETH or INH.  
 Thiols with histidine as their core amino acid 
The second group of thiols have a histidine core. These include Ovothiol (OSH) and 
ergothioneine (ERG) (Figure 1.6).  
 
Figure1.6 Thiols with histidine in their core 
On the left is histidine; in the middle is ovothiol that differs from histidine by the extra suphhydryl group (SH) 
(blue) and the methyl group (CH3) (yellow) and on the right is ergothioneine that has the SH-group (blue), and 
three extra methyl groups (yellow). 
Ovothiol has been identified in sea urchins [113], marine invertebrates [114] and the 
pathogenic Trypanosome and Leischmania [115]. There are 3 derivatives of OSH: OSH A, B 
and C. These are all π-N-methyl-5-thiohistidines and their highly acidic sulphydryl group 
make them potent anti-oxidants [116]. Ergothioneine (2-mercapto histidine trimethyl betaine) 
was first identified in the ergot fungus in 1909 [117]. Plants absorb ERG through their roots 
from microorganisms in the soil. Ergothioneine is abundant in mushrooms, black beans, red 
beans and oat bran [118]. Ergothioneine is synthesized by fungi and actinomycetes but not in 
animals. Ergothioneine is ingested from food by animals; and is distributed in various tissues 
[119-121]. Ergothioneine is found in the seminal fluid [122], ocular tissues [123], in the 
plasma (where it is bound to specific proteins) [121], brain [124, 125], fibroblasts [126], 
myocardiocytes [127], bone marrow, cord blood, foetal liver, trachea ileum, kidney and 
peripheral leukocytes [128]. Ergothioneine is transported into these cells via An organic 
cation transporter known as OCTN1 or ETT [127][128][129]. Ergothioneine import 
efficiency is enhanced when co-transported with sodium ions. OCTN1 can only import ERG 
into the cells but can’t export it. On the other hand, ERG does not easily diffuse across the 
Histidine Ovothiol Ergothioneine







membrane. Consequently, cells lacking the OCTN1 transporter do not contain ERG [128]. 
Ergothioneine is a zwitterion, prevailing in its thione form more than its thiol form and it has 
a high redox potential at physiological pH ( E0=-60mv) and is able to chelate divalent metals 
[130, 131]; that makes it very stable, and less susceptible to auto-oxidation than other thiols 
[132]. It is worth noting that the redox potential of GSH is -250mv while that of OSHA is 
170mv making ERG more stable in its reduced form than GSH while is more stable in its 
reduced form than OSHA [133]. In addition, as opposed to other thiols ERG is not consumed 
and can accumulate in cells throughout their lifespan [128, 134]. Ergothioneine is sub-
cellularly located in the cytoplasm, microsomes and in mitochondria but not in the nucleus 
[121, 127]. The role of ERG in eukaryotes has been extensively studied. It inhibits the copper 
induced oxidation of protein and DNA in the serum [135] electrically stimulate the 
cerebellum [125], prevents neuronal injury [136], protects skin cells against UV irradiation 
effects [137], protect the eye and protozoa against damage caused by oxidative stress and 
prevent the formation of cataract [123, 138-140] and is able to suppress inflammatory 
responses by indirectly supressing IL-8 via TNF-α mediated activation of NF-kappa β [141]. 
Ergothioneine can also be a potential diagnostic marker. Patients with autoimmune disorders 
have a high level of ERG in their erythrocytes [142]. The OCTN1 gene variant 503F is 
associated to Crohn’s disease and the transport efficiency of ERG is high in patients suffering 
from this disease [143]. The role of ERG in microorganisms is still under investigation. It 
was shown that it is a potent anti-oxidant in bacteria [144], in fungi [145] and in M. 
smegmatis [99]. In addition it has been shown that ERG is involved in the biosynthesis of the 
antibiotic lincomycin A by Streptomyces lincolnensis where it serves as a sulphur carrier [93] 
(Figure 1.5) and was found to be a moety of Spithioneines A and B implicating the 
inplication of ERG in the synthesis of these polyketides in Streptomyces spinoverrucosus 
[146]. 
Histidine has been suggested to be a precursor of ERG in previous studies when 
14
C labelled 
histidine was shown to be converted to ERG in Neurospora crassa cultures, then it was 
speculated that thiolhistidine could be an intermediate of ERG biosynthesis which was 
disproved later since ERG production did not result from the in 
14
C labelled thiolhisditine 
introduced in the Neurospora crassa culture [119] . However, it was shown that hercynine 




labelled hercynine was added in 




labelled ERG [147] (Figure 1.7).  









Figure1. 7 Ergothioneine biosynthesis pathway suggested in 1962 [147]. 
It was speculated that thiohistidine could be converted to ERG or hercynine could be converted to ERG in the 
presence of cysteine. The second speculation is true, but however involves more intermediates. 
But the enzymes catalysing the reactions were unknown until EgtA, EgtB, EgtC, EgtD and 
EgtE were identified as the enzymes catalysing ERG biosynthesis in mycobacteria [148]. The 
biosynthesis was expounded as follows: Histidine is methylated in the presence of S-
adenosylmethionine (SAM) by the methyltransferase EgtD to yield trimethylhistidine 
(hercynine) which will react with γ -glutamylcysteine (γ -GC) (synthesized in a reaction 
catalysed by γ -GC synthetase (EgtA) ) catalysed by an FGE-like protein (EgtB) to a form a 
compound from which glutamine will be cleaved by glutamine amido transferase (EgtC) to 
yield S-(β-amino-β-carboxyethyl)-ergothioneine sulfoxide from which pyruvate and 
ammonia will be released catalysed by a pyridoxal phosphate (PLP) dependant β-liase (EgtE) 

















Figure 1. 8 Ergothioneine biosynthesis [149] 
The enzyme EgtA catalyses the formation of ƴ-glutamyl cysteine (6), EgtD catalyses the methylation of 
histidine (2), EgtB catalyses the ligation of 6 to 2, EgtC catalyses the cleavage of glutamate to form 4 and EgtE 
catalyses the cleavage of pyruvate and NH3 to form ERG (5) (indicated in black). However, in N.crassa only 
one enzyme involved in ERG biosynthesis has been identified so far (Egt1) which catalyses the conversion of 2 
to 4 (indicated in blue). Ƴ-glutamyl cysteine (6) formed by EgtA can also be used in the synthesis of glutathione 
in organisms that synthesized glutathione as well. Ergothioneine can exist either in a thiol configuration (5a) or 
a thione configuration (5b) but exist more predominantly at physiological pH in the thione configuration, 
conferring its stability [150]. 
In this new reaction scheme, thiolhistidine is not an intermediate confirming what was shown 
in previous studies that the sulphur atom is incorporated through a more complex 
intermediate (S-(β-amino-β-carboxyethyl)-ergothioneine sulfoxide; 4 in Figure 1.8). However 
the gene cluster coding for enzymes involved in ERG biosynthesis is found mainly in 







actinomycetes, most organisms lack orthologs of EgtA, EgtC and EgtE [151]. There are 
bacterial species lacking EgtA, EgtC, and EgtE that still produce ERG [152], indicating that 
they may not be universal ERG essential enzymes or may be compensated for by other 
enzymes or by spontaneous chemical reactions. In addition, the expression of egtB and egtD 
is positively correlated while there is no evidence that the expression of either egtC, or egtA, 
or egtE is positively correlated with that of egtB or egtD [153]. The first two steps of ERG 
biosynthesis in N. crassa is catalysed by NcEgt-1 (Figure 1.8). This enzyme contains 
domains found in EgtD and EgtB, thereby playing the catalytic role of both enzymes in the 
fungus N. crassa [145]. However, the enzymes catalysing the downstream reaction have not 
yet been identified. On the other hand it has been shown that EgtB binding is specific to γ –
GC. However, any mutation on its residue (D416) may affect its sulphur donor specificity 
[154]. The enzyme EgtD on the other hand, catalyses methylation of histidine by a proximity 
and orientation effect in a successive reaction. It consists of two domains, the 
methyltransferase domain and the substrate binding domain. The histidine binding pocket 
primarily recognises the imidazole ring and carboxylate group of histidine accounting for its 
methylation selectivity and specificity. In other words EgtD can only methylate histidine 
and/or mono, di methyl histidine [155].   
I.6 Rational of this study 
It is known that eukaryotic cells import ERG via the OCTN1 transporter [127, 129, 156], and 
ERG was observed in the buffer of resting M. smegmatis pellicle [157], leading to the 
hypothesis that ERG is secreted by mycobacteria.  
The anti-oxidative role of ERG in eukaryotes is well documented [150]. In addition to that, 
MSH-deficient M. smegmatis mutants produce more ERG than the wild type [100]. Leading 
to our second hypothesis that ERG plays a protective anti-oxidative role in mycobacteria.  
Therefore, our first aim is to prove that ERG as opposed to MSH is secreted by mycobacteria. 
This aim can be achieved by quantifying ERG in the extracellular medium of mycobacteria 
culture, and proving that the ERG detected in that culture does not result from dead cells or a 
leakage through the mycobacterial membrane.  
The second aim is to prove that ERG protects mycobacteria against oxidative stress and may 
complement MSH in that regard. To prove this, we must first generate an ERG-deficient 
mycobacteria mutant, then an ERG/MSH-deficient double mutant and investigate their 
survival under in vitro stress conditions.                                                                                          







Further, the objective of this study is to validate ERG biosynthesis as a potential drug target. 
  















CHAPTER 2: METHODOLOGY 
2.1 Investigation of ERG secretion in M. smegmatis and M.tuberculosis 
 ERG and MSH extraction and quantification in M. smegmatis 
Approximately 50µl of M. smegmatis frozen stock (OD600~1) was used to inoculate 10 ml of 
Difco
TM
  middlebrook 7H9  broth (Becton Dickinson South Africa) supplemented with 1% 
Glucose salt (GS) solution (5% Tween 80, 8.5% NaCl, 20% glucose). This was grown in a 
100ml Erlenmeyer flask overnight at 37
◦
C in a shaking incubator set to 200-250 rpm. The 
next day, a sterile, autoclaved Erlenmeyer flask containing 200 ml of 7H9 was inoculated 
with the starter culture to an OD600 ~0.0025 for the wild type and OD600 ~0.005 for the ∆mshA 
mutant and allowed to grow to the desired OD600.   
A serial dilution of each culture was performed and a 100µl aliquot was plated on Luria-
Bertani (LB) agar (Merck or Sigma Aldrich) to determine colony forming units (CFUs)/ml. 
Cultures were harvested for extracellular and intracellular ERG (EE and IE) extractions. For 
EE, 10 ml of culture was pelleted at 4000rpm, and the supernatant was filtered sterilized 
(0.22µm diameter, PVDF membrane), snapped freezed in liquid nitrogen and lyophilised 
overnight in a vacuum pump (Labconco; 8811 Prospect Avenue Kansas City, MO 64132-
2696; USA) . For IE, 150 ml of culture was pelleted by centrifugation, and the pellet was re-
suspended in the lysis buffer (2mM EDTA (pH ~8)+0.25M perchloric acid (PA) + 40% 
acetonitrile (ACN)). All chemicals used in the lysis buffer were supplied by Sigma Aldrich 
(St. Louis, MO, USA). In case of stationary phase cultures, the volume of the lysis buffer was 
doubled. The suspension was sonicated using a probe sonicator (Qsonica, LLC. 53 Church 
Hill Rd; Newtown, CT 06470) for 5 mins for exponential cultures and for 10 mins for 
stationary cultures at 25-50 pulses/s. The cell lysate was collected by centrifugation at 4ºC for 
10 mins (4000rpm), the pH of the supernatant was adjusted to between 8 and 10 with 
potassium carbonate (Sigma-Aldrich) and lyophilised overnight (26, 27). The lyophilised 
extracellular and intracellular portions were re-dissolved in a solution containing 25% 
acetonitrile and 0.05% formic acid and analysed by ultraperformance liquid chromatography-
electrospray ionization-tandem mass spectrometry (UPLC-ESI-MS/MS) [118, 137]  
 Extraction and quantification of ERG, MSH, cysteine and hercynine in 
M.tuberculosis 







Ergothioneine was extracted as previously described [99] with slight modifications. 
Approximately 35 ml or 15 ml of actively growing exponential or stationary liquid cultures 
respectively, (middlebrook 7H9 (Difco) broth supplemented with 10% Middlebook OADC 
(Becton Dickenson, USA) and 0.05% Tween 80 (Sigma Aldrich) and 0.2% (v/v) glycerol 
grown in tissue culture flasks without shaking) was pelleted for IE extraction. The pellet was 
re-suspended in the lysis buffer (40% ACN+0.25 M PA+ 2mM EDTA) and cells were lysed 
in tubes containing 0.1mm beads (Biospec Products Inc., Bartlesville, United Kingdom) 
using FastPrep-24 (MP Biomedicals) (5 m/s) 5 times for 50 s with 1-min intermittant cooling 
steps on ice. The cell extract was clarified by centrifugation, and the pH equilibrated to 
between 8 and 9 using potassium carbonate. The precipitate was removed by centrifugation 
and the supernatant was filtered, lyophilised and re-suspended in the running buffer. This was 
subsequently analysed for ERG content using UPLC-ESI-MS/MS as previously described 
[99]. For extracellular ERG quantification, 1ml of the supernatant was filtered twice using 
13mm PVDF 0.2um membrane filter or 13mm PTFE 0.2um membrane filters (SIGMA 
ALDRICH), lyophilised (Concentrator plus / Vacufuge® plus; £ppendorf, Becton Dickinson, 
Franklin lakes, NJ, USA) re-dissolved in 400μl of the running solvent (25% acetonitrile, 
0.05% formic acid) and analysed for ERG concentration by ultra-performance liquid 
chromatography-electrospray ionization-tandem mass spectrometry (UPLC-ESI-MS/MS). 
For every extraction, serial dilutions of every culture were plated on 7H11 media for CFU 
counts. ERG concentration was expressed as pg/10
5
 CFUs. Results are representative of the 
mean value of at least 3 biological replicates. 
 Mass spectrometry analysis of samples 
UPLC-ESI-MS/MS analysis was performed with a Waters Acquity UPLC system coupled to 
a Waters Xevo TQ MS system (Waters Corporation, Milford, MA, USA). Compounds were 
separated on a Waters Acquity BEH phenyl column (100 by 2.1 mm; 1.7 µm) at 50°C using a 
1% formic acid (in water) (solvent A) - acetonitrile (solvent B) gradient, starting with 100% 
solvent A for 1.5 min at a flow rate of 0.3 ml/min. The acetonitrile concentration was 
increased linearly to 2% over 2 min at a flow rate of 0.4 ml/min and then increased to 100% 
over 0.3 min at a flow rate of 0.5 ml/min and maintained for 0.2 min. The column was re-
equilibrated for 2 min (the total run time was 6 min). ERG was analyzed in the ESI-positive 
mode, and the multiple-reaction-monitoring (MRM) transition m/z 230.1 > 127.1 (cone 
voltage = 18 V; collision energy =18 eV) was monitored. The source capillary was at 3.5 kV. 
The source and desolvation temperatures were 140°C and 400°C, respectively. The 







desolvation and cone gas flows were 600 and 50 liters/h, respectively. A standard curve was 
generated for ERG quantification. Intracellular and extracellular ERG was expressed as 
pg/10
5
CFU for each time point, and the results are representative of at least 3 experiments, 
expressed as means ± standard deviations of the means. For MSH quantification, samples 
were treated with 0.02 M dithiothreitol (DTT) prior to analysis. Since no MSH standard is 
commercially available, we used liquid chromatography–electrospray ionization–high-
resolution mass spectrometry (LC-ESI-HRMS) and the known exact m/z value for MSH ([M 
– H
-
] of 485.1441 to detect MSH in the cell lysate of wild-type M. smegmatis, as previously 
described [158]. Briefly, LC-ESI-HRMS was performed with a Waters Synapt G2 MS 
(Waters Corporation, Milford, MA, USA). Compounds were separated on a Phenomenex 
Synergi Fusion column (250 x 2 mm, 4 μm) at 25 °C using a 0.1% formic acid (in water) 
(solvent A) / acetonitrile (solvent B) gradient: Starting with 100% solvent A for 6 min at a 
flow rate of 0.2 ml/min. The acetonitrile was increased linearly to 95% over 21 min and 
maintained for 3 min.  The column was re-equilibrated for 7 min (total run time was 32 min).  
Mycothiol was analyzed in ESI negative and the MS instrument was operated in scan mode 
(cone voltage = 15 V).  The source capillary was at 2.5 kV.  The source and desolvation 
temperatures were 120 ºC and 275 ºC, respectively. The desolvation and cone gas flows were 
650 and 50 L/h, respectively.  Hercynine was quantified as well by LC-ESI-HRMS. 
Compounds were separated on a BEH Amide column (2.1 x 100mm; 1.7µm) in an ESI 
positive mode; m/z 198.1 [148].The mobile phases constituted of 0.1% formic acid (solvent 
A) and 95% ACN (solvent B). Samples did not require DTT treatment prior hercynine 
quantification. Because hercynine standard was not available, it was expressed as well as 
peak area/10
7 
CFUs. Cysteine was quantified by UPLC-ESI-MS/MS. Compounds were 
separated on a BEH Amide column (2.1 x 150mm; 1.7µm). The mobile phase constituted of 
0.1% formic acid (solvent A) and 95% ACN (solvent B). Samples were treated with 0.02M 
DTT prior analysis [159, 160]. 
 Evaluation mycobacteria membrane integrity 
-Evaluation of the membrane of M.smegmatis 
A volume of 10ml of growing cultures was pelleted and re-suspended in 1ml 150mM NaCl 
(Sigma Aldrich) and incubated for ~30 mins at room temperature. The suspension was mixed 
by pipetting every 15 mins. This was then centrifuged at 4000rpm room temperature and the 
pellet was re-suspended in NaCl and washed two more times. The pellet was then re-
suspended in 1 ml of NaCl and 10 µl of the suspension was added in 5 ml polystyrene round-







bottom 12 X 75mm falcon tubes (BD Biosciences Discovery Labware-Two Oak Park, 
Bedford, MA 01730 USA) containing 987µl NaCl, 1 µl of propidium iodide (PI) and 1.5 µl 
of Syto9 LIVE/DEAD® Baclight™ bacterial Viability and counting kit (Molecular 
PROBES®; life technologies) [161]. The suspension (protected from light) was analysed by a 
flow cytometer (BD FACSCalibur). A total of 100000 events was acquired for each sample. 
Results were analysed using the software FlowJo (Version 6). Syto9 is a membrane 
permeable green fluorescence dye that stains every cell in a suspension by binding to the 
nucleic acids, while PI is a red fluorescence that stains only cells with disrupted membrane, 
because it cannot penetrate through intact membrane due to its high molecular weight [161]. 
Heat treated mycobacteria (2 hours at 80
o
C) were included as a control for the dead cell 
population [162, 163]. Fluorescence was collected in channel 1 (FL1) for Syto9 and channel 
3 for PI. The forward scatter, side scatter and fluorescence were collected on a logarithmic 
scale.  
-Evaluation of the membrane intergrity of slow growing mycobacteria 
M. bovis membrane integrity analysis was achieved using the Live/Dead Baclight bacterial 
viability and counting kit (Molecular Probes), as previously described [99, 161]. A volume of 
10 ml of culture was pelleted and re-suspended in 1ml of 150mM NaCl. Cells were washed 2 
to 3 times in this buffer for ~1 hour, and finally re-suspended in 1 ml of 150mM NaCl. 10μl 
of the suspension was added in BD falcon tubes containing 990µl of the running buffer 
(148mM NaCl + 22µM PI + 5µM Syto9). After a brief vortex, each sample (protected from 
light) was analysed by a BD FACSCalibur (Becton Dickinson Biosciences, San Jose, CA), 
using linear amplifiers to measure forward- and side-light scatter (FSC, SSC) and logarithmic 
amplifiers for all fluorescence measurements. A total of 100000 events were acquired for 
each sample. The BD FACSCalibur instrument settings optimized for BCG are shown in 
Table 2.1. 
 
Table 2.1 FACSCalibur instrument setting for the analysis of M. bovis 
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M.tuberculosis membrane integrity was analysed following the same procedure with a few 
modifications. One millilitre of growing M. tuberculosis culture was pelleted, washed and re-







suspended in 150mM NaCl. Hundred microliter of the cell suspension was added in BD 
Falcon tubes containing 977.4μl of the running buffer. Stained M. tuberculosis cells were 
analysed by a BD FACSJazz cell sorter (Becton Dickinson Biosciences, Belgium), using 
linear amplifiers to measure forward-light scatter (FSC) and logarithmic amplifiers for side-
scatter and all fluorescence measurements. A total of 200000 events were acquired for each 
sample. The BD FACSJazz instrument settings optimized for M. tuberculosis are found in 
Table 2.2. As controls, dead cell and/or cells with damaged membranes were generated by 
heat treatment for 1h at 80
0
C [99, 163, 164]. Results are representative of the mean of 3 
different cultures at each growth stage. 
 
Table 2.2 FACSJazz instrument setting for the analysis of M. tuberculosis 
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Photomultiplier Tube, FSC: forward scatter, SSC: size scatter, PI: propidium iodide 
 Investigation of ERG transporter 
In order to identify the transporter of ERG, the protein sequence of OCTN1, the ERG 
transporter in eukaryotes [128, 129, 165] was blasted against H37Rv proteome in NCBI Blast 
tool 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&PAGE_TYPE=BlastSearch&LI
NK_LOC=blasthome). Fifteen closely related proteins were identified. The gene coding for 
the proteins were searched in Uniprot (http://www.uniprot.org/). Available transposon 
mutants where these genes were deleted were identified in www.beiresources.org. 
Transposon mutants of four genes coding each for a transporter were available. The four 
transposon mutants are MT 3434 Transposon mutant 212, MT 1926 Transposon mutant 1015, 
and MT 1289 Transposon mutant 1643, MT 1953 Transposon mutant 2730. These transposon 
mutants were requested from the American tissue type culture (ATCC). Strains were grown 
and IE and EE were quantified in each strain. 
2.2 Generation of M. smegmatis and M.tuberculosis mutants 
 Methods used to mutate genes 
Genes can be knocked out by chemical mutagenesis, transposon mutagenesis and 
homologous recombination (which can be through a one step or two-step selection method). 
Chemical mutagenesis involves the use of chemicals to disrupt the gene of interest, but this 







method does not allow a rational selection of the target gene, and may lead to the disruption 
of many other genes.  
Transposon mutagenesis involves the use of a transposon gene to disrupt another gene. A 
transposon gene carried by a phage that will infect the bacteria, will use a copy and cut 
mechanism to be inserted into a gene thereby disrupting it. Transposon mutagenesis is more 
advantageous than chemical mutagenesis because mutants can be distinguished from wild 
type by selectively growing them in an antibiotic rich medium because phages can be 
designed with an antibiotic marker, so that the transposon should mark its site of insertion. 
The other advantage is, a single mutation can be achieved by transposon mutagenesis, and the 
transposon can be useful in case of transcriptional or translational fusions [166-168]. 
Transposon mutagenesis cannot enable a rational selection of the target gene.  
Homologous recombination mutagenesis on the other hand allows a rational selection of the 
target gene. Homologous recombination is an event that occurs in eukaryotes allowing allelic 
exchange between a pair of chromosomes thereby allowing exchange of genetic information. 
This event is mediated by the RecA protein when performed in bacteria where two 
homologous sequences (one is engineered with the mutated gene) undergo recombination 
leading to a mutant strain. Homologous recombination involves two methods: A one-step 
method where selection of the recombinant is done in one step usually because the gene of 
interest is replaced by an antibiotic resistance marker which enables discrimination of the 
mutants from the wild type by growing them in antibiotic containing media; generating 
marked mutants (gene disrupted or replaced by an antibiotic marker cassette). The two-step 
method involves the selection of the recombinant strains in two steps that is: a single cross 
over event is detected when all the included antibiotic markers are expressed. The second 
cross over event is identified when all the selectable markers present on the plasmid 
backbone are no longer expressed (except the one used to disrupt the gene in case of marked 
mutation). It is always difficult to perform homologous recombination in slow growing 
species like M. tuberculosis, but the two steps homologous recombination is more efficient 
than the one step method in slow growing mycobacteria like M. tuberculosis. A two-step 
homologous recombination can be designed for the generation of marked mutants 
(replacement of the gene by a marker) and unmarked mutants (replacement of the gene by 
either a truncated gene, or a point mutated gene or no gene at all). Unmarked mutagenesis 
allows performing many gene deletions on the same strain since the markers can be reused 
for subsequent mutagenesis, while in a marked mutation the number of deletions is limited 
due to the limited number of the marker cassettes. Furthermore, a marker can have a polar 







effect on the transcription of the surrounding genes or an unknown physiological effect on the 
bacteria [169-173]. Therefore we made use of a two-step selection procedure to achieve 
genes deletion in this study (Figure 2.1).  
 
Figure2.1 Two-step homologous recombination event 
US: upstream, DS: downstream, SacB: gene that encode the protein characteristic for the sucrose sensitivity 
phenotype, LacZ: gene that encodes β thiogalactosidase characteristic for a blue phenotype in media containing 
X-galactose, Kan: gene coding for the kanamycin resistant protein, DCO: double cross over. The first 
homologous event can happen either at the upstream region (1) or at the downstream region (2). The second 
event is known as a double cross over which leads to the deletion of the target gene (DCO 1) or to the same 
unchanged genome (DCO 2). 
 
 







 Generation the ∆egtD and the ∆mshA/egtD M. smegmatis mutant 
strains 
An unmarked egtD (MSMEG_6247) deletion was generated by homologous recombination as 
described previously [170]. Briefly, upstream (US) and downstream (DS) fragments flanking 
egtD were amplified from M. smegmatis mc
2
155 genomic DNA using the primers listed in 
Table 2.3. The enzyme used for the polymerase chain reaction (PCR) was Phusion 
polymerase (Thermo Scientific, Thermo Fisher Scientific Inc. 81 Wyman Street Waltham, 
MA USA 02451), the reaction set up is found in Table 2.4 and the thermo cycling conditions 
are found in Table 2.5. The resulting fragments were cloned individually into CloneJet™ 
Vector (Thermo scientific) and subsequently used to construct the suicide plasmid 
p2NILegtD. The sacB-lacZ fragment from pGOAL17 or the sacB-hyg-lacZ fragment from 
pGOAL19 was cloned into the PacI site of p2NILegtD to generate p2NILegtD17 or 
p2NILegtD19 respectively [170] (Table 2.5). p2NILegtD17 or p2NILegtD19 were 
electroporated into M. smegmatis mc
2
155 and the ∆mshA mutant respectively [86] (kindly 
donated by Yossef Av gay and Adrie Steyn; see Table 2.6), and egtD deletion was achieved 
in each strain by a two-step allelic exchange (Figure S 1 in the additional information found 
in the appendix describes the entire process). The integrity of the allelic exchange substrates 
and complementation vector were confirmed by sequencing (Table 2.3) and the genotypes of 
the mutant strains were confirmed by Southern blotting and colony PCR (6247SF, 6247SR1, 
6247SR2, Table 2.6). 
Table 2.3 Primers used to generate the suicide plasmid and the complementation vector  
Name Sequences (5’ to 3’ direction) Restriction 
enzymes 
PCR product 
6247 USF GCATATGGTAGTTGGCCAGTGAGAG NdeI 1923bp upstream MSMEG_6247 
including 18bp of its 5’end 
 
6247 USR AAGCTTGAACTGCATCGCCAGTACA HindIII 
6247 DSF GATGCATGGCGATACCGACAACAG Nsil I 1955bp downstream 
MSMEG_6247 including 129bp 
of its 3’ end 
 
6247 DSR GCATATGCTCACCGAGGTGTCC NdeI 
6247 CF AAGCTTCTCGACATGACGCGAACAT HindIII 4528bp product that includes  
2398bp upstream MSMEG_6247 
to  1169bp downstream 
MSMEG_6247 
6247 CR AAGCTTGAGGCCGACCTGGACTATA HindIII 
6247 SF GTTCTCGGGACGGAACTTG NA  
Screening primers, 279bp and 
976bp for mc
2
155 and 169bp for 
the mutant 
6247 SR1 ACCGATCTGGTGAAGGACAC NA 
6247 SR2 AACCCTACGACGACGATCC NA 







SeqF CAGACCGGCGAGCATGAA NA Sequencing primer 
SeqR AACAGCGTCATCGATTCCTCG NA Sequencing primer 
6247 S’1 GTTCGACGACGCGCCAC NA Sequencing primer 
6247 S’2 CGCCCGTCGTCGTCGAC NA Sequencing primer 
6247 S’3 GCGGGATCTTGCCCAGA NA Sequencing primer 
6247 S’4 AGCGCAGCACGCCCGCG NA Sequencing primer 
6247 S’5 CCGACAGCGTGTCCCCC NA Sequencing primer 
6247 S’6 CGGCGGGTCGAGCACCA NA Sequencing primer 
6247 S’7 TCGGGGTTCCAGAACTG NA Sequencing primer 
6247SBF GGGATCGTCGTCGTAGGGTT NA Sequencing primer 
6247SBR CGCACTCACTGGACAACGAA NA Sequencing primer 
 
Table 2.4 Reaction set up of Phusion polymerase 
Components Final concentration 
5X Phusion Buffer 1X 
2.5mM dNTP 0.2mM 
10µM foward primer 0.5µM 
10µM Reverse primer 0.5µM 
2u/µl Phusion polymerase 0.02u/µl 
H20 make it up to final volume 
DNA 100-200ng 
 
Table 2.5 Thermo cycling conditions of Phusion polymerase 
Temperature 
◦
C Time cycle 
98 30s 1 
98 10s  
40 59-72 30s 
72 2mins 
72 10mins 1 
4 +∞ 1 
 
Table 2.6 Plasmids and strains used in this study 
 
Name Description Source/ 
Reference 
Plasmids 
p2NIL Cloning vector, kan
r 
[170] 
p2NILegtD p2NIL vector carrying 1955bp region downstream egtD and 1923bp 
region upstream egtD 
This study 
pGOAL17 Plasmid carrying lacZ and sacB genes as a PacI cassette; Ap
r 
[170] 





p2NILegtD17 p2NILegtD containing the pGOAL17 PacI cassette This study 







p2NILegtD19 p2NILegtD containing the pGOAL19 PacI cassette This study 
pMV306 E.coli- Mycobacterium integrating shuttle vector, Hyg
r 
[174] 
pMV306D pMV306 carrying the region from 2398bp upstream of egtD to 
1169bp downstream of egtD 
This study 
Strains   
mc
2




∆mshA Derivative of mc
2








∆egtD Derivative of mc
2
155 carrying an unmarked deletion of  egtD This study 
∆mshA/∆egtD Derivative of ∆mshA carrying an unmarked deletion of  egtD This study 
∆egtD attB:: 
pMV306D 












DH5α E.coli for routine cloning experiments Laboratory 
stock 
 
 Generation of M.tuberculosis mutants 
Homology search was done to identify genes that code for enzymes involved in ERG 
biosynthesis in M. tuberculosis. This was achieved by aligning M. smegmatis ERG validated 
biosynthetic genes against M. tuberculosis genome as seen below (Figure 2.2). 
 
Figure2.2 Genomic alignment of the operon of genes coding for enzymes involved in ERG biosynthesis 
Two-step allelic exchange mutagenesis was used to delete the genes involved in ERG 
biosynthesis as described above. The primers used to amplify the regions flanking each gene 
are listed in Table 2.7. Allelic exchange substrates were generated by cloning these 
fragments, along with selection markers into p2NIL vectors as described in Table 2.8 
To obtain a marked construct for the deletion of mshA, a hygromycin cassette was amplified 
along with its promoter region from pMV306hyg
r
 [174] ( primers in Table 2.7), cloned into 
the SpeI site between the US and DS regions of mshA in p2NIL. The PacI fragment of 
pGOAL17 was subsequently ligated to the p2NIL construct (Table 2.8). Mutants were 
MSMEG_6246 MSMEG_6247 MSMEG_6248 MSMEG_6249 MSMEG_6250
MT3803 MT3804 MT3805 MT3806 MT3807
Rv3700 Rv3701 Rv3702 Rv3703 Rv3704











identified by colony PCR and confirmed by Southern blotting. PCR screening primers can be 
seen in Table 2.7 and Southern blotting probes and restriction enzymes are indicated in Table 
2.9. 
 




Construct Design  
A-USF GCTGTACAGATACTACGACCCGGTTCCCA BsrgI 2451bp US 
MT3807 including 
a 60bp flank A-USR GCACTAGTGTCGTCCGGGGCAGCGTTA SpeI 
A-DSF GCACTAGTCCGGCAGACGATTTCTCCGA SpeI 2462bp DS 
MT3807 including 
a 81bp flank A-DSR GCAAGCTTGCGTTGATTTCGACACCACTG HindIII 
B-USF GCTGTACACGCTATTACCACCACGGCA BsrgI 2488bp US 
MT3806 including 
a 100bp flank B-USR GCACTAGTCATACTGGCAGCAAAGCTCG SpeI 
B-DSF GCACTAGTCCAGCTTCCGCAACTGGGAT SpeI 2468bp DS 
MT3806 including 
a 74bp flank B-DSR GCAAGCTTCTCCATCAGCTCAGGACGAAC HindIII 
C-USF GCTGTACAAGATGGAGGCGCACTGCTT BsrgI 2484bp US 
MT3805 including 
a 58bp flank C-USR GCACTAGTCCAGCACCAACGAAGAAACC SpeI 
C-DSF GCACTAGTACCTGGTGGAGGTAACCCAA SpeI 2456bp DS 
MT3805 including 
68bp flank C-DSR GCAAGCTTTGGAAGTCAAGCCAAACGAAG HindIII 
D-USF GCTGTACACTCGGCAATGGCTGGAAA BsrgI 2452bp US 
MT3804 including 
a 110bp flank  D-USR GCACTAGTCACTTGGGCGGTAACGATTT SpeI 
D-DSF GCACTAGTGACCGATGAAGCCGGTGACT SpeI 2521bp DS 
MT3804 including 
a 46bp flank D-DSR GCAAGCTTGCATAACGGCACGGTGTACC HindIII 
E-USF GCTGTACAACCAACGGTGAATGGCAAGACTTC BsrgI 2444bp US 
MT3803 including 
a 100bp flank E-USR GCACTAGTCCGCGCTGTCCAGG SpeI 
E-DSF GCACTAGTACAACACCGCCGATGACCT SpeI 2367bp DS 
MT3803 including 
a 59bp flank E-DSR GCAAGCTTGCGCATACATCAGATGCTAACTCG HindIII 
mshA-




a 40bp flank 
mshA-
USR GCACTAGTCGATCAACCCTGAACCGT SpeI 
mshA-
DSF GCACTAGTTGATATCGGACCTGGTAGCG SpeI 2532bp DS 
MT0504 including 
a 68bp flank 
mshA-
SR GCAAGCTTTTCACATGCTGTTTGGCA HindIII 
HF ACTAGTTCAGGCGCCGGG SpeI 
1608bp HR ACTAGTCCGCTGGTAGCGGT SpeI 
 
Screening 





A-SR1 GCGATCATCGTCGGCCCCAA NA 
A-SR2 TGATCACCATCGCGAACA NA 
B-SF GCGGGTACCGACTGAACTCA NA Set1: WT= 504bp 




B-SR1 CTGTCGCCGTCTTCAGGTAGA NA 
B-SR2 GAATGGCACCGTCGAAGAAG NA 
C-SF TTCGTCCCGATGGTCTATGA NA Set1: WT=562bp; 
∆egtC=0bp 
Set2: WT=1128bp 
C-SR1 GATTCGGCCGCCGGGCC NA 
C-SR2 AACTCGACCAAAGTATCGGC NA 














D-SR1 GGGCGTGAGGTTGCCGA NA 
D-SR2 GAAACTCTGGCGCGAACA NA 
E-SF GGTGACTTTGGCCTGTCGCT NA Set 1:WT=861and 
∆egtE= 0bp 
Set2: WT= 1782bp 
and ∆egtE=1782-
996= 786bp 
E-SR1 ACTCGCGCAGCTACATTG NA 
E-SR2 CGCCGAACTGTCATTGGCCC NA 
MshA-
SF1 ATCAGCAAGCCAAGGAGC NA 
WT=0bp ∆mshA, or 
∆egtB/mshA=507bp 
MshA-
SR1 TCTCTCCGGCTTCACCGATCC NA 
MshA-




SR2 CCGAAACATTCCGATTGG NA 
Complemention-1 
PF AAGCTTCGCTATTACCACCACGGCA Hind III 1093bp promoter 
region and  
MT3807 yield 
2392bp A-GR AAGCTTTCACGACGCCCCGTGCATCA Hind III 
B-PR GGTGAAGTCACATCACGATCCCTCC NA Fusion of MT3806 
to promoter 
(1093bp) to yield 
2377bp 
B-GF TCGTGATGTGACTTCACCCGAGC NA 
B-GR AAGCTTTCAGATGTCCCACGCCA Hind III 





C-GF TCGTGATATGTGTCGTCACCTG NA 
C-GR AAGCTTTCATCGAGGTCCTTTCGCGC Hind III 




D-GF TCGTGATATGAGAGTGTCGGTTG NA 
D-GR AAGCTTTCACTTGGCGGCCAGCGACA Hind III 
E-PR TTCTCCTCATATCACGATCCCTCCG NA Fusion of MT3803 
to promoter (1093) 
to yield 2272bp 
E-GF TCGTGATATGAGGAGAAGCGGCGCAAAC NA 
E-GR AAGCTTCTAACGTTCGCCGCTGGTCG Hind III 
mshA-
CF AAGCTTGGGACAACTCTAATAAACG Hind III 3536bp (from 
1575US MT0504 to 
547DS MT0504 
mshA-
CR AAGCTTCTAACCGCCCAACTCCTTC Hind III 
Complementation-3A 
AF AAGCTTAGAAGGAGAAGTACCGATGACGCTTGCCGCCATGAC Hind III egtA (Rv3704, 
MT3807) AR GCATCGATTCACGACGCCCCGTGCATC ClaI 
BF AAGCTTAGAAGGAGAAGTACCGGTGACTTCACCCGAGCAGCT HindIII egtB (Rv3703, 
MT3806) BR GCATCGATTCAGATGTCCCACGCCAACC ClaI 
CF AAGCTTAGAAGGAGAAGTACCGATGTGTCGTCACCTGGGGTG HindIII egtC (Rv3702, 
MT3805) CR GCATCGATTCATCGAGGTCCTTTCGCGC  
DF AAGCTTAGAAGGAGAAGTACCGATGAGAGTGTCGGTTGCCAAC HindIII egtD 
(Rv3701,MT3804) DR GCATCGATTCACTTGGCGGCCAGCGACAG ClaI 
EF AAGCTTAGAAGGAGAAGTACCGATGAGGAGAAGCGGCGCAAAC HindIII egtE (Rv3700, 
MT3803) ER GCATCGATCTAACGTTCGCCGCTGGTCG ClaI 
mshAF AAGCTTAGAAGGAGAAGTACCGATGGCAGGTGTGCGGCACGATG Hind III mshA (RV0486, 
MT0504) mshAR GCGTTAACTCACGCGCCCACCCCGCGAC HpaI 
A Optimized Shine-Dalgarno sequence [175] , underlined are the restriction sites 
 
 


















p2NIL plasmid and the PacI fragment of pGOAL17 carrying a 
2451 bp upstream fragment and a 2462 bp downstream 





P2NIL plasmid and the PacI fragment of pGOAL17 carrying a 






p2NIL plasmid and the PacI fragment of pGOAL17 carrying a 






p2NIL plasmid and the PacI fragment of pGOAL17 carrying a 






P2NIL plasmid and the PacI fragment of pGOAL17 carrying a 





p2NIL plasmid and the PacI fragment of pGOAL17 carrying a 
2597 bp US fragment and a 2532 bp DS fragment of mshA 













Mycobacteria integrating vector carrying the hsp60 promoter  
and a kanamycin resistance gene 





pMV306 integrating plasmid carrying MT3806 (Rv3703) joint 







pMV  integrating plasmid carrying MT3805( Rv3702) joint to 







pMV306 integrating plasmid carrying MT3804 (Rv3701) joint 






pMV306 integrating plasmid carrying MT3803 (Rv3700) joint 
to the 1093bp region US MT3807(Rv3704), Kan
r




pMV306 integrating plasmid carrying region from 1545 US to 
547bp DS MT0504 ( Rv0486), Kan
r
  This study 
pMVhspA 
pMV306 integrating plasmid carrying MT3807(Rv3704) cloned 
downstream the hsp60 promoter ,Kan
r
 This study 
pMVhspB 
pMV306 integrating plasmid carrying MT3806(Rv3703) cloned 
downstream the hsp60 promoter ,Kan
r
 This study 
pMVhspC 
pMV306 integrating plasmid carrying MT3805(Rv3702) cloned 
downstream the hsp60 promoter ,Kan
r
 This study 
pMVhspD 
pMV306 integrating plasmid carrying MT3804(Rv3701) cloned 
downstream the hsp60 promoter ,Kan
r
 This study 
pMVhspE 
pMV306 integrating plasmid carrying MT3803(Rv3700) cloned 




pMV306 integrating plasmid carrying (Rv0486,MT0504)cloned 
downstream the hsp60 promoter ,Kan
r
 This study 
pMVOP pMV306 integrating plasmid carrying entire ERG operon This Study 
 
Strains 









Table 2.9 Design of Southern blotting screening of M. tuberculosis mutants 
Strains probe Restriction 
enzyme 
Fragment sizes 
∆egtA  DS fragment of ∆egtA deletion 
construct 
EspI H37Rv = CDC1551=  4569bp, ∆egtA=10265-
1158=9107bp 
∆egtB  US fragment of ∆egtA deletion 
construct 
BamHI H37Rv = CDC1551=  5318bp, ∆egtB=10218-
1105=9113bp 
∆egtC  DS fragment of ∆egtC deletion 
construct 
ApaBI (BstAPI) H37Rv = CDC1551= 4089bp, ∆egtC=12424-
576=11848 
∆egtD  egtC gene from the 
complementation construct 
BclI H37Rv = CDC1551= 2266bp, ∆egtD=7539-
810=6729bp 
 
H37Rv M. tuberculosis laboratory strain 
[102] , kindly 
donated by Catherine 
Vilcheze 
CDC1551 M. tuberculosis clinical laboratory strain 
Kindly donated by 
Adrie Steyn 
∆egtA Derivative of CDC1551 carrying an unmarked deletion of egtA This study 
∆egtB(H37Rv and 
CDC1551) 
Derivatives of CDC1551 and H37Rv carrying an unmarked 
deletion of egtB This study 
∆egtC Derivative of CDC1551 carrying an unmarked deletion of egtC This study 
∆egtD Derivative of CDC1551carrying an unmarked deletion of egtD This study 
∆egtE(H37Rv and 
CDC1551) 
Derivative of CDC1551 and H37Rvcarrying an unmarked 
deletion of egtE This study 
∆mshA,hyg
r Derivative of CDC1551 carrying an marked deletion of mshA This study 
∆egtAattB::pMVA (kan
r
) Derivative of ∆egtA carrying pMVA at the attB site This study 
∆egtApMVhspegtA (kan
r
) Derivative of ∆egtA carrying pMVhspA at the attB site This study 
∆egtB attB::pMVB Derivative of ∆egtB carrying pMVB at the attB site This study 
∆egtBpMVhspegtB (kan
r






) Derivative of mshA/∆egtB carrying pMVhspB at the attB site This study 
∆egtCpMVhspegtC (kan
r





 Derivative of ∆egtD carrying pMVD This study 
∆egtDpMVhspegtD (kan
r
) Derivative of ∆egtD carrying pMVhspD This study 
∆egtE pMVhspegtE (kan
r
) Derivative of ∆egtE carrying pMVhspE This study 
∆mshA attB::pMVmshA Derivative of ∆mshA carrying pMVmshA This study 
∆egtApMV OP (kan
r
) Derivative of ∆egtA carring pMVOP This study 
∆egtBpMV OP (kan
r
) Derivative of ∆egtB carring pMVOP This study 
∆egtDpMV OP (kan
r
) Derivative of ∆egtD carring pMVOP This study 
∆MT1289 (kan
r
) Derivative of CDC1551 carrying a transposon at MT1289 
Kindly donated by  
the BEI resources 
∆MT1953 (kan
r
) Derivative of CDC1551 carrying a transposon at MT1289 
Kindly donated by  
the BEI resources 
[176] 







∆egtE  DS fragment of ∆egtA deletion 
construct 
NcoI H37Rv = CDC1551= 4198bp, ∆egtE=8776-
996=7780bp 
∆mshA US fragment of the ∆mshA 
deletion construct 
ClaI H37Rv = CDC1551=6361bp, ∆mshA=18469-
1335+1608=15526bp 
 
 Generation of complementation strains 
-Generation of the genetically complemented ∆egtD attB::pMV306D and ∆mshA/egtD 
attB::pMV306D 
A complementation vector was generated by amplifying the region from 2398bp upstream 
of egtD to 1169bp downstream of egtD (primers in Table 2.3) using Long PCR 
polymerase (Thermo Scientific) (reaction set up found in Table 2.10,and thermo 
cycling conditions found in Table 2.11) and cloning it at the HindIII site of 
integrating vector pMV306 [174] (Table 2.4). The integrity of the vector was confirmed by 
sequencing (Primers in Table 2.3). 
Table 2.10 Long Polymerase reaction set up 
Components volume 
10X long PCR Buffer (15mM Mgcl2 ) 1X 
2.5mM dNTP 0.25mM 
10µM forward primer 1µM 
10µM Reverse primer 1µM 
5u/µl long polymerase 0.05u/µl 
H20 




Table 2.11 Long Polymerase thermo cycling 
Temperature 
◦
C Time cycle 




59 (0.5 decrease every cycle) 30s 
68 5mins 





68 10mins 1 
4 +∞ 1 
 
-Generation of M.tuberculosis complemented strains 
Different sets of complementation constructs were generated for genes involved in ERG 
biosynthesis. 
Firstly, complementation constructs were generated by amplifying the 1000bp region 
upstream of the ERG operon and fused to each gene of interest by overlap extension PCR 







(Figure 2.3, Table 2.7, Table 2.8 and Table 2.12). This was based on the results obtained on 
http://www.fruitfly.org/seq_tools/promoter.html , which predicts promoter regions. Resulting 
fragments were then cloned to either the Pjet vector (Fermentas), or PgemTeasy (Promega) or 
Pdrive (Qiagen), and subsequently cloned into pMV306hsp [177] which is an integrating 
vector (Table 2.8). The resulting constructs were used to transform the mutants to achieve 
complementation. Due to insert toxicity to E.coli, ∆ egtC complementation constructs were 
redesigned by amplifying instead the 583bp region upstream of the ERG operon and ligated it 
to the gene of interest. The sequence of forward primer in this case was: 
AAGCTTAACTACCGGCGTGCAACA. 
The second complementation construct was designed by amplifying the entire operon from 
the first gene egtA to 100bp DS from egtE (primers are PF and E-GR in Table 2.7) 
The third set of complementation constructs were generated by amplifying each gene and 
cloning it into the HindIII and ClaI sites of the pMV306hsp downstream of the hsp60 
promoter (Table 2.8). 
Two constructs were designed for the complementation of mshA. 
The first construct was designed by cloning the region from 1545 US to 547bp DS mshA to 
the Hind III site of pMV306hsp (Table 2.8). The second construct was designed by cloning 












Figure2.3 Illustration of the Joint PCR technique used to design the complementation constructs 
1: primers flanking the promoter and the gene are designed. Either the reverse primer of the promoter or the 
forward primer of the gene or both is designed with and over hanged  10-40 bases end that is complementary (or 
identical) to the first few bases of the proximity of  the fragment to be ligated. RS: restriction site, the promoter 
forward primer and the gene reverse primer are designed with a specific restriction enzyme site (at the 
extremity), not found in the gene, neither in the promoter but found at the multiple cloning site of the integration 
vector. The probe and the gene are amplified separately. 2: The two products from the previous step are brought 
together in a reaction and allowed to hybridize to each other, and then a polymerase will fill in the gap between 
two hybridized fragments thereby linking them. 3: The resulting joint fragment will be amplified using the 









































Table 2.12 Joint PCR reaction set up 
Step 1: Amplification of the promoter and the gene by Phusion polymerase ( see Table 2.2) 
Step 2 
Reagents Final concentration 
5X Phusion HF or GC buffer 1X 
2.5mM dNTPs 0.25mM 
Amplified promoter product ≤200ng 
Amplified gene product ≤200ng 
Phusion polymerase 0.025u 
H2O Up to 40ul 
Thermo-cycling 98
◦
C for 1mins and 60
◦
C for 10mins 
Step 3 
Total reaction product above 40µl 
Forward primer of the promoter 0.4µM 
Reverse primer of the gene 0.4µM 
5X Phusion HF or GC buffer 0.2X 
Phusion polymerase 0.025u 
H2O Up to 50ul 
Thermo-cycling 
Phusion polymerase thermo-cycling conditions as 
described in Table 2.3 
 
2.3 Genotyping of the mutants 
Southern blotting was performed as previously described [178]. 
 Genotyping of M.smegmatis mutants 
PstI was used to digest the genomic DNA while 6247SBF and 6247SBR primers (Table 2.3) 
were used to amplify the probe of interest that will hybridize to the target genomic region. 
-Genomic DNA extraction 
In order to extract genomic DNA, mycobacteria were allowed to grow on plates until they 
formed a thick layer of cells. These cells were scrapped using sterile loops into tubes 
containing 9ml of the extraction buffer (made up of 5% monosodium glutamic acid, 50mM 
Tris-HCl and 25mM EDTA) and glass beads (5mm diameter) Lysozymes (Roche Diagnostics 
Deutschland GmbH Sandhofer Straße 116; 68305 Mannheim, Germany) and RNaseA 
(Roche) were added to final concentration of 2.8mg/ml and 2.8µg/ml respectively and the 
suspension was vortexed for 2 mins and mixed by inversion every 30 mins at 37°C. A 
volume of 650µl of proteinase buffer and 150ul 10mg/ml proteinase K (Roche, Germany) 
were added in the suspension which was mixed by inversion and incubated at 45°C 
overnight. 
The next day, 2.5ml phenol, 2.4 chloroform and 1ml isoamyl alcohol (Kimix) were added to 
the suspension, which was gently mixed every 30 mins at room temperature for 2 hrs and 
later centrifuged for 20 mins at room temperature at 4000rpm. The top phase was transferred 
into another tube containing 4.8ml chloroform and 200µl isoamyl alcohol. The resulting 







suspension was centrifuged again for another 20 mins. The top phase was transferred into 
another tube containing 600µl sodium acetate. After adding 7ml ice cold isopropanol, the 
precipitated DNA was fished out of the solution using a glass rod. The precipitated DNA was 
immersed in 70% ethanol for 10mins, and then transferred to a clean eppendorf and allowed 
to dry. The resulting DNA was dissolved in nuclease free water or TE (1M Tris-HCl pH 8, 
0.5M EDTA pH 8, Kimix; Unit 1, Shop 4, Ruco Park, Boston Cir, Cape Town, 7490) at room 
temperature overnight. Six micrograms of the genomic DNA was digested with pstI (40000-
60000 U) in a 100µl reaction volume overnight. The digested sample was precipitated: by 
adding 1/10
th
 volume of 3M sodium acetate and 2.5 volumes of ice cold ethanol and 
incubating overnight at -20°C. The next day, the sample was centrifuge at 4°C for 30 mins 
(10000rpm) and the supernatant discarded. Then the DNA pellet was washed with 500µl of 
70% ice-cold ethanol and centrifuged again for another 30 mins at 4°C (10000rpm). The 
supernatant was discarded again and the DNA pellet was air-dried overnight. 
The next day the pellet was re-suspended in 20µl loading dye containing 0.2ng/µl marker 10 
(Roche, ranging from 938bp to 13900bp) and TE buffer (pH 8.0). A 10µl aliquot of this 
sample was separated on a 0.8% agarose gel using a 1X TAE buffer system (0.4 M Tris 
acetate, 0.001M EDTA) for 3 hours at a voltage of 65mV. 
-Southern transfer of the DNA onto a membrane 
Thereafter the gel was visualised to confirm complete digestion of the DNA. The DNA on the 
gel was thereafter denatured by incubating it for 30 mins at RT in 500ml of a denaturing 
buffer (1.5M NaCl, 0.54M NaOH). After the denaturing buffer was discarded, the gel was 
neutralized for 30 mins in a neutralization buffer (1.5M NaCl and 0.5M Tris-HCl, pH7.5). 
The digested DNA was then transferred onto a positively charged Hybond N1 membrane (GE 
Healthcare, UK) by capillary action according to the manufacturer’s recommendations. 
- Probe labelling, membrane hybridisation and detection  
This was performed with the Amersham ECL Nucleic acid Labelling kit (GE Healthcare, 
UK) according to the manufacturer’s instruction as follows: Approximately 200ng of the 
probe was rendered single stranded by heating it at 100°C for 5mins and snap freezing it for 5 
mins. A volume of 15µl of Gluteraldehyde and 15µl of horse radish peroxidase were added to 
the probe and incubated at 37°C for 10 mins. The labelled probe was added to a plastic bag 
containing the hybridization buffer and the membrane (pre-hybridized at 42°C for at least an 
hour). Hybridization was allowed to occur overnight at 42°C in a water bath incubator. The 
membrane was washed twice in a pre-warmed 42°C wash buffer (36% urea, 0.4% SDS, 0.5X 







SSC). Then the kit detection reagents were added into a plastic bag containing the washed 
membrane. The membrane was then exposed to an X-ray film which was later developed. 
 Genotyping of M.tuberculosis mutants 
Extracted and digested genomic DNA (4-6µg) was separated on a 1% agarose gel, then the 
DNA was depurinated in 250mM HCl for 10 mins at RT then rinsed in dH2O. 
-Soutern transfer of DNA onto the membrane 
Then DNA was denatured by incubating the gel at RT for 30mins in the denaturing buffer 
(0.5MNaOH, 1.5mNaCl) and neutralised in the neutralization buffer (0.5MTris/HCl Ph7.5, 
1.5MNaCl) for another 30mins. Southern transfer was performed using the positively charged 
nylon membranes (Roche Diagnostic GmbH Mannheim, Germany) overnight in 20XSSC 
(3M NaCl, 300mM sodium citrate, pH 7). The membranes were washed in 2X SSC the next 
day and baked for 2hrs at 80
◦
C between 2 Wattman papers.  
-Probe labelling 
The DIG High Prime DNA labelling and detection kit II and the DIG wash and block Buffer 
set (Roche) were used for the labelling of the probe. An amount of 150-200ng of probe DNA 
was denatured at 100
◦
C for 10mins and snapped cooled on ice for 5mins and then was added 
in 1X DIG High prime and incubated for 24-48hr at 37
◦
C for the labelling reaction to occur. 
The reaction was stopped at 65
◦
C for 10mins.  
-Prehybridization and hybridization of the membrane 
The membranes were pre-hybridized at 65
◦
C for 30-60mins (optimal hybridization 
temperature is equal to the melting temperature of the probes minus forty two) in the pre-
hybridization buffer supplied with the detection kit in a shaking water bath. Then the 
individual denatured probes were added in the hybridization buffer of each membrane that 
was preheated at 65
◦
C. The pre-hybridization buffer was replaced with the individual 
hybridization buffers and the sealed membranes were incubated at 65
◦
C overnight without air 
bubbles. Then next day, the membranes were washed in a high stringency buffer 
(2XSSC/0.1%SDS) preheated to 65
◦
C at RT for 5mins twice, then in a preheated low 
stringency buffer (0.5XSSC/0.1%SDS) twice for 15mins at 65
◦
C in a shaking water bath. 
Then the membranes were incubated with shaking at RT for 2 mins in 1X maleate buffer, 
then for 30mins to 3hr in the blocking solution. The membranes were then incubated for 
30mins in the blocking solution containing the specific antibody, washed twice in 1X 
washing buffer at RT for 15mins and then equilibrated with the detection buffer for 3mins. 
-Detection 







Finally each membrane was placed in hybridization bags, 1-3ml CSPD (chemiluminescent 
substrate for alkaline phosphatase) was applied to each membrane, air bubbles were removed 
and the membranes were heat sealed in the bag. Following, incubation at RT for 5mins, 
excess fluid was removed, and the membrane were sealed again and these were incubated at 
37
◦
C for 10mins. The bands were then detected by the ChemiDoc™ MP System (BioRad; 
2000 Alfred Nobel Drive, Hercules, California 94547, USA). 
2.4 Drug susceptibility testing of mutants 
This was achieved by the broth micro-dilution assay. A two-fold serial dilution of the drug 
was performed across a V-bottom 96 well plate (Cellstar
®
 Greiner Bio-One GmbH) in a 
volume of 50µl.  An equal volume of exponential mycobacterial culture diluted to 10
4
 
CFU/ml was aliquoted in every well except the first row of wells, which served as the 
negative control (Figure 2.4). After incubation for 3-4 days for M. smegmatis or 8 days for M. 
tuberculosis, resazurin or alamar blue (Sigma Aldrich; St. Louis, MO, USA) was added in 
every well to a final concentration of 0.001% to determine growth which is indicated by a 
pink coloration (Figure 2.4). Alternatively, growth was assessed visually by looking for a 
white pellet at the bottom of the well. The MIC was reported as the range between the 
concentration of the well where 99% of the growth is inhibited and the well just before it 
(where growth is obvious) (Figure 2.4). Results are representative of 2 to 6 independent 
experiments. 
 
Figure 2.4 Illustration of broth micro-dilution 
Cells of the first two and last two columns except the first row represent positive controls where no drugs were 




















well 2 and well 3 







2.5 Growth curve of mutants 
 Growth curve of M.smegmatis mutants 
All strains were maintained as frozen stocks at -80
◦
C. Frozen stocks were used to inoculate 
10ml (M. smegmatis) of starter cultures which were incubated overnight in a shaking 
incubator at 37
◦
C. These were then sub-cultured in 200ml of culture media to an OD600 
(optical density at 600 nm wavelength) of 0.05. The subcultures were incubated in sterile 1L 
Erlenmeyer flasks in a shaking incubator at 37
◦
C for approximately 48 hours. Every 3 hours, 
a 500µl aliquot of each culture was taken and the OD600 measured using a spectrophotometer 
(ULTROSPEC 4051, LKB BIOCHROM LTD, Science park, Cambridge cb4 4bh, England). 
Where appropriate, culture was diluted to obtain a reading below 1 in order to be within the 
concentration range that will give a reliable reading. 
 Growth curve of M. tuberculosis mutants 
Frozen stocks of each strain were used to inoculate ~5ml of a starter culture that was 
incubated at 37
◦
C for approximately 7 days in tissue culture flasks. A 35ml of culture was 
then inoculated to a starting OD600 of ~0.05. The OD600 was recorded every second day for a 
period of 25 days. Results are representative of 3 independent experiments. 
Chemical complementation of the mutants was achieved by supplementing the culture media 
of the mutants with ERG to a final concentration of ~1mg/ml. Results are representative of 3 
independent experiments for all tested mutants except ∆egtD which is represented by 2 
independent experiments because the third biological replicate got contaminated before it 
entered stationary phase. 
We also evaluated the growth rate of each mutant using the MGIT (mycobacterial growth 
indicator tubes) system. Tubes containing BBL MGIT medium (Becton, Dickinson and 
Company) were supplemented with 800µl OADC and 100µl (103-104) of diluted cultures 
were added to each vial and growth was monitored by the MGIT fluorescence reader. This 
experiment was repeated nine times. 
2.6 Oxidative, acidic and nitrosative stress susceptibility testing of mutants 
 Testing of M.smegmatis mutants 
M. smegmatis was grown to an OD600 of 1 and exposed to 2mM, 0.6 mM of Luperox® Tert-
Butyl hydroperoxide (TBHP, 70% in water, Sigma Aldrich) and Cumene hydroperoxide 
(CuOOH in DMSO, Sigma Aldrich) respectively for 2 hours. Cell viability was assessed by 
colony forming unit (CFU) counts before and after exposure to oxidative stress. 







To assess response to nitrosative stress, mycobacteria were grown to an OD600 of 0.5 and 
exposed to 5mM Diethylaminetriamine nitric oxide adduct (DETA/NO, Sigma Aldrich) for 3 
hours, and CFU counts were assessed before and after exposure. 
 Testing of M. tuberculosis mutants 
Exponentially growing mycobacterial cultures were washed in phosphate buffered saline 
(PBS, Sigma Aldrich). The washed cultures were used to inoculate 5ml of acidified PBS 
(pH~4.5, prepared fresh for every experiment) to an OD600 of ~0.2-0.3. Each culture was 
serially diluted and plated on the day of exposure, the third day and the fifth day [191][193]. 
The percentage survival was evaluated as the CFU of each time point divided by the initial 
CFU multiply by 100. Results are representative of 3 to 4 independent experiments. 
On the other hand, early to mid-exponential mycobacteria were washed in PBS and re-
inoculated in PBS to an OD600 of ~0.2-0.3 and exposed to either 1mM DETA-NO [194], to 
1mM CuOOH or 500µM pyrogallol (PRG). Cultures were serially diluted and plated before 
exposure, 24 and 48 hours after exposure. 
2.7 SDS-PAGE analysis of the mutants 
Mycobacteria were grown on 7H11 agar plates for 9 days. Cells were scraped off the plates 
and re-suspended in Middlebrook 7H9 liquid medium. The suspension was centrifuged and 
the pellet re-suspended in cold (4°C) lysis buffer (10mM Tris-HCL, 0.1% Tween-80 and 
complete protease inhibitor cocktail). Cells were homogenized using the FastPrep-24 (MP 
Biomedicals, LLC; 3 Hutton Center Drive; Suite 100; Santa Ana, CA92707 USA) (6m/s) in 
tubes containing 0.1mm beads (Biospec Products Inc; Bartlesville, UK) 6 times for 20 
seconds, with 1 minute intermittent cooling steps on ice [179]. Total protein was quantified 
using the RCDC protein assay kit (Bio-Rad Laboratories, Hercules, CA 94547) according to 
the manufacturer’s instructions. Five micograms of total protein from each strain was treated 
with 2-mercaptoethanol and SDS and separated on an SDS-PAGE gel containing of 4% 
stacking gel (0.124 M Tris-HCl, 0.1%SDS, 0.05% Ammonium persulfate, 0.09% TEMED 
(N,N,N-,N-tetramethylethylenediamine) , 4% Acrylamide, 0.1% Bis-acrylamide) and 15% 
separating gel (0.375 M Tris-HCl, 0.1%SDS, 15% Acrylamide, 0.375% Bis-acrylamide, 
0.05% ammonium persulfate, 0.581M TEMED). The running buffer (pH~8.3) contained 
25mM Tris, 192mM glycine and 0.1% SDS. Bands were visualized with the aid of the 
Coomassie brilliant blue (CBB) solution  (2.5% CBB, 45% methanol, 10% acetic acid) and 
the identity of the 15KDa MSMEG_0447 (Ohr) was confirmed by mass spectrometry using 







the Thermo Scientific EASY-nLC II connected to a LTQ Orbitrap Velos mass spectrometer 























































CHAPTER 3: THE ROLE OF 
ERGOTHIONEINE IN Mycobacterium 
smegmatis 
The aim of this study was to evaluate the role of ERG in a non-pathogenic mycobacterium 
which is a well-documented model for M. tuberculosis research. This study has been 
published in the Journal Of Antimicrobial Agent And Chemotherapy; see reference [99]. 
Mycobaterium smegmatis is a fast-growing mycobacteria closely related to M. tuberculosis. 
Since M. smegmatis is non-pathogenic (does not require a biosafety level 3 laboratory) and 
grows faster than M. tuberculosis (doubling time 3hrs versus 24hrs), it is often used as the 
model organism for studying mycobacterial physiology [180, 181].  In this study we aimed to 
evaluate the role of ERG in mycobacteria by generating strains of M. smegmatis deficient in 
ERG alone or both ERG and MSH.  
The enzyme EgtD catalyses the methylation of histidine in ERG biosynthesis (Figure 1.8). 
The gene coding for that enzyme (egtD) was deleted in the wild type mc
2
155 and the MSH- 
deficient mutant ∆mshA by two-step allelic exchange mutagenesis. The susceptibility of the 
mutants to oxidative stress, nitrosative stress and antibiotics was subsequently evaluated. In 
addition, ERG secretion was investigated by liquid chromatography tandem mass 
spectrometry (LC-MS) and flow cytometry. 
Our first aim in this study was to prove that EgtD is essential for ERG biosynthesis 
Our second aim was to show that ERG protects M. smegmatis from toxic compounds, ROS 
and NOS. 
It has been discussed in the previous chapter that ERG redox potential is lower than that of 
many other thiols. This makes it more stable and therefore do not require enzymatic recycling 
as other thiols. Therefore it is more likely to be found extracellularly.  











3.1 M. smegmatis secretes ERG 
Investigation of extracellular ERG was prompted by a previous observation that ERG was 
detected in the buffer fluid surrounding resting cell preparations of M. smegmatis [157]. ERG 
was detected both in the culture media and in the cell lysate of M. smegmatis at the three time 
points investigated (Table 3.1).  
Legend: IE: intracellular ERG, EE: extracellular ERG, the majority of ERG is extracellular and ERG is higher 
in the MSH-deficient mutant, data representative of 3 biological replicates 
Furthermore, the percentage of extracellular ERG was significantly higher than intracellular 
ERG at all three time points. In order to confirm that the ERG detected in the media was not 
due to leakage from cells with disrupted cell membranes, the membrane integrity of the cells 
within the population was determined by flow cytometry (Figure 3.1). 
 
Figure 3.1Characterization of M. smegmatis membrane integrity by flow cytometry  
UT: untreated sample. HT: heat treated sample, DC: dead cells, CD/BN: cellular debris and background noise, 
LCDM: live cells with damaged membrane, LCIM: live cells with intact membrane, HT+UT: mixture of an 
Table 3.1 Ergothioneine concentration (pg per 105 CFU) in mc2155 and ∆mshA 
 
Strain 
OD600 ~0.5 OD600 ~1 OD600 >2 
IE EE IE EE IE EE 
mc
2
155 4.07±0.66 17.03±3.5 1.74±0.30 7.6±1.45 0.83±0.80 12.66±2.65 
∆mshA 7.50±3.5 44.30±4.0 6.3±2.61 39 ±10.5 1.62±0.48 37.61±2.55 







equal ratio of the UT and HT samples. The program Flowjo (version 6) was used to analyse the population 
distribution of mycobacteria, which was represented by a pseudocolor plot. Using automatic and manual gating 
options, we could count the number of events per population and therefore estimate the representative 
percentage of each population.  When the untreated sample was stained with SYTO-9 and propidium iodide 
(PI), the analyses indicated that an average of 92% of the population is LCIM, while 3.7% is LCDM and 4.5% 
are DC. In the heat treated sample, an average of 99% of the population was indicated to be dead, while 0.5 % 
was LCDM and 0.3% was LCIM. When an equal amount of the treated (HT) and untreated (UT) cells were 
mixed, 67% of the population was indicated as dead, while 27% was LCIM and 27% was LCDM. This shows 
that this technique was sensitive enough to detect cells with damaged membranes even in a population mixture, 
implicating consistency of the result showing that in an actively growing wild type M. smegmatis culture of OD 
600 ~0.5, the membrane integrity of ~92% of the cells is still intact (Table 3.2). 
Dual nucleic acid staining was performed using the membrane permeable dye SYTO-9 and 
the non-permeable propidium iodide (PI), that is able to enter cells and displace SYTO-9 only 
when the membrane is damaged [182]. Cells were gated into three populations corresponding 
to their membrane integrity on the basis of PI and SYTO-9 intensities. Cells with the highest 
PI fluorescence and the lowest SYTO-9 fluorescence represent dead cells (DC) in the 
population, and heat treatment of M. smegmatis results in 99% of the cells gating into this 
subpopulation. The population with the lowest PI fluorescence and the highest SYTO-9 
fluorescence represent living cells with intact membranes (LCIM), and this was absent 
following heat treatment of M. smegmatis. A third intermediate population was observed, and 
is thought to represent cells in the population which are live but have damaged membranes 
(LCDM), as described previously [161] (Figure 3.1).  
Analysis of M. smegmatis grown to an OD600 ~ 0.5, 1 and >2 revealed that approximately 
92%, 87% and 86% of the culture population was made of LCIM respectively, while the 
minority was made of the population of LCDM and DC (Table 3.2). 
Table 3.2 Estimation of the different mycobacterial population in mc2155 culture at different growth stage  by 
Flow cytometry 
OD600 DC (%) LCDM (%) LCIM (%) 
~0.5 4.5±5.2 3.7±2 92±4.5 
~1 2.6±0.84 10.1±2.17 87.22±2.06 
>2 2.5±1.6 11.2±2.5 86.3±4.02 
The majority of cells have an intact membrane during every growth stage; data are representative of 3 biological 
replicates 
 
To further confirm the membrane integrity of the cells within the population, the culture 
medium was assayed for MSH, which is not normally present extracellularly [91, 183]. MSH 
was analysed by LC-ESI-HRMS in the cell lysate of wild-type M. smegmatis as previously 
described (Figure 3.2 A&B) [158].  








Figure 3. 2 Detection of mycothiol in M. smegmatis 
Figure 3.2A: The ESI negative mass spectrum (of the peak at 3.87 min; Figure 3.2B) of the cell lysate of the 
wild type. Analysis was performed using LC-ESI-HRMS.  Accurate mass measurement (m/z 485.1444) was 
performed within 0.6 ppm of the calculated exact mass (m/z 485.1441) of the deprotonated mycothiol ion 
[158], which strongly indicates the presence of mycothiol. Figure 3.2B, 3.2C, and 3.2D: The extracted ion 
chromatograms at m/z 485.144. Mycothiol was detected (retention time of 3.87 min) of the cell lysate of the 
wild type (Figure 3.2B), but not in its culture media (Figure 3.2C). As a negative control the cell lysate of the 
∆mshA mutant was analysed (Figure 3.2D). 
The identity of the ion was verified by its absence in the ΔmshA mutant, which is MSH-
deficient (Figure 3.2 D). No MSH was detected in the culture media from wild-type M. 
smegmatis (Figure 3.2 C), supporting the flow cytometry data. Therefore, while a small 
percentage of ERG present in the media may originate from cells with disrupted membranes, 





























































mycothiol_121101_4 Sm (Mn, 3x2) 1: TOF MS ES- 
485.14 0.2000Da
61.3
mycothiol_121101_3 Sm (Mn, 3x2) 1: TOF MS ES- 
485.14 0.2000Da
61.3
mycothiol_121101_2 Sm (Mn, 3x2) 1: TOF MS ES- 
485.14 0.2000Da
61.3



















































media whilst the majority of cells display an intact membrane (~90% at OD600 0.5 and 1), 
implies that ERG is secreted by M. smegmatis. 
ERG exists as a thione in solution at neutral pH, and as a result it is relatively resistant to 
oxidation [184]. It is therefore better suited to function extracellularly than MSH, since it 
does not require an enzyme to maintain it in the reduced form [132]. While MSH is not 
detected extracellularly, a study utilizing MSH-deficient mutants demonstrated that M. 
smegmatis is able to actively transport MSH into cells [183] and MSMEG_1642 was 
proposed as a possible MSH transporter. Since ERG is unable to diffuse across membranes 
[128, 185], an ERG transporter would also be required in M. smegmatis. In humans the 
OCTN1 transporter is required for ERG transport into cells and involves co-transport of Na
+
 
[128]. This leads us to speculate that the ERG transporter in mycobacteria may be a member 




 translocating F-type, V-type 
and A-type ATPase superfamily, which both utilise Na
+
 as a substrate [186]. Since ERG has 
anti-inflammatory properties [141], the potential secretion of this molecule by M. 
tuberculosis may play a role in modulating the immune response by the host during infection 
and therefore warrants further investigation.  
A previous study found that the ERG concentration is higher in the MSH-deficient mutant of 
M. smegmatis, suggesting that ERG compensates for the loss of MSH in this organism [100]. 
Our analysis revealed a similar trend with a 2-5 fold increase in intracellular and extracellular 
ERG levels observed for the ∆mshA M. smegmatis mutant (Table 3.1), which appears to be 
lower than was previously reported, but this may be due to the different methods for thiol 
quantification. The previous study used a method based on the HPLC separation and 
fluorescent detection of thiols conjugated to monobromobimane (mBBr) [187, 188], whereas 
we used UPLC-ESI-MS/MS to quantify ERG. 
3.2 EgtD is essential for ERG biosynthesis 




and ∆mshA M. smegmatis mutant. The 
genotype of the mutants was confirmed by colony PCR (Figure 3.3), and by Southern blotting 
(Figure 3.4). 








Figure 3.3 Colony PCR of the ∆egtD mutant 
A: Map indicating the fragment sizes expected after PCR screening to confirm deletion of egtD (F: forward 
primer, R: reverse primer, US: upstream region, DS: downstream region); B: PCR screening of egtD deletion, 
WT: wild type band 297bp, SCO: single cross over; consists of the wild type band 297bp and the mutant band 































Figure 3.4 Validation of egtD deletion by Southern blotting 
Southern blotting of digested genomic DNA of the different strain was performed as previously 
described [178] 
A: Restriction map of the wild-type and mutant strains. PstI cuts within egtD and on the a the 
downstream region in the wild type strain, while in the mutant strain PstI cuts within the cloned DS 
region and outside the cloned US region to rule out illegitimate homologous recombination.   
B: Southern blotting of the fragment restricted by PstI, the band (2116bp) in the first and second 
lanes represents the wild type and the ∆mshA mutant which have an intact egtD gene, while the 
7057bp for ∆mshA/ΔegtD and ∆egtD strains indicates the deletion of egtD and the loss of the PstI 
site. 
Our primary concern when targeting egtD was the potential compensation by other 
methyltransferases found in mycobacteria [189]. However when EgtD was blasted against M. 
tuberculosis proteome, very few proteins share similarities with it, and the percentage 
coverage and similarity is lower than 50%. Indicating already that EgtD-deficiency may not 
be compensated for. In addition, it was shown that EgtD as opposed to other 
methyltransferase, is highly specific to histidine, N-monomethylhistidine and N, N-
dimethylhistidine [155]. It does not bind to other substrates indicating how important is EgtD 
for ERG biosynthesis. And we could show as well in this study that EgtD is indeed essential 
for ERG biosynthesis since the EgtD-deficient mutants lack ERG as well. Loss of ERG 
biosynthesis in the ΔegtD single and ∆mshA/ΔegtD double mutants and restoration of ERG 




































   














   






   






   





















*∆egtDc: complemented ∆egtD, ∆mshA/egtDc: ∆mshA/egtD where egtD has been complemented; data are 
representative of three biological replicates 
 
It was previously indicated that the ΔmshA mutant has a longer lag phase, however no growth 
deffect was associated with the deletion of egtD in the wild-type strain (Figure 3.5); and the 
extended lag phase [107] and sensitivity to the inoculum size [100] observed previously for 
the ΔmshA mutant, was slightly exacerbated by the loss of ERG in this mutant.  
 
 
Figure 3. 5 Growth curves of M. smegmatis strains 
Starter cultures were used to inoculate main cultures to an OD600 of 0.05, and growth was monitored by OD600 
readings every 3 hours for ~48hours 
Since the ERG level in the ΔmshA mutant is elevated relative to the wild type strain, we 
compared the level of MSH in the ERG-deficient single mutant and the wild type via LC-
ESI-HRMS. Relative comparison of the MSH peak area revealed no significant difference in 
the MSH levels between the two strains (Table 3.4, Figure 3.6). Therefore, while the ERG 
level is elevated in the MSH-deficient mutant, the MSH level is unchanged in the ERG-
deficient mutant. This implies that the wild type MSH level may be adequate to compensate 
for the loss of intracellular ERG or that compensation occurs by another mechanism or there 
is no compensation. 
         growth curves of M.smegmtis strains
















Table 3.3 ERG concentration (pg/105 CFU) in M. smegmatis mutants at OD600~ 1 
Fraction mc
2
155 ∆mshA ∆egtD ∆mshA/egtD ∆egtDc* ΔmshA/egtDc* 
Intracellular 1.74±0.3 6.3±2.6 0 0 0.88±0.3 2.2±0.5 
Extracellular 7.6±1.5 39±10.5 0 0 4.3±2 16±5.1 








Table 3.4 Relative abundance of MSH expressed by the peak area of the extracted ion chromatogram m/z 485. 
mc
2
155 398.55  ± 19.36 
∆egtD 458.86 ± 23.04 




Figure 3.6 Relative quantification of mycothiol by LC-ESI-HRMS 
Figure 2.8A: The ESI negative mass spectrum (of the peak at 3.87 min) of the cell lysate of the wild type and of 
the ERG-deficient single mutant. Figure 2.8B: The extracted ion chromatograms at m/z 485.144.of the cell 
lysate of the wild type and of the ERG-deficient single mutant  
3.3 ERG does not protect M. smegmatis from antibiotics 
In order to determine whether the absence of ERG in M. smegmatis alters its sensitivity to 
antibiotics, we investigated the susceptibility of the different strains to antibiotics by a broth 
micro-dilution method [190]. Besides a slight ethionamide resistance in the ERG-deficient 
mutants, the susceptibility of the ∆egtD mutant and the ΔmshA/ΔegtD mutant to isoniazid, 
ethambutol and kanamycin did not differ significantly from their respective parental strains 















Table 3.5 Anti-tuberculosis drugs MIC (µg/ml) of M. smegmatis strains  
Strains Kanamycin Isoniazid Ethionamide Rifampicin Ethambutol 
mc
2
155 0.5-1 5-20 12.5-25 0.3-0.6 0.4-0.75 
∆mshA ND 312-625 375-400 0.3-0.6 0.4-0.75 
∆egtD 0.5-1 5-20 25-50 0.3-0.6 0.4-0.75 
∆egtDc ND ND 12.5-25 ND ND 
∆mshA/ΔegtD ND 312-625 400-425 0.3-0.6 0.4-0.75 
Legend: ND: not determined; ERG deficiency do not affect mycobacteria deficiency to current anti-tuberculosis 
drugs; data are representative of three biological replicates 
3.4 ERG protects M. smegmatis from oxidative stress 
A marginal increase in susceptibility to TBHP and CuOOH was observed for both the ∆mshA 
and the ∆egtD single mutants, while a distinct increase in susceptibility was observed for the 



























Figure 3.7 Survival of M. smegmatis mutants during in vitro oxidative stress  
Mycobacteria were grown to the exponential phase and exposed to oxidative stress generated by either 2mM 
TBHP or 0.6mM CuOOH. The data were analysed by using GraphPad Prism version 5.01 and are represented as 
means with standard errors of the means. Two-way analysis of variance followed by a Bonferroni test was 
performed. The double mutant (∆mshA egtD) was more sensitive to oxidative stress than any other strain used in 
this study, it was significantly (p<0.01) sensitive to oxidative stress generated by CuOOH (bottom panel) 
relative to the wild type and the ∆egtD mutant. The same trend was observed when bacteria were exposed to 
TBHP (top panel, p>0.05). 
This demonstrates that both ERG and MSH are involved in protecting M. smegmatis against 
peroxide, and that the loss of either low molecular weight thiol is potentially compensated for 
by the presence of the other. This compensation appears, at least in the MSH-deficient 
mutant, to involve increasing the amount of the remaining thiol molecule [100]. A previous 
study demonstrated that MSMEG_0447, annotated as Ohr (organic hydroperoxide resistance 
protein) is highly induced in the ∆mshA mutant, and that over-expression of Ohr in M. 
smegmatis increases resistance to CuOOH [100]. We therefore investigated the Ohr 


























Figure 3. 8 SDS PAGE of M. smegmatis cell extract 
The different M. smegmatis strains were grown on 7H11 solid culture for 11 days, and proteins were extracted 
and analysed as previously described [100, 179]. Relative intensities of protein fragment bands at 15KDa 
between the different strains were determined using the UN-SCAN-IT automated digitizing system (V 5.1, Silk 
Scientific Corporation) and showed at least a 7-fold increase in band intensity in the ∆mshA and ∆mshA/egtD 
mutants. A similar banding pattern was observed when mycobacteria were grown in liquid culture to an 
OD600~0.8 (Figure not shown). The identity of the 15KDa fragment was revealed to be MSMEG_0447 (Ohr) by 
mass spectrometry using the Thermo Scientific EASY-nLC II connected to a LTQ Orbitrap Velos mass 
spectrometer (Thermo Scientific, Bremen, Germany). Quantification revealed a slight increase in the expression 
of Ohr in the MSH/ERG-deficient double mutant relative to the MSH-deficient single mutant. As was shown 
previously, Ohr is over-expressed in the mshA M. smegmatis mutant, but Ohr remained over-expressed in this 
same strain even when egtD was deleted. The wild type and ∆egtD mutant do not exhibit an over-expression of 
Ohr.  
Ohr expression was elevated in the ∆mshA and ∆mshA/egtD mutants relative to the wild type 
strain and ∆egtD mutant. This indicates that the Ohr expression level is not influenced by the 
loss of ERG. In addition, the increased sensitivity of the ERG/MSH-deficient double mutant 
to peroxides, despite the elevated Ohr level suggests that ERG also plays a role in protecting 
M. smegmatis against peroxide. Despite the increased sensitivity of the MSH-deficient M. 
tuberculosis ΔmshA mutant to oxidative stress, it survives during the mouse-model of 
infection [102]. Considering the fact that M. smegmatis Ohr has no homolog in M. 
tuberculosis [100], we speculate that ERG may compensate for the loss of MSH in this 
































mouse model is potentially due to compensation by ERG; however this remains to be 
demonstrated. 
3.5 ERG does not protect M. smegmatis from nitrosative stress 
The sensitivity of ERG-deficient mutants to nitrosative stress was not different to their parent 
strains (Figure 3.9). MSH-deficient mutants were slightly resistant to nitrosative stress 
generated by DETE/NO. A previous study showed that MSH-deficient mutants were not 
sensitive to nitrosative stress generated by sodium nitrite in a broth dilution assay [108], 
while another study demonstrated that MSH-deficient mutants were sensitive to nitrosative 
stress generated by a gaseous nitric oxide donor [106]. This therefore indicates that, the 
susceptibility of MSH-deficient M. smegmatis mutants to nitrosative stress is variable, 
depending on the nitric oxide donor, the method and the exposure time. However these 
variables were not optimized in this study. 



















Figure3.9 Survival of M. smegmatis strains to nitrosative stress generated by DETA/NO 
Strains were grown to an early log phase (OD600~0.5) and exposed to nitrosative stress for 3 hours. Results are 
representative of at least 2 biological replicates. The data were analysed by using GraphPad Prism version 5.01 
and are represented as means with standard errors of the means. Two-way analysis of variance followed by a 
Bonferroni test was performed. Mycothiol deficient mutants (∆mshA, ∆mshA/egtD) were slightly resistant to 
nitrosative stress (P<0.05). 
3.6 Conclusion  
The protective role of ERG in eukaryotes has been well documented [150]. However, little is 
known of its role in microorganisms. Its anti-oxidative role was reported in fungi [145] and in 
bacteria [144]. However in M. smegmatis it was reported that the MSH-deficient mutants 
produce more ERG [100], and then we demonstrated that ERG protects M. smegmatis from 
oxidative stress [99]. This study investigated the role of ERG in M. smegmatis. In order to 







achieve that, we deleted the gene that code for the enzyme that catalyses the first step of ERG 
biosynthesis (egtD, the methylation of histidine) via a homologous recombination based 
cloning technique. This gene was deleted in a wild type strain of M. smegmatis (mc
2
155) and 
a MSH-deficient mutant strain of M. smegmatis (∆mshA) generating ERG-deficient mutants 
(Table 3.3). This indicates that the enzyme EgtD is essential for ERG biosynthesis in M. 
smegmatis, and that it cannot be compensated for by any other enzyme. 
The susceptibility of the ERG-deficient mutants to antibiotics was evaluated, and no 
significant change in the susceptibility of the mutants was observed (Table 3.5), indicating 
that ERG does not protect M. smegmatis from the antibiotics tested in this study. 
Investigation of the ERG-deficient mutants’ susceptibility to nitrosative stress indicated as 
well that ERG does not protect M. smegmatis from nitrosative stress in the tested conditions 
(Figure 3.9). 
However, the viability of the ERG/MSH-deficient double mutant was significantly affected 
by oxidative stress (Figure 3.7). The investigation of the expression of Ohr in the double 
mutant indicated that it was still up-regulated in this strain (Figure 3.8). Therefore, though 
Ohr may protect MSH-deficient M. smegmatis from oxidative stress as previously shown 
[100], the absence of ERG in this strain renders it more susceptible to oxidative stress, 
indicating the anti-oxidative role of ERG in M. smegmatis. 
In this study we were also able to quantify extracellular ERG by UPLC/MS and could 
demonstrate that the majority (>80%) of biosynthesized ERG was found extracellular (Table 
3.1). To rule out a possible leakage from damaged cells as being the reason for an elevated 
extracellular ERG, we investigated the membrane integrity of M. smegmatis cells before ERG 
quantification. We were able to show by flow cytometry that the majority of cells of 
exponentially growing culture of M. smegmatis process an intact membrane (Table 3.2). 
Further, this enabled us to conclude that ERG is secreted by M. smegmatis. 
This study indicates the protective role of ERG in mycobacteria, and has prompted us to 
further investigate its role in M. tuberculosis, the causative agent of tuberculosis aiming to 





































CHAPTER 4: THE ROLE OF 
ERGOTHIONEINE IN M.tuberculosis 
The investigation of the role of ERG in M. smegmatis, detailed in the preceding section, 
revealed that ERG protects M. smegmatis from oxidative stress. Since M. tuberculosis is 
known to encounter oxidative stress within the host [191], ergothioneine biosynthesis may 
represent a novel target for the development of anti-TB drugs. In addition, we observed that 
inhibiting ERG biosynthesis does not affect its susceptibility to the current anti-tuberculosis 
drugs, suggesting compounds targeting this pathway would be compatible with the current 
first line drugs. We therefore sought to further validate ERG biosynthesis as a novel drug 
target by investigating its role in the pathogenic organism M. tuberculosis. This is important 
since M.smegmatis and M. tuberculosis differ in their proteomic and genomic profiles, which 
points to differences in their physiology [148]. 
Approach: 
We have shown that ERG is secreted by M. smegmatis, and ERG secretion was recently also 
reported in Streptomyces coelicolor [159]. We therefore sought to investigate ERG secretion 
in the slow growing mycobacteria M. bovis BCG (Bacille Calmette Guerin), M. tuberculosis 
H37Rv and M. tuberculosis CDC1551 strain. 
In vitro enzymatic assays demonstrated that five enzymes are involved in ERG biosynthesis 
namely EgtA, EgtB, EgtC, EgtD and EgtE [148]. We attempted to evaluate the role of each of 
these enzymes in the production of ERG and in the physiology of M. tuberculosis by 
generating targeted deletion mutants for each gene individually and characterising the 
resulting mutants. In addition, since we have shown in previous studies that ERG 
compensates for MSH in the M. smegmatis ∆mshA mutant [99], we investigated the 
compensatory anti-oxidative role of ERG in M. tuberculosis as well. This was achieved by 
generating a MSH-deficient M. tuberculosis mutant by deleting mshA and an ERG/MSH-
deficient double mutant by deleting egtB and mshA in M. tuberculosis. 
The aims of this study were: 
 To investigate and demonstrate ERG secretion in slow growing mycobacteria. 
 To evaluate the role of each enzyme involved in ERG biosynthesis in the physiology 
of M. tuberculosis and the production of ERG. 







 To investigate the anti-oxidative role of ERG. 
 To determine if ERG and MSH compensate each others. 
 To validate ERG biosynthesis as a potential TB drug target. 
4.1 Slow growing mycobacteria secrete ERG 
Approximately 76% and 58% of ERG is found in the extracellular medium of exponential 
and stationary M. bovis cultures respectively (Table 4.1), while analysis of M. bovis 
membrane integrity indicates that approximately 70% and 58% of cells have intact membrane 
during exponential phase and stationary phase respectively (Table 4.2, Figure 4.1). This 
implies that although a small percentage of extracellular ERG (EE) may result from leakage 
through the membrane of dead cells and live cells with damaged membrane, the majority of 
extracellular M. bovis ERG results from secretion. This was also observed in M. tuberculosis 
H37Rv, as approximately 81 and 90% of ERG was extracellular in exponential and stationary 
M. tuberculosis H37Rv cultures respectively, while analysis of the membrane integrity 
indicated that approximately 91% and 52% of H37Rv cells had intact membrane during 
exponential and stationary phase respectively (Table 4.1, 4.3 and Figure 4.1). As for  M. 
tuberculosis CDC1551 approximately 73% and 15% of ERG was extracellular during 
exponential and stationary phase respectively while the analysis of the membrane integrity 
indicates approximately 91% and 83% of CDC1511 had intact membrane respectively (Table 
4.1 and 4.4). 
Table 4.1 ERG concentration in M.tuberculosis and M. bovis (BCG) in pg/105 CFU 
 
Strains 
OD600 ~1 OD600 >2 
IE EE IE EE 
M. bovis 3.93 ± 0.59 12.02 ± 1.30 10.47 ± 1.72 14.76 ± 1.21 
M. tuberculosis (H37Rv) 4.10 ± 1.94 17.00 ± 3.06 1.82 ± 0.43 17.24 ± 2.69 
M. tuberculosis (CDC1551) 2.63 ± 1.65 7.20 ± 5.63 10.31 ±12.34 1.81 ± 1.37 
∆MT1289 0.75 ± 0.82 3.17 ± 4.49 1.99 ± 2.8 4.60 ± 3.43 
∆MT1953 1.55 ± 0.40 15.42 ± 15.79 0.14 ± 0.10 1.93 ± 1.36 
 
Table 4.2 Subpopulation ratio (%) of BCG cultures analysed by flow cytometry 
 LCDM DC LCIM 
OD600~1 7.91 ± 2.50 30.4 ± 0.87 61.69 ± 2.34 
OD600 >2 6.49 ± 0.37 36 ± 6.10 57.5 ± 5.87 
Heat treated cells 20.27 ± 1.56 60.28 ± 1.70 19.45 ± 1.46 
 








Figure 4.1 Population distribution of M. bovis (first row), M. tuberculosis H37Rv (2
nd
 row) and M. 
tuberculosis CDC 1551 culture (3
rd
 row)                                                    
FlowJo (version 7.6.4 and version 10.07 r2) software (Tree Star, Inc.) was used to visualise and analyse the flow 
cytometric data. Exponential (Figure 4.1A), stationary (Figure 4.1B) and heat treated (Figure 4.1C) M. bovis 
BCG cultures, stained with PI and Syto9, are shown as zebra plots. M. tuberculosis H37Rv and M. tuberculosis 
CDC1551 exponential (Figure 4.1D and 4.1G), stationary (Figure 4.1E and 4.1H) and heat treated cultures 
(Figure 4.1F and I) are shown as pseudo-colour plots. The fluorescence intensities defining the population 
distribution differs between M. tuberculosis and M. bovis since they are different mycobacteria species. A sub-
population with relatively high PI and high Syto 9 intensities was defined as the sub-population of dead cells 
(DC) in M. bovis (Figure 4.1A, B, C) while the sub-population of DC in M. tuberculosis  (H37Rv and CDC 
1551) had a relatively high PI and low Syto 9 intensities (Figure 4.1D, E, F,G,H,I). The M. bovis sub-population 
with a relatively low PI and Syto 9 intensities was defined as live cells with intact membrane (LCIM) while in 
M. tuberculosis the sub-population with a relatively high Syto9 and low PI intensities represent LCIM. The 
intermediate sub-population in both species represents live cells with damaged membrane (LCDM). LCIM 
constitute the major sub-population in exponential M. bovis culture (Figure 4.1A, ~61.69%), exponential M. 
tuberculosis H37Rv culture (Figure 4.1D, 90.85%) and M. tuberculosis CDC1551 (Figure 4.1G, 91.14%) while 
in heat treated cultures LCIM constitute the minority (Figure 4.1C, Figure 4.1F and Figure 4.1I). As opposed to 
M. tuberculosis CDC1551 that has few dead cells, approximately one third of the population is dead during 




































Table 4.3 Subpopulation ratio (%) of H37Rv cultures analysed by flow cytometry  
 LCDM DC LCIM 
OD600~1 3.33 ± 1.70 5.82 ± 0.75 90.85 ± 2.21 
OD600 >2 14.11 ± 1.91 34.21 ± 18.70 51.70 ± 17.4 
Heat treated cells 11.29 ± 1.53 61.57 ± 0.97 27.13 ± 1.70 
 
 
Table 4.4 Subpopulation ratio (%) of CDC1551 cultures analysed by flow cytometry 
 LCDM DC LCIM 
OD600~1 6.35 ± 0.25 2.5 ± 0.5 91.14 ± 0.61 
OD600 >2 9.85 ± 3.95 7.01± 0.90 83.13 ± 4.80 
Heat treated cells 6.83 ± 0.70 60.81 ± 0.73 32.35± 0.57 
 
It was previously shown that M. smegmatis secretes ERG [99], and in this study we could 
show that M. bovis and M. tuberculosis secretes ERG as well. Mycothiol and ERG are the 
only thiols known to be synthesized by mycobacteria. The anti-oxidative role of MSH in 
mycobacteria has been shown. However, MSH cannot be secreted by mycobacteria but can 
be imported [91, 183]. This makes ERG the only thiol known to be secreted by mycobacteria. 
It was previously speculated that MSH constitute the major thiol in actinomycetes [131], but 
subsequent studies revealed that MSH-deficient mutants have a high level of ERG relative to 
the wild type strain [99, 100] and we have shown that ERG is not only found intracellularly 
but also extracellularly making ERG a major thiol in mycobacteria. In addition, the anti-
oxidative role of ERG has been shown in eukaryotes [150], fungi [145] and more recently in 
M. smegmatis [99].This suggests that ERG can play an anti-oxidative role in slow growing 
mycobacteria as well. Therefore ERG may protect mycobacteria from extracellular and 
intracellular oxidative stress as opposed to MSH which plays just an intracellular anti-
oxidative role. Ergothioneine is very stable, resists auto-autoxidation and does not require 
enzymatic recycling [132, 184] and therefore will function more efficiently in the 
extracellular medium than MSH. In addition, it has been shown that M. tuberculosis redox 
homeostasis is highly perturbed when it encounters intracellular oxidative stress leading to 
intracellular damage. Therefore, M. tuberculosis would alleviate the exogenous ROS 
generated by macrophages to prevent influx by secreting ROS detoxifying enzymes (SOD 
and catalase) and ERG [191]. Hence ERG secretion may constitute the primary defence 
mechanism of M. tuberculosis during infection. On the other hand, it was shown that ERG 
could prevent inflammatory response in higher eukaryotes by supressing IL-8 [141]. This 
indicates the ability of ERG to modulate the immune system and therefore suggests a role for 







secreted ERG during infection by M. tuberculosis since this will be able to modulate the 
immune system, which may suit its survival in macrophages. It is worth noting that CDC1551 
membrane integrity indicates that ~ 17% of cells have a damaged membrane during 
stationary growth while only 15% of ERG is extracellular (Table 4.4 and Table 4.1). 
Therefore CDC1551 may not secrete ERG during stationary growth or may secrete a low 
level of ERG during stationary phase. It is tempting to speculate that this may explain why it 
was observed that infection with CDC1551 induced a higher cytokine production (TNF-α, Il-
10, IL-6 and IL-12) relatively to H37Rv [192] and that the high EE in H37Rv hampers the 
immune system by lowering cytokine production making H37Rv more virulent than 
CDC1551 [192].  
In attempt to identify an ERG transporter, ERG was quantified in mutants carrying a 
transposon on a gene coding for an ortholog of OCTN1 (ERG transporter in humans). Four 
transposons mutants were investigated namely ∆MT3434, ∆MT2926, ∆MT1289, ∆MT1953. 
The mutant ∆MT3434 failed to grow, while the level of ERG was unchanged in ∆MT2926 
(data not shown). Though the extracellular level of ERG was still high in ∆MT1289 and 
∆MT1953, the intracellular level of ERG was significantly lower than the wild type level in 
both strains (Table 4.1). This was pronounced in ∆MT1953 as IE during stationary phase of 
this strain was 74-fold lower than the wild type level. The proteins MT1953 and MT1289 are 
both integral component of the membrane. The protein MT1289 (Rv1250) is an 
uncharacterized MFS-type transporter while MT1953 (Rv1902c) known as nanT is a 
hypothetical sugar transporter [59, 193]. The results obtained in this study indicate that these 
proteins may be involved in ERG metabolism, however their specific function is not known 
and further investigation is required. 







 4.2 Ergothioneine biosynthetic genes are not essential in vitro 
The integrity of the allelic exchange substrate of each gene was confirmed by restriction 
enzyme digestion (Figure 4.2). Each substrate was used to transform M. tuberculosis to 
achieve deletion. 
 
Figure 4.2 Restriction map of M. tuberculosis deletion constructs generated in this study 
Constructs were individually digested by PvuII, PstI and EcoRI. Expected bands size are indicated in purple 
The genes egtA, egtB, egtC, egtD, and egtE were successfully deleted individually in 
CDC1551. In addition, mshA was successfully deleted in CDC1551 and in the ∆egtB mutant 
of CDC1551. egtB and egtE were deleted individually in H37Rv as well (Figure 4.3 to Figure 
4.16). This concurs with previous work that indicated that these genes are not essential in 
vitro [194]. Though it was speculated that egtD may have an essential region in M. 
tuberculosis [195], we proved the opposite as the entire gene was deleted in this case except 
for a few bases at the start and the end of the gene. Previous studies speculated that mshA was 
essential [196] as an attempt to delete in the Erdman strain was unsuccessful using the 
specialized transduction method. However, it was later successfully deleted using the same 
method in H37Rv, CDC1551 and the Erdman strain [102]. In this study we successfully 







deleted it in CDC1551 and in the ∆egtB mutant of CDC155 by a homologous recombination 
based method. This indicates that this gene is not essential in M. tuberculosis and that MSH, 
neither ERG, is essential for M. tuberculosis growth in vitro (in cultures supplemented with 
OADC). However, strains lacking either MSH or both MSH and ERG grew very slowly on 
solid culture (4-8 weeks for visible colonies to appear on plates) and are very sensitive to the 
decrease of catalase concentration in the culture media. They fail to grow in the absence of 
OADC (because of the absence of catalase) or in low level of OADC (data not shown). 
Caution must be taken when making the solid culture that the OADC supplemented is not 
added when the media is too hot, as this may cause degradation of catalase and therefore 



















Figure 4.3 Screening PCR design of the unmarked mutants                                                  
When amplified with primer set 1, only wild type and SCO will get amplified since they both have a copy of the 
gene, while the mutant will not be amplified since the gene has been deleted. When amplified with primer set 2, 
the wild type, the SCO and the mutant will be amplified, since the reverse primer R2 hybridizes outside the 
deleted region. However the mutant band will be smaller than the wild type band, since the gene has been 
deleted. 








Figure 4.4 Screening PCR of egtA mutant generated in CDC1551                                
A 537bp region of egtA was completely deleted from CDC1551, therefore when screened with primer set 1; 
only primer dimers were observed in the mutants while a 616bp fragment could be amplified in the SCO and 
WT. When screened with primer set 2, the WT with the intact gene has a 1682bp fragment while the mutant and 




Figure 4.5 Screening PCR of egtB mutant generated in CDC155 and H37Rv            
A 1105bp region of egtB was completely deleted from CDC1551 and H37Rv, therefore when screened with 
primer set 1; the mutants could not be amplified while a 504bp fragment could be amplified in the SCO and 
WT. When screened with primer set 2, the WT with the intact gene has a 1584bp fragment while the mutant and 







































Figure 4.6 Screening PCR of egtC mutant generated in CDC155                                  
A 570bp region of egtC was completely deleted from CDC1551, therefore when screened with primer set 1; the 
mutants could not be amplified while a 562bp fragment could be amplified in the SCO and WT. When screened 
with primer set 2, the WT with the intact gene has an 1128bp fragment while the mutant and the SCO have a 
smaller fragment of 558bp which is 1128bp minus the deleted 570bp 
 
 
Figure 4.7 Screening PCR of egtD mutant generated in CDC155                                  
An 804bp region of egtD was completely deleted from CDC1551, therefore when screened with primer set 1; 
the mutants could not be amplified while a 791bp fragment could be amplified in the SCO and WT. When 
screened with primer set 2, the WT with the intact gene has a 1400bp fragment while the mutant and the SCO 
have a smaller fragment of 516bp which is 1400bp minus the deleted 804bp 








Figure 4.8 Screening PCR of egtE mutant generated in H37Rv and CDC155           
A 996bp region of egtE was completely deleted from H37Rv and CDC1551, therefore when screened with 
primer set 1; the mutants could not be amplified while an 861bp fragment could be amplified in the SCO and 
WT. When screened with primer set 2, the WT with the intact gene has a 1782bp fragment while the mutant and 
the SCO have a smaller fragment of 786bp which is 1782bp minus the deleted 996bp. 
 
Figure 4.9 Screening PCR design of the marked mutants 
When amplified with primer set 1, only mutants and SCOs will get amplified since they both have the 
hygromycin cassette, while the wild type will not be amplified since the gene has been deleted. When amplified 
with primer set 2, the wild type and the SCO will be amplified but not the mutant, since the reverse primer R2 
hybridizes in the deleted region. 









Figure 4.10 Screening PCR of ∆mshA, ∆egtB/mshA mutant generated in CDC1551        
A 1335bp region of mshA was completely deleted and replace with hygromycin cassette with its promoter. 
When amplified by primer set 1 that hybridizes outside the deleted region and within the hygromycin cassette, 
only the mutant and the SCO that still has the construct are amplified giving a 507bp band. Then when 
amplified with primer set 2 that hybridizes in the intact gene, only the wild type and the SCO are amplified 
giving a 388bp fragment. 
 









Figure 4.11 Southern blotting analysis of the CDC1551 ∆egtA mutant 
Right panel describes the Southern blot design; the genomic DNA of the wild type and the mutant was digested 
with ESPI. ESPI cuts within egtA, egtE and outside the operon. A DNA fragment that hybridizes to the digested 
region that will enable distinction of the wild type from the mutant was used as the probe (table 3.5). The mutant 
band on the left panel is longer than that of the wild type (9107bp for the mutant and 4569bp for the wild type) 
as the ESPI site found within egtA does not exist in the mutant since it has been deleted as illustrated in the right 
panel. 
 









Figure 4.12 Southern blotting analysis of egtB deletion in H37Rv ∆egtB, CDC1551 ∆egtB and the 
mshA/egtB mutants                                                                                         
Top panel describes the Southern blot design; the genomic DNA of the wild type and the mutants was digested 
with BamHI. BamHI cuts within egtB, and outside the operon. A DNA fragment that hybridizes to the digested 
region to enable distinction of the wild type from the mutant was used as the probe (table 3.5). The mutants’ 
band  on the bottom panel is longer than that of the wild type (9113bp for the mutant and 5318bp for the wild 
type) as the BamHI site found within egtB does not exist in the mutants since it has been deleted as illustrated 
inthe top panel. 
 









Figure 4.13 Southern blotting analysis of egtC deletion in the CDC1551 ∆egtC mutant 
Right panel describes the Southern blot design; the genomic DNA of the wild type and the mutant was digested 
with ApaBI. ApaBI cuts within egtC, and outside the operon. A DNA fragment that hybridizes to the region to 
enable distinction of the wild type from the mutant was used as the probe (table 3.5). The mutant band on the 
left panel is longer than that of the wild type (11848bp for the mutant and 4089bp for the wild type) as the 













Figure 4.14 Southern blotting analysis of egtD deletion in the CDC1551 ∆egtD mutant   
Right panel describes the Southern blot design; the genomic DNA of the wild type and the mutant was digested 
with BclI. BclI cuts within egtC, and outside the operon. A DNA fragment that hybridizes to the digested region 
to enable distinction of the wild type from the mutant was used as the probe (table 3.5). The mutant band on the 
left panel is longer than that of the wild type (6729bp for the mutant and 2266bp for the wild type) as the BclI 















Figure 4.15 Southern blotting analysis of egtE deletion in H37Rv ∆egtE and CDC1551 ∆egtE        
Top panel describes the Southern blot design; the genomic DNA of the wild type and the mutants was digested 
with NcoI. NcoI cuts within egtE, and outside the operon. A DNA fragment that hybridizes to the digested 
region to enable distinction of the wild type from the mutant was used as the probe (table 3.5). The mutants’ 
band on the bottom panel is longer than that of the wild type (7780bp for the mutants and 4198bp for the wild 
type) as the NcoI site found within egtB does not exist in the mutants since it has been deleted as described in 
the top panel. 









Figure 4.16 Southern blotting analysis of mshA deletion in CDC1551 ∆mshA and the mshA/egtB mutant    
Top panel describes the Southern blot design; the genomic DNA of the wild type and the mutants was digested 
with ClaI. ClaI cuts within mshA, and outside the operon. A DNA fragment that hybridizes to the digested 
region to enable distinction of the wild type from the mutant was used as the probe (table 3.5). The mutants’ 
band  on the bottom panel is longer than that of the wild type (15526bp for the mutant and 6361bp for the wild 
type) as the ClaI site found within mshA does not exist in the mutants since it has been deleted as illustrated 
inthe top panel. 
 
 







4.3 Deletion of ERG biosynthetic genes does not affect M. tuberculosis susceptibility to 
current anti-tuberculosis drugs 
In this study, two mutants were generated in H37Rv namely H37Rv ∆egtE and ∆egtB and 7 
mutants in CDC1551 namely ∆egtA, ∆egtB, ∆egtC, ∆egtD, ∆egtE, ∆mshA and ∆egtB/mshA. 
The susceptibility of the CDC1551 mutants to RIF, ETH, EMB and INH were investigated. 
Deleting either egtA, egtB, egtC, egtD or egtE in CDC1551 did not affect its susceptibility to 
the antibiotics tested, as was previously shown in M. smegmatis [99]. Therefore ERG does 
play a role in protecting mycobacteria from current anti-tuberculosis drugs (Table 4.5). 
However MSH deficiency affects mycobacterial susceptibility to antibiotics, as they are 
resistant to INH and ETH. As was previously shown in M. smegmatis [99], the loss of ERG 
in the MSH-deficient mutants does not alter their susceptibility to current anti-tuberculosis 
drugs (Table 4.5). Thus, ERG and MSH do not compensate each other in the protection of 
mycobacteria against current anti-tuberculosis drugs. It was speculated that MSH protects M. 
tuberculosis from the bactericidal effect of RIF as the ∆mshB mutants that produced low but 
detectable level of MSH were more sensitive to RIF [104]. However, in this study, MSH 
deficiency was achieved by deleting mshA in CDC1551 and the susceptibility of the resulting 
mutant to RIF was not affected. This implies that the previous observed phenotype was 
associated to the lack of MshB and not of MSH.  
Table 4.5 Drugs MIC (µg/ml) of  mutants generated in this study 
RIF ETH INH EMB Strains 
0.98E-03 _1,95E-03 0,39_0,78 0,012_0,02 0,39_0,78 CDC1551 
0.49E-03_0.98E-03 0,78_1,56 0,012_0,02 0,19_0,39 ∆egtA 
1,95E-03_3,91E-03 0,39_0,78 0,012_0,02 0,39_0,78 ∆egtB 
0.98E-03 _1,95E-03  0,78_1,56  0,012_0,02  0,39_0,78 ∆egtC 
0.98E-03 _1,95E-03 0,78_1,56 0,012_0,02 0,19_0,39 ∆egtD 
0.98E-03 _1,95E-03 0,39_0,78 0,012_0,02 0,39_0,78 ∆egtE 
1,95E-03_3,91E-03 125-250 0.06-0.12 0.39-0.78 ∆egtB\mshA 
1,95E-03_3,91E-03 125-250 0.06-0.12 0.78-1.56 ∆mshA 
ND 3.9-7.8 0.015-0.03 ND ∆mshAc* 
*complemented ∆mshA with pMVhspmshA 
4.4 The enzyme EgtE is not essential for ERG biosynthesis 
The genes egtE and egtB were individually deleted in H37Rv and CDC1551 while egtA, egtB 
egtC, egtD and egtE were individually deleted in CDC1551. The gene mshA was deleted in 
CDC1551 and in the ∆egtB mutant of CDC1551. Thus, nine mutant strains were generated in 
M. tuberculosis. In order to confirm the function of each enzyme on ERG biosynthesis, ERG 
was quantified in each mutant. The ∆egtB mutant is ERG deficient in both CDC1551 and 
H37Rv, the ∆egtD mutant of CDC1551 is ERG deficient as well. The ∆egtA mutant of 
CDC1551 has lost 78% of IE and completely lost EE. The ∆egtC mutant of CDC1551 has 







lost 30% of IE and 45% of EE while the ∆egtE mutant has an increased level of ERG; ~1.5-
fold increase of IE in the CDC1551 ∆egtE mutant, ~4-fold increase of IE and ~ 3-fold 
increase of EE in the H37Rv mutant (Table 4.6). In addition the level IE was ~ 3-fold higher 
in the ∆mshA mutant indicating compensation of MSH by ERG (Table 4.6). It was shown 
that transcription of integrated genes under their native promoter is problematic, since they 
are integrated at a different site of the genome (attB site). This is pronounced when the gene 
is not the first in the operon [197]. This was observed in this study as well, since 
complementation with the endogenous promoter was successful only with the ∆egtA mutant 
(∆egtA+ in Table 4.6). 
 
Table 4.6 ERG level in mutants generated in this study (pg/105CFUs) 
Strains IE EE 
 1 2 3 Average 1 2 3 Average 
H37Rv 0.83 0.51 2.26 1.20 ± 0.76 4.92 8.16 0 4.6 ± 3.35 
∆egtE (H37Rv) 7.63 0.44 6.10 4.73 ± 3.09 13.45 6.70 17.90 12.68 ± 4.6 
∆egtB (H37Rv) 0.18 0 0.18 0.1 ± 0.08 0 0 0 0 
CDC1551 0.77 2.35 4.77 2.6 ± 1.64 13.76 7.84 0 7.19 ± 5.63 
∆egtA (CDC1551) 1.05 0.69 0 0.58 ± 0.43 0 0 0 0 
∆egtB (CDC1551) 0 0 0 0 0 0 0 0 
∆egtC (CDC1551) 1.44 3.14 0.90 1.8 ± 0.95 11.76 0 0 3.92 ± 5.54 
∆egtD (CDC1551) 0 0 0 0 0 0 0 0 
∆egtE (CDC1551) 1.18 7.16 3.44 3.93 ± 2.46 0 13.09 0 4.36 ± 6.17 
∆mshA (CDC1551) 1.97 12.46 5.04 6.50 ± 4.4 14.53 4.30 11.82 10.21 ± 4.33 
∆egtB-mshA (CDC1551) 0 0 0 0 0 0 0 0 
∆egtAc (CDC1551) 4.59 30.92 4.3 13.27 ±12.47 28.07 107.66 35.73 57.16 ± 35.84 
∆egtBc (CDC1551) 0.82 0.47 0.198 0.50 ± 0.25 0 0 0 0 
∆egtCc (CDC1551) 2.90 4.36 1.12 2.80 ± 1.3 0 47.20 0 15.73 ± 22.25 
∆egtDc (CDC1551) 2.84 6.07 0.83 3.25 ± 2.15 9.50 4.80 0 4.77 ± 3.88 
∆mshAc (CDC1551) 4.48 1.90 1.20 2.52 ± 1.14 0 22.88 0 7.63 ± 10.78 
∆egtBop (CDC1551) 2.35 0.77 1.11 1.41 ± 0.68 0 0 0 0 
∆egtA
+
 (CDC1551) 2.60 1.13 0.23 1.32 ± 0.97 17.782 19.96 5.76 14.5 ± 6.2 
∆egtB
+
 (CDC1551) 0 0 0.22 0.075 ± 0.1 0 0 0 0 
∆egtD
+
 (CDC1551) 0 0 0.19 0.064 ± 0.09 0 0 0 0 
c: mutants complemented with genes expressed under the hsp60 promoter, op: mutant complemented by the 
entire operon,
+
: mutants complemented by the gene fused to a  1000bp US the operon; IE: intracellular ERG, 
EE: extracellular ERG. Results are representative of three independent extractions and three independent 
quantifications 
 
The enzyme EgtD catalyses the methylation of histidine to hercynine during ERG 
biosynthesis (Figure 1.8). Therefore, deletion of egtD will obstruct the production of 
hercynine which is what we observed (Table 4.7). To verify if the low level of ERG in all the 
mutants except ∆egtE was due to a polar effect on egtD, we quantified the level hercynine, an 
intermediate in ERG biosynthesis. The ∆egtB mutant which is ERG-deficient still produce 
hercynine (Table 4.7), indicating that the deletion of egtB does not affect the expression of 
egtD and that the enzyme EgtB is essential for ERG biosynthesis as well. However, when the 
∆egtB mutant was complemented under hsp60 promoter or the endogenous promoter, 







hercynine was below detection limit. This may be due to some unknown metabolic 
regulations. The mutant ∆egtA and ∆egtC also produced hercynine indicating that deletion of 
these genes did not affect egtD expression (Table 4.7). Since ∆MT1289 and ∆MT1953 had a 
very low level of ERG (Table 4.1), hercynine was quantified in them as well, and results 
indicate that hercynine is also produced in these mutants (Table 4.7). 
 
Table 4.7 Hercynine level during exponential growth of mutants generated in this study (Area/107CFUs) 
Strains IH EH 
H37Rv 3.15 ± 1.42 0 
∆egtE (H37Rv) 1.61 ± 1.30 0 
∆egtB (H37Rv) 0.68 ± 0.53  0 
CDC1551 4.32 ± 1.54  0 
∆egtA (CDC1551) 12.36 ± 6.57 0 
∆egtB (CDC1551) 0.93 ± 0.38 0 
∆egtC (CDC1551) 2.18 ± 1.42 0 
∆egtD (CDC1551) 0 0 
∆egtE (CDC1551) 1.50 ± 0.94 0 
∆mshA (CDC1551) 8.96 ± 11.36 0 
∆egtB-mshA (CDC1551) 3.63 ± 3.17 0 
∆MT1289 (CDC1551) 5.62 ± 2.24 0 
∆MT1953 (CDC1551) 2.15 ± 1.76 0 
∆egtAc (CDC1551) 3.37 ± 4.11 0 
∆egtBc (CDC1551) 0 0 
∆egtCc (CDC1551) 3.54 ± 3.62  0 
∆egtDc (CDC1551) 29.46 ± 30.27  13.35 ±6.89 
∆mshAc (CDC1551) 4.24 ± 1.35  0 
∆egtBop (CDC1551) 5.00 ± 4.33  0 
∆egtA
+
 (CDC1551) 42.68 ± 36.38 0 
∆egtB
+
 (CDC1551) 0  0 
∆egtD
+
 (CDC1551) 0  0 
c: mutants complemented with genes expressed under the hsp60 promoter, op: mutant complemented by the 
entire operon,
+
: mutants complemented by the gene fused to a  1000bp US the operon; IH: intracellular 
hercynine, EH: extracellular hercynine. Data are representative of three independent extractions and three 
independent quantifications. 
It is worth noting that, the level of hercynine in the mutants is not the same (Table 4.7), this is 
may be due to differential metabolic regulations in these strains as a result of different levels 
of ERG or other intermediates in the pathway in these strains. To date, the mechanism of 
regulation of this pathway has not been investigated in mycobacteria. 
In addition, hercynine is not detected in the extracellular medium (Table 4.7) except in the 
complemented ∆egtD. This is an indication that either hercynine is not secreted, or it is 
secreted at a very low level during exponential phase of growth. To verify this, we quantified 
hercynine in stationary cultures of the CDC1551, ∆MT1289 and ∆MT1953. Hercynine was 
detected at a concentration of 5.16 ± 3.3, 33 ± 19, 11 ± 4.3 respectively in the extracellular 
medium, while it was detected at a concentration of 2.27 ± 0.92, 6.42 ± 1.75 and 1.58 ± 0.35 
area/10
7
 CFUs respectively in the cell lysate. Since these data indicates that extracellular 
hercynine constitute ≥70% of total hercynine in these strains, it is less likely that the 







extracellular hercynine observed is due to leakage through damaged cells because we have 
shown that approximately 17% of CDC1551 mycobacterial cells have a damaged membrane 
during stationary growth (Table 4.4). It is possible that hercynine is secreted at a very low 
level (below detection limit) during exponential phase but is secreted at a detectable level 
during stationary phase. Since the complemented strain is not genetically identical to the wild 
type, secretion of hercynine may be regulated differently in these two strains. We have shown 
that CDC1551 may not secrete ERG during stationary phase. Therefore it is possible that 
when ERG is being secreted during exponential phase hercynine is not and when hercynine is 
secreted during stationary phase, ERG is not in CDC1551. However, due to the large 
variation between biological replicates, more quantification experiments are needed to 
confirm this assertion. 
We previously showed that deleting egtD in M. smegmatis abolished ERG biosynthesis [99], 
therefore this result is consistent in mycobacteria. This indicates that EgtD is the only 
methyltransferase involved in ERG biosynthesis and cannot be compensated for by any other 
enzymes. The enzyme EgtD catalyses the methylation of histidine by a proximity and 
orientation effect in a successive reaction. It consists of two domains, the methyltransferase 
domain and the substrate binding domain. The histidine binding pocket primarily recognises 
the imidazole ring and the carboxylate group of histidine accounting for its methylation 
selectivity and specificity [155]. Similarly, it has been shown that EgtB binding is specific to 
ƴ-glutamyl cysteine (GGC) and any mutation on its residue (D416) may affect its sulphur 
donor specificity [154]. This indicates that EgtB is the only enzyme that catalyses the third 
step of ERG biosynthesis. Similarly searches revealed no homolog of EgtB in M. tuberculosis 
or enzymes that can perform the same function. Therefore EgtB is specific to ERG 
biosynthesis. To further confirm that this finding is not strain specific egtB was deleted in 
H37Rv as well and this lead to the loss of ERG biosynthesis in this strain (Table 4.6). This is 
supported by some studies that identified ERG producing organisms that posses only have 
EgtB and EgtD but not EgtA, EgtC and EgtE. In addition the expression of egtD and egtB are 
positively correlated [153]. Furthermore, the first two steps of ERG biosynthesis in N.crassa 
are catalysed by NcEgt-1 which is an enzyme that contains domains found in EgtD and EgtB, 
thereby playing the catalytic role of both enzymes in the fungus N.crassa [145]. These results 
support the previous speculation that EgtB and EgtD are the key enzymes in ERG 
biosynthesis across species [151]. 








Mycobacterial nitrogen metabolism has been explored to identify new drug targets. 
Glutamine synthetases (GS) are the key enzymes in this metabolism. These enzymes are 
inhibited by L-methioneine-S,R-sulphoximine (MSO) which is known to inhibit 
mycobacterial growth in vitro and in vivo [198, 199]. There are four glutamine synthethases 
in M. tuberculosis (GlnA1, GlnA2, GlnA3 and Gln4) whose activities are regulated by other 
enzymes. Few examples of the GS regulatory enzymes are adenylyl transferase (GlnE), 
gamma-glutamylcysteine synthase (GshA or EgtA), UDP-N-acetylmuramoylalanine-D-
glutamate ligase (MurD) and glutamate racemase (MurI) [200]. It has been shown that EgtA 
(GshA) is inhibited weakly by MSO and strongly by D,L-buthionine-S-R-sulphoximine 
(BSO) indicating that EgtA shares functional similarities with the GS [200]. Therefore, it is 
more likely that EgtA is partially compensated for by one of these enzymes which play 
similar functions. A low level of ERG was detected in the ∆egtA mutant of S.coelicolor as 
well and it was suggested that EgtB could use cysteine instead of GGC as a substrate in the 
absence of EgtA (since it catalyses the synthesis of GGC) [159] . However, it was previously 
shown that cysteine is a poor substrate of EgtB [148] which make that speculation 
questionable.  
The enzyme Rv1061 (MT1091) is a glutamine amidotransferase hypothetical protein that 
shares 87% similarity with the amidohydrolase EgtC. It is more likely this enzyme 
compensates for the loss of EgtC in the ∆egtC mutants, which explains the detectable low 
level of ERG in this mutant. A validation of this assertion will be to delete Rv1061 in the 
∆egtC mutant and measure the level of ERG in the resulting double mutant. 
The first attempt of the recombinant production of soluble EgtE was unsuccessful; and the 
function of EgtE in ERG biosynthesis was assigned by homology, when an enzyme of similar 
activity from Erwinia tasmaniensis was assayed [148]. Recently it was shown that EgtE 
could catalyse the formation of ERG only in the presence of a reducing agent [149]. In this 
study the level of ERG was higher in the CDC1551 ∆egtE mutant and in the H37Rv ∆egtE 
mutant (Table 4.6). It was shown that PLP alone could induce the formation of ERG in the 
absence of EgtE [201]. Therefore, EgtE is not essential for ERG biosynthesis. It is possible 
that there is a spontaneous production of ERG in the presence of PLP with or without EgtE. 
On the other hand EgtE is a homologue of enzymes involved in Fe-S metabolism namely 
Rv1464/MT1511 (71%) and Rv3025c/ MT3109 (52%); known as cysteine desulfurases. 
Cysteine desulfurases are PLP-dependent enzymes which are the central components of the 
multiprotein systems ISC (iron-sulfur cluster) and SUF (sulphur metabolism). These systems 
are required for the Fe-S cluster biogenesis. Iron-sulfur proteins are involved in many critical 








biological processes such as RNA modification, DNA repair and others. In gram negative 
bacteria, it is believed that the SUF system is active only under oxidative stress and iron 
limitation conditions, while the ISC system is a housekeeping system. Proteins involved in 
this system are encoded by gene clustered in the same operon (the iscRSUA-hscBA-fdx 
operon or the sufABCDSE operon) [202-204]. However in gram positive bacteria such as M. 
tuberculosis, only one cysteine desulfurase is found in the ISC operon which is Rv3025c 
(IscS). Phenotypic experiments revealed that IscS is involved in Fe-S metabolism and may be 
active under oxidative stress conditions (as seen with components of the SUF system) since 
M. tuberculosis mutants lacking Rv3025c (IscS) are sensitive to oxidative stress [202]. The 
propensity of the SUF system to be active only under oxidative stress conditions and iron 
depletion may be dependent on the ability of mycobacteria to produce or regulate the level of 
ERG and/or MSH which are known antioxidants. Since we definitely know that it is a PLP 
dependent cysteine desulfurase that catalyses the last step of ERG biosynthesis, it is possible 
that IscS (Rv3025c) catalyses that step and/or the production of IscS is elevated in the ∆egtE 
mutant to compensate for the loss of the cysteine desulfurase EgtE resulting in the increased 
level of ERG in the ∆egtE mutants. However, it is worth noting that Rv1464 shares a 71% 
homology with EgtE, and it is a hypothetical protein denoted as a cysteine desulfurase as 
well. This enzyme is situated in the Rv1460-Rv1461-Rv1462-Rv1463-Rv1464-Rv1465-
Rv1466 operon in M. tuberculosis, which is thought to encode the major Fe-S cluster 
biogenesis machinery in this organism. In addition, it was shown recently that the gene 
coding for this enzyme was highly expressed when H37Rv was treated by an intracellular 
ROS generating molecule (ATD-3169) [191]. This enzyme may also have the ability to 
compensate for the loss of EgtE during ERG biosynthesis. Therefore in the absence of EgtE, 
there is probably a defect in the Fe-S metabolism causing the up-regulation of another 
cysteine desulfurase Rv3025c (IscS) or/and Rv1464 and consequently an increase production 
of ERG. However, this remained to be shown. One way to investigate this interplay between 
these enzymes would be to quantify ERG in the ∆iscS mutant. 
4.5 ERG is necessary for growth during the stationary phase 
The ∆egtE mutant growth was not different from the wild type (Figure 4.17E). However, this 
strain does not exhibit any visual aggregation in comparison with the wild type and other 
strains, even after incubation for up to 60 days (Figure 4.17). To verify if this particular 
phenotype was unique to the ∆egtE mutant of the CDC1551, the ∆egtE M. tuberculosis 
H37Rv mutant was incubated for about a month and clumping was observed from 
approximately the third week of incubation. To further investigate if this unique phenotype 








was associated with the metabolism of the detergent Tween 80 in the culture media, or to the 
structure of the membrane of the CDC1551 ∆egtE mutant, it was incubated without Tween 
80 which resulted in aggregation of the mycobacteria; indicating that the absence of a visual 
aggregation of the ∆egtE mutant may not be due to an alteration of its membrane structure. 
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Figure 4.17 Growth curve of CDC1551 M. tuberculosis mutants 
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Cultures were inoculated to and OD600 of approximately 0.05 and the OD600 was measured every second day.  
Data are representative of three independent experiments (except ∆egtDE) and are represented as mean and SD 
(standard deviation). *** (P<0.001), ** (P<0.01), * (P<0.05), WT: wild type, VS: versus 
Figure 4.17A Growth curves of the ∆egtA mutant (left panel), Figure 4.17B Growth curves of the ∆egtB mutant 
(left panel), Figure 4.17C Growth curves of the ∆egtC mutant (left panel), Figure 4.17D Growth curves of the 
∆egtD mutant (left panel);  genetic complements (middle panel) and chemical complements (right panel) 
relative to the wild type.  Figure 4.17E Growth curve of the ∆egtE mutant (left panel), culture granularity after 
60 days of the wild type (middle panel) and the mutant (right panel). Figure 4.17F Growth curves of the ∆mshA, 
∆egtB and ∆egtB-mshA and Figure 4.17G Growth curves the genetically complemented ∆mshA, ∆egtB and 
∆egtB-mshA (only egtB) 
 
During in vitro growth, mycobacteria exhibit three main growth phases.  The lag phase where 
the metabolism of the mycobacteria is slow; this stage is observed in M. tuberculosis when 
bacteria starting inoculum is less than 0.05, but in this study, we could not start the cultures at 
an OD600 lower than 0.05 because some of the mutants failed to grow at a lower inoculum. 
The exponential phase (characterized by a high metabolic level) and finally the stationary 
phase (where mycobacteria growth slows down as they become metabolically less active) 
which can lead to the death phase (Figure 4.17A). Under electron microscopy, mycobacteria 
appear as corded aggregates throughout every growth stage. However during the stationary 
phase these cords are bigger more compact and round, probably due to an increase in their 
hydrophobicity which stands out when the culture is observed visually [205] (Figure 4.17E). 
On the other hand, Tween 80 is a detergent known to induce homogenous growth of 
mycobacteria [206]. The exact biochemical mechanism of action of Tween 80 is not known, 
but it was observed that the polar C-mycosidic glycopeptidolipids (GLPs) of the 
Mycobacterium avium-Mycobacterium intracellulare complex (MAC) superficial L1 layer 
decreases with an increase Tween 80 concentration [207]. However, the dispersing ability of 
Tween 80 is not effective during stationary phase as mycobacteria aggregate more during that 
stage. It has been speculated that Tween 80 slowly hydrolyses in culture media. It has also 
been speculated that lipases from mycobacteria may accelerate hydrolysis of Tween 80 to an 
un-esterified oleic acid [208]. On the other hand, it was shown that Traustochytrium aurium 
was able to use Tween 80 as a carbon source or directly incorporate the Oleate of Tween into 
its fatty acid content [206]. Irrespective, we can deduce that Tween 80 decreases in bacterial 
culture over time which explains the increase in the mycobacterial aggregation. The enzyme 
EgtE belongs to a family of enzymes known as the cysteine desulfurase family, whose main 
function is basically to cleave the sulphur residue of cysteine in order to transfer it to another 
amino acid [209]. However, it has been shown that desulfurization of cysteine or methionine 
leads to a change of the configuration of fatty acids which can lead to their degradation [210]. 
Therefore, EgtE may be involved in the degradation of the oleic acid of Tween 80, which 








explains why the ∆egtE mutant does not aggregate as much as the wild type during stationary 
phase because the level of Tween 80 in the ∆egtE culture is possibly higher. However, it 
should be noted that EgtE could be compensated for by other cysteine desulfurases and that 
the H37Rv ∆egtE mutant does not exhibit that phenotype. There is no data indicating that 
these cysteine desulfurases are secreted, it is possible that EgtE is the only secreted cysteine 
desulfurase in CDC1551, that’s why it could directly affect the extracellular level of Tween 
80. However, the opposite could be true in the case of H37Rv; this assertion is supported by 
previous studies that demonstrated that the crude lipid fraction of CDC1551 was different to 
that of H37Rv and it is worth noting this was shown with mycobacteria grown in 7H9 
containing the same percentage (0.05%) of Tween 80 we used in this study [192]. More 
experiments need to be done to confirm this assertion. Gas or liquid chromatographic 
measurement of the unsaturated oleic acid in the stationary culture of the wild type and of the 
∆egtE mutant will be useful to confirm degradation of Oleate by EgtE. In this case the 
extracellular Tween 80 lipid will be isolated by the phenol chloroform method as previously 
described [211].  
On the other hand, ERG-deficient mutants and the MSH-deficient mutant grew poorly from 
late exponential phase to stationary phase. 
The ∆egtA mutant grew poorly from day 14 throughout the stationary phase (P<0.001 each 
time point) and genetic complementation of egtA under the control of the hsp60 promoter, 
ameliorated the growth of this mutant while chemical complementation of this mutant 
restored its growth to the wild type level (Figure 4.17A). The ∆egtB mutant grew poorly from 
day 18 throughout the stationary phase (P<0.001) and genetic complementation of egtB under 
the control of the hsp60 promoter, ameliorated the growth of this mutant while chemical 
complementation restored its growth to wild type level (Figure 4.17B). Strangely, the ∆egtC 
mutant grew better than the wild type from day 8 to 12 (P<0.05), then grew normally 2 days 
later, but then grew better than the wild type again on day 16 (P<0.01) and grew normally 
from day 18 to 22. However, on the 24
th
 day, the wild type grew better than it. Genetic 
complementation of egtC under the hsp60 promoter partially restored its phenotype to the 
wild type level, while chemical complementation of this mutant completely restored its 
growth phenotype to the wild type level (Figure 4.17C). The ∆egtD mutant had a growth 
defect from day 18 throughout the stationary phase (P<0.001 throughout). Genetic 
complementation of egtD under the hsp60 promoter ameliorated the growth of this mutant 
while chemical complementation restored its growth to the wild type level (Figure 4.17D) 








The ∆mshA mutant had a growth defect only from day 18 to 22 (P<0.05), and at day 26 
(P<0.01) (Figure 4.17F), but genetic complementation aggravated the phenotype as the 
complement showed a growth defect from day 16 throughout the stationary phase (Figure 
4.17G). 
The ∆egtB-mshA grew poorly relatively to the wild type from day 18 throughout the 
stationary phase (P<0.001) (Figure 4.17F). Results indicate that the effect of the deletion of 
egtB and mshA in CDC1551 is additive. Genetic complementation egtB in this mutant 
ameliorated its growth phenotype (Figure 4.17G). With the exeption of the ∆egtE mutant 
which is not an ERG-deficient mutant (Table 4.6), all the ERG-deficient strains grew poorly 
during stationary phase. The MSH-deficient ∆mshA mutant also grew poorly during 
stationary phase but not as much as the ERG deficient mutants.  
The stationary phase is characterized mainly by depletion of nutrients, and the metabolism of 
the mycobacteria gradually shuts down while they enter a dormant state and stop multiplying 
[212]. Dormancy in other hand is characterized by a slow replication rate or complete 
replication shut down of mycobacteria residing within necrotic cells known as granuloma. 
Their metabolic shut down has been proposed to more driven by conditions such as nutrient 
limitation and low oxygen tension found within the granuloma [213]. Therefore these results 
suggest that ERG potentially protects M. tuberculosis during dormancy in latent tuberculosis. 
These results are supported by recent studies that showed that an ERG-deficient ∆egtD 
H37Rv mutant viability decreased after three weeks of incubation in a nutrient deprived 
media [214]. The ability of chemical complementation to ameliorate the stationary growth 
defect suggests either that this effect is as a result of a function of EE, or that ERG can also 
be imported. Previous work showed that ERG-deficient M. smegmatis mutants did not have 
any growth defect [99] while ERG-deficient Streptomyces coelicolor grew poorly during 
stationary phase [159]. Organic hydroperoxide is known to be overproduced in the MSH-
deficient M. smegmatis mutant [100] , however there is no ortholog of Ohr in M. tuberculosis 
and the Ohr ortholog in Streptomyces coelicolor is not overproduced in the MSH-deficient 
mutants neither in the ERG-deficient mutant. This implies that M. smegmatis uses other 
protective molecules during harsh conditions and therefore does not require ERG for its 
survival during dormancy. On the other hand, MSH-deficient mutants present a slight growth 
defect but not as aggravated as in the ERG-deficient mutants. Furthermore, complementation 
worsens its growth defect. It is has been observed that MSH-deficient M. smegmatis and M. 
tuberculosis mutants produce more ERG than the wild type strain ([99, 100]; Table 3.3, Table 
4.6) which explains why the ERG-deficient mutants grew more poorly than the MSH-








deficient mutant as the high level of ERG in the MSH-deficient mutant may enable it to grow 
better during stationary phase. That’s why, complementation of MSH which implies 
restoration of ERG and MSH more or less to the wild type level in this strain, aggravated the 
growth defect phenotype. As opposed to M. tuberculosis, it was shown that the MSH-
deficient S. coelicolor grew as poorly as the ERG-deficient strain during stationary phase 
[159]. This is explained by the fact that S.coelicolor MSH-deficient mutant produces the 
same amount of ERG as the wild type as opposed to M. tuberculosis and M. smegmatis [159]. 
In addition, MSH deficiency was obtained in S.coelicolor by deleting mshC causing an 
accumulation of the metabolites whose reaction are catalysed by MshC which are cysteine 
and GlcN-Ins. However, excess cysteine is toxic to bacteria, inhibiting growth [215]. This is 
because cysteine forms complexes with redox-active transition metals which consecutively 
enhance the production of ROS [216]. However, in this study MSH-deficient mutants were 
obtained by deleting mshA instead of mshC hence there is no accumulation of cysteine in this 
strain. 
It is worth noting that the ∆egtC mutant grew better than the wild type during the exponential 
phase but gradually grew poorly during the stationary phase (Figure 4.17C). This is an 
indication that the accumulated intermediary metabolite in this strain may favour the growth 
of this strain during the exponential phase. On the other hand, it is possible that the absence 
of the enzyme EgtC may have induced the overproduction of another enzyme that lead to an 
enhance growth phenotype. A mass spectrometry analysis of the cell extract of this mutant to 
identify any potential up-regulated protein that may have caused this phenotype will bring 
more clarification. On the other hand, LC-MS analysis of the cell extract of this mutant may 
enable to identify the accumulated compound that may have caused this phenotype. However, 
whatever mechanism is involved, it was not good enough to enable that strain to also grow 
better during the stationary phase, as the growth of the mutant gradually decreased to the wild 
type level from day 18 and it began to grow less than wild type from day 24. 
Since we know mycobacteria have the tendency to aggregate more during stationary phase, 
we investigated if aggregation may have affected the viability of the mutants. This was 
achieved by monitoring the viability of the mutants using the MGIT system. The MGIT 
system is a method used to evaluate the drug susceptibility of M. tuberculosis strains. It is 
based on the growth unit of the tested strain when the growth unit of the control sample is 
400. Mycobacteria are inoculated into MGIT tubes containing 7H9 supplemented with 
OADC and the oxygen-quenched fluorochrome, tris 4, 7-diphenyl-1, 10-phenanthroline 








ruthenium chloride pentahydrate, embedded in silicone at the bottom of the tube. But there is 
no Tween 80 in this culture media to prevent aggregation. As the mycobacteria grow, they 
release CO2 and consume O2 which causes the release of the fluorochrome whose 
fluorescence is detected by the MGIT 960 instrument and reported as growth units [217, 
218]. When the growth unit of the mutants were compared to the wild type from the day they 
all became positive to the day of the last reading, there was no significance difference (Figure 
4.18); indicating that aggregation or the absence of  Tween80 does not affect the viability of 
the mutants. 
 
Figure 4.18 Evaluation of the mutants’ viability when grown without Tween80 




 CFUs and incubated at 37
◦
C in the MGIT 960 instrument which 
recorded the growth units. 
In view of this, we can conclude that ERG and MSH enable mycobacteria to survive during 
stationary growth. However, M. tuberculosis needs more ERG than MSH during this stage. It 
would be interesting to investigate the survival of ERG-deficient mutants during dormancy.  
4.6 ERG deficiency does not affect M. tuberculosis susceptibility to in vitro stress 
Oxidative stress and nitrosative stress are the major stresses that mycobacteria encounter 
upon infection. However, it has been shown that MSH protects M. smegmatis from oxidative 
stress [104], but there is no published data indicating the role of MSH in M. tuberculosis 
during nitrosative stress. In this study, we investigated the role of ERG, its biosynthetic 
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The susceptibility to nitrosative stress of the mutants tested in this study was not affected 
(P>0.05); However, the ∆egtB mutant was resistant to nitric oxide 24 hrs post-exposure 
(P<0.01) but became sensitive 48hrs later (Figure 4.19). This indicates that neither ERG nor 
MSH, protect M. tuberculosis from nitrosative stress. 
 









Figure 4.19 Susceptibility of M. tuberculosis mutants to nitrosative stress generated by DETA-NO  
CFUs were counted before exposure and 24 and 48 hours post-exposure. Data are plotted as percentage survival 
calculated from CFUs counts before exposure. Data are representative of three to four independent experiments 
and are represented as mean and SEM (standard error of the mean). Figure 4.19A describes ∆egtA ,Figure 4.19B 
describes ∆egtB(p<0.01), Figure 4.19C describes ∆egtC, Figure 4.19D describes ∆egtD, Figure 4.19E describes 
∆egtB and ∆mshA and Figure 4.19F describes ∆egtB-mshA susceptibility to nitrosative stress relative to the wild 
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type. Figure 4.19G describes ∆egtB-mshA susceptibility to nitrosative stress relative to ∆egtB. Figure 4.19H 
describes ∆egtB-mshA susceptibility to nitrosative stress relative to ∆mshA 
Mutants were not sensitive to oxidative stress generated by 1mM CuOOH (Figure 4.20). 
However, when PRG was used to generate oxidative stress, the ∆egtA mutant was more 
sensitive to the wild type 3 hours post-exposure (P<0.05), then its phenotype was restored to 
the wild type level 24hrs later (Figure 4.21A). Attempts to complement this phenotype were 
unsuccessful either with the hsp60 promoter (Figure 4.21A) or with the endogenous promoter 
(data not shown). The susceptibility of the other tested mutants to PRG was not affected 
(Figure 4.21).  
 









Figure 4.20 Susceptibility of M. tuberculosis mutants to oxidative stress generated by CuOOH   
CFUs were counted before exposure and 3 hours post-exposure. Data are plotted as percentage survival 
calculated from CFUs counts before exposure. Data are representative of three to four independent experiments 
and are represented as mean and SEM (standard error of the mean). Figure 4.20A describes ∆egtA, Figure 4.20B 
describes ∆egtB,  Figure 4.20C describes ∆egtC, Figure 4.20D describes ∆egtD , Figure 4.20E describes ∆egtB 
and ∆mshA and Figure 4.20F describes ∆egtB-mshA susceptibility to CuOOH relative to the wild type while 
Figure 4.20G describes ∆egtB-mshA susceptibility to CuOOH relative to ∆egtB and Figure 4.20H describes 
∆egtB-mshA susceptibility to CuOOH relative to ∆mshA 
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Figure 4.21 Susceptibility of M. tuberculosis mutants to oxidative stress generated by PRG         
CFUs were counted before exposure and 3 hours post-exposure. Data are plotted as percentage survival 
calculated from CFUs counts before exposure. Data are representative of three to four independent experiments 
and are represented as mean and SEM (standard error of the mean). Figure 4.21A describes ∆egtA (P<0.05), 
Figure 4.21B describes ∆egtB, Figure 4.21C describes ∆egtC, Figure 4.21D describes ∆egtD, Figure 4.21E 
describes ∆egtB and ∆mshA, and Figure 4.21F describes ∆egtB-mshA susceptibility to PRG relative to the wild 
type. While Figure 4.21G describes ∆egtB-mshA susceptibility to PRG relative to ∆egtB and Figure 4.21H 
describes ∆egtB-mshA susceptibility to PRG relative to ∆mshA 
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In addition, the susceptibility of every mutant to acidic stress was not altered as well (Figure 
4.22). 
 
Figure 4.22 Susceptibility of M. tuberculosis mutants to acidic stress (pH~4.5)                               
CFUs were counted before exposure, 3 and 5 days post-exposure. Data are plotted as percentage survival 
calculated from CFUs counts before exposure. Data are representative of three to four independent experiments 
and are represented as mean and SEM (standard error of the mean). Figure 4.22A describes ∆egtA  (p<0.01),  
Figure 4.22B describes ∆egtB, Figure 4.22C describes ∆egtC,  Figure 4.22D describes ∆egtD, Figure 4.22E 
describes ∆egtB and ∆mshA and Figure 4.22F describes ∆egtB-mshA susceptibility to acidic stress relative to the 
wild type. Figure 4.22G describes ∆egtB-mshA susceptibility to acidic stress relative to ∆egtB. Figure 4.22H 






































































































































































Acidification of macrophages during maturation is a mechanism used by the host to fight 
invading mycobacteria. However, it has been shown that M.tuberculosis is able to escape this 
defence mechanism by neutralizing the acidic effect [219]. In order to evaluate if ERG or 
ERG biosynthetic genes and/or MSH are involved in this process, we exposed the mutants 
generated in this study to an acidified medium. This study indicates that neither MSH, nor 
ERG protects mycobacteria from acidic stress. However, it was shown that MSH-deficient M. 
smegmatis mutants were sensitive to acidic stress (pH~4) [108]. It may be due to the strain 
difference; it could be that M. tuberculosis evolves a different survival mechanism under 
acidic stress as compared to M. smegmatis. The difference in the result may also be due to the 
method of testing. The authors exposed the mycobacteria to acidified 7H9 medium while we 
exposed the mycobacteria to acidified PBS medium. Since it was shown that mycobacteria 
are more sensitive to acidic stress in acidified 7H9 medium relative to other media, to 
perform an acidic stress experiment that better reflects the in vivo condition, it is 
recommended to use a buffer that will not influence interpretation of the data [220], which in 
this case was PBS.  
It has been shown that MSH-deficient ∆mshB mutants are sensitive to oxidative stress 
generated by 0.5mM CuOOH [104]. But the susceptibility of the ∆mshA mutants to oxidative 
stress has never been investigated [102]. In this study it was shown that the ∆mshA mutant 
which totally lacks MSH as opposed to the ∆mshB mutant which still produces low level of 
MSH [102, 104], was not sensitive to oxidative stress. Therefore the ∆mshB mutants were 
sensitive to oxidative stress generated by CuOOH either because of other biological 
consequences resulting from mshB deletion or because a different strain was used (Erdman 
strain instead of the CDC1551 strain) or because mycobacteria were plated on 7H9 agar 
media instead of 7H11 which is known to contain more nutrients and therefore will maximize 
growth recovery. Further, none of the ERG-deficient mutants (except the ∆egtA mutant) were 
sensitive to oxidative stress generated either by CuOOH or by PRG. It was previously shown 
that bacterial sensitivity to oxidative stress differs depending on the compound used to 
generate the oxidative stress. S.coelicolor ∆egtA mutant was sensitive to oxidative stress 
generated by CuOOH and hydrogen peroxide but not to diamide [159]. In addition, it is worth 
noting that it was previously shown that MSH-deficient M. smegmatis mutants were 
sensitivitive to oxidative stress generated by hydrogen peroxide and TBHP but not by the 
aromatic compound CuOOH [108]. It is possible that the ERG-deficient single mutants and 
the MSH-deficient mutant generated in this study are not sensitive to oxidative stress 
generated by aromatic compounds since PRG is also an aromatic compound. In M. smegmatis 








(Chapter 3); ERG and MSH single mutants were not sensitive to oxidative stress generated by 
CuOOH ; however the ERG/MSH-deficient double mutant was [99]. So to investigate if that 
was the case as well in M. tuberculosis, we generated an ERG/MSH-deficient double mutant 
by deleting mshA in the ∆egtB mutant, but unexpectedly, this mutant was not sensitive to 
oxidative stress neither to nitrosative stress nor to acidic stress (Figure 4.19F-H, 4.20F-H, 
4.21F-H, and 4.22F-H). To understand this contradiction, we first had to look at the 
difference between the double mutant that was generated in M. smegmatis and the double 
mutant generated in this study. The double mutant in M. smegmatis was obtained by deleting 
egtD in the ∆mshA mutant, whereas in this study the double mutant was obtained by deleting 
mshA in the ∆egtB mutant. The enzyme EgtD catalyses the methylation of histidine in the 
first step of ERG biosynthesis to produce hercynine while EgtB is an iron (II)-dependent 
enzyme that catalyses oxidative sulfurization of hercynine by GGC (synthesized by EgtA) 
(Figure 1.8). Therefore, deletion of egtB will abolish that reaction and may cause 
accumulation of gamma glutamyl-cysteine (GGC). However, it was shown that GGC plays 
the same role as glutathione in the detoxification of ROS and RNS in eukaryotes [221-223]. 
Therefore the potential accumulation of GGC in ∆egtB protects it from nitrosative and 
oxidative stress. Hence, the ERG/MSH-deficient double mutant could still survive under 
oxidative stress probably because of the protective effect of excess GGC. We have shown 
that neither MSH nor ERG , nor both protect M. smegmatis from nitrosative stress ( Chapter 
3) [99] which concurs what we saw in this study and may explain why neither the double 
mutant nor the single mutants were sensitive to nitrosative stress. Since ERG does not protect 
mycobacteria from nitrosative stress, the protective effect of accumulated GGC in the ∆egtB 
mutant could not be neutralized by the lack of ERG; making this mutant resistant to 
nitrosative stress (Figure 4.19B; P<0.01). The same trend was observed in the double mutant 
(Figure 4.19F-H) though it was not significant (P>0.05). It is not known how exactly that 
happens, but the discovery of gamma glutamyl transferase in M. smegmatis, the evaluation of 
its activity and the discovery of glutathione biosynthetic enzymes in M. smegmatis, indicate 
that GGC definitely plays a protective role in mycobacteria as well [224-226]. 
The ∆egtA mutant in this study was sensitive to oxidative stress generated by PRG but not to 
oxidative stress generated by CuOOH (Figure 4.21A &4.20A); in accordance with previous 
findings [159]. However, they showed that the ∆egtA mutant of S.coelicolor was sensitive to 
oxidative stress generated by CuOOH which was not observed in this study. The discrepancy 
in the result may be due to the difference on the methods used to evaluate mutant sensitivity 
to oxidative stress. They used the disk-agar diffusion assay while we investigated the survival 








after exposure to stress by CFU counts. They concluded that the sensitivity of the ∆egtA 
mutant was due to the lack of ERG or the toxic effect of the accumulated cysteine. The 
results obtained in this study enabled us to deduce that the susceptibility of the ∆egtA mutant 
is not solely due to the lack of ERG as the other ERG-deficient mutants were not sensitive. 
EgtA is known as GGC synthethase, it catalyses the ligation of cysteine to glutamate to form 
GGC in ERG biosynthesis (Figure 1.8). So, when EgtA is abolished, there is more likely 
accumulation of cysteine (Table 4.8) and glutamate and a decrease in the level of GGC.  
Table 4.8 Cysteine concentration in the cell extract of the CDC1551 mutants pg/107 CFUs 
Strains 1 2* average 
CDC1551 0 0 0 
∆egtA 17.12 3.87 10.50 ± 6.62 
∆egtB 7.08 0 3.54 ± 3.54 
∆egtC 5.60 0 2.80 ± 2.80 
∆egtD 5.14 0 2.56 ± 2.56 
∆egtE 0 0 0 
∆egtAc 0 0 0 
*Data are representative of two independent experiments and two independent quantifications; cysteine was 
below detection limit in all samples during the second quantification except in the ∆egtA mutant which contains 
a higher level of cysteine as seen in the first replicate 
 
Hence, this mutant may be sensitive because of the toxic effect of the accumulated cysteine 
[215] and/or the low level of GGC (which is known to protect against oxidative stress) and/or 
the low level of ERG in this mutant. A similar trend was observed when this strain was 
exposed to nitrosative stress; it became slightly sensitive 24 hrs later (Figure 4.19A, P>0.05). 
One baffling observation is the inability to complement this mutant susceptibility to oxidative 
stress generated by PRG (Figure 4.21A) while its phenotype is complemented during 
nitrosative stress (Figure 4.19A). There was no data indicating complementation of the ∆egtA 
mutant S.coelicolor as well [159]. Nevertheless, since we know that ERG production was 
restored in this mutant (Table 4.6), then the lack of complementation during oxidative stress 
may be due to the chemical properties of PRG. Pyrogallol is a compound used to evaluate the 
antioxidant capacity of foods, beverages and human fluids. It is induced by free radicals and 
ROS (to yield a quinone derivative and peroxides) and is inhibited by antioxidants. Pyrogallol 
has three hydroxyl groups that enable it to chelate metals and to be oxidized [227]. Since it is 
known that that gene expression can be altered by metal chelation [228, 229], it is more likely 
that complementation was not observed because of the metal chelating ability of PRG which 
inhibited the expression of the complemented gene. Another plausible explanation of the lack 
of complementation is the possible residual effect of accumulated cysteine in the ∆egtA 
mutant. To further understand why the ERG-deficient mutants are resistant to oxidative stress 
generated by CuOOH, we quantified MSH in the mutants generated in this study. Every 








ERG-deficient mutant (except ∆egtB and ∆egtC) had a high level of MSH relative their wild 
type counterpart (Table 4.9). The CDC1551 ∆egtB, ∆egtC and the ∆egtE mutants had a 
relatively low level of MSH, the H37Rv ∆egtB and ∆egtE mutants had more or less an 
unchanged level of MSH (Table 4.9). 
Table 4.9 MSH level during exponential growth of the mutants generated in this study (Area/10
7
 CFUs) 
H37Rv 2.75 ± 1.65 
∆egtE (H37Rv) 3.26 ± 1.07 
∆egtB (H37Rv) 2.86 ± 0.83 
CDC1551 2.64 ± 0.29 
∆egtA (CDC1551) 3.60 ± 0.61 
∆egtB (CDC1551) 1.13 ± 0.35 
∆egtC (CDC1551) 1.97 ± 1.16 
∆egtD (CDC1551) 3.69 ± 1.02 
∆egtE (CDC1551) 0.685 ± 0.07 
∆mshA (CDC1551) 0 
∆egtB-mshA (CDC1551) 0 
∆MT1289 (CDC1551) 4.32 ± 0.37 
∆MT1953 (CDC1551) 5.33 ± 1.77 
∆mshAc (CDC1551) 3.79 ± 1.2 
∆egtAc (CDC1551) 7.46 ± 2.99 
∆egtBc (CDC1551) 2.34 ± 0.16 
∆egtCc (CDC1551) 4.13 ± 0.62 
∆egtDc (CDC1551) 5.03 ± 2.90 
∆egtBop (CDC1551) 2.63 ± 0.13 
c: mutants complemented with genes expressed under the hsp60 promoter, op: mutant complemented by the 
entire operon,
+
: mutants complemented by the gene fused to a  1000bp US the operon; IH: intracellular 
hercynine, EH: extracellular hercynine. Data are representative of two independent extractions and two 
independent quantifications. 
The ∆egtE mutants produce a low to normal level of MSH because they produce a relatively 
high level of ERG. The ∆egtC mutant produces a low to normal level of MSH because it still 
produces 70% of ERG (table 4.6). The ∆egtB mutant produces a low level of MSH because 
though it is ERG-deficient, it is likely to have excess GGC which protects it and therefore 
does not need MSH. The ∆egtA and ∆egtD mutants known to be ERG-deficient (Table 4.6) 
produce a high level of MSH. This is seen as well in the ∆MT1289, ∆MT1953 mutants known 
to produce a very low level of ERG (Table 4.1, Table 4.9). These results indicate that MSH 
compensates for the loss of ERG. In addition, we have shown as well that the MSH-deficient 
mutants produce more ERG (Table 4.6). Therefore, since ERG and MSH are the only known 
thiols in M. tuberculosis, they compensate for each other to protect M. tuberculosis during 
infection. Therefore a drug or drug combination that targets both thiols in a therapy can be 
effective against TB; however the drug target should be carefully decided as choosing the 
wrong target (EgtB) may cause resistance instead.  
 
 








4.7 Conclusion  
Ergothioneine is known to play an anti-oxidative role in many organisms including higher 
eukaryotes [230-232]. However it is important to determine whether it plays the same role in 
M. tuberculosis the causative agent of TB. Moreover, it is important to assess other potential 
roles of this compound in M. tuberculosis since we know it is not synthesized in higher 
eukaryotes. Understanding the role of ERG will enable us to validate its biosynthesis as a TB 
drug target. However, to be able to validate the right drug target, we have to study the role of 
each enzyme involved in the production of ERG and in the physiology of the mycobacteria. 
In this study, to reach that goal, we deleted each gene coding for the enzymes involved in 
ERG biosynthesis. And we investigated the physiological effect due to the abolishment of 
each enzyme. In addition, based on past studies indicating ERG secretion in M. smegmatis 
(Chapter 3,[99] ), we investigated ERG secretion as well in slow growing mycobacteria (M. 
bovis, M. tuberculosis (CDC1551 and H37Rv). We could show that slow growing 
mycobacteria secrete ERG as well. This is a unique feature because MSH that has been 
previously described as the major thiol in mycobacteria is not secreted [80, 183]. However, it 
is worth therefore investigating why ERG and not MSH is secreted by microorganisms. 
Mycothiol as opposed to ERG requires enzymatic recycling when oxidized [90]. The 
oxidized form of ERG (ERG disulphide) is very unstable at physiological pH (stable only in 
acid pH), and rapidly degrades to yield free ERG [184]. This feature makes ERG a more 
stable thiol as opposed to MSH, therefore it is more suitable to function both intracellular and 
extracellular. However, it is possible that ERG does not only play an anti-oxidative role in the 
extracellular environment. It was previously shown that ERG modulates the immune system 
in order to inhibit the inflammatory response [141]. Therefore, it is more likely that 
mycobacteria, more precisely pathogenic mycobacteria secrete ERG to promote their survival 
within the host. To support this assertion, CDC1551 was shown in this study to have a lower 
percentage of EE relative to the H37Rv strain which is in accordance with previous studies 
that showed that the CDC1551 strain was less virulent relative to H37Rv and induced a 
higher level of cytokine production during infection [192]. Furthermore, we have shown in 
this study that not every gene involved in ERG biosynthesis is essential for ERG production. 
EgtA and EgtC are partially compensated for by other enzymes probably a glutamine 
synthetase and Rv1061 respectively. However, we have found that EgtE is not essential for 
ERG biosynthesis, as the level of the ERG in the mutant deficient in this enzyme was higher 
than the wild type. It could be due to a spontaneous production of ERG in the presence of 
PLP, or the catalysis of another PLP dependent cysteine desulfurase, either Rv1464/MT1511 








or Rv3025c/ MT3109 since there are data indicating the anti-oxidative role of these enzymes 
[191, 202]. In addition, we have shown in this study that ERG enables M. tuberculosis to 
survive during stationary phase of growth, as every mutant except the ∆egtE mutant (which is 
not ERG-deficient) grew poorly during stationary phase. This is an indication of the potential 
role of ERG during dormancy which is also characterized by a metabolic shutdown of 
mycobacteria. Therefore, may highlight the role of ERG in mycobacteria in latent TB. 
However, we were unable to demonstrate the anti-oxidative role of ERG in this study. Based 
on previous information on M. smegmatis, we predicted that ERG could be compensated for 
by MSH or other anti-oxidants and therefore characterized an ERG/MSH-deficient double 
mutant, however this mutant may have accumulated GGC making it resistant to oxidative 
stress and nitrosative stress due to the anti-oxidative role of GGC [222, 233]. In addition, it 
was observed that the ∆egtB and the ∆egtC mutants generated in this study do not produce a 
high level of MSH as opposed to the ∆egtA and ∆egtD mutants. This probably is because the 
∆egtC mutant still produce a high level of ERG (only ~30% of ERG is loss in this strain) and 
therefore do not require compensation by MSH, while the ∆egtB mutant is protected by the 
accumulated GGC and hence do not require compensation as well. The relatively high level 
of ERG in the MSH-deficient mutant (∆mshA) and the relatively high level of MSH in the 
ERG-deficient mutants (∆egtA and ∆egtD) generated in this study suggest the anti-oxidative 
role of ERG in M. tuberculosis; then MSH and ERG compensate for each other in the 













































CHAPTER 5: FUTURE/CURRENT 
STUDIES 
5.1 Final conclusion 
In this study, we have investigated the role of ERG biosynthetic enzymes in the production 
and physiology of M. tuberculosis and have shown that ERG is secreted across many species. 
In addition, we could show that ERG plays an anti-oxidative role in M. smegmatis. This study 
is the first to evaluate the role of each enzyme involved in ERG biosynthesis by generating 
mutants deficient in the respective enzymes. It is the first study to show and report ERG 
secretion in mycobacteria. The key messages from this work are: 
1. Ergothioneine appears to be the only thiol to be secreted by mycobacteria 
2. Ergothioneine protects mycobacteria from oxidative stress; therefore secreted ERG 
may play an important role during infection of the host by M. tuberculosis. 
3. Ergothioneine may play a key role during latent TB when mycobacteria are dormant 
as mycobacteria deficient in ERG struggle to grow during stationary phase. This 
could be a therapeutic benefit of drugs that target ERG biosynthesis since latent TB is 
not yet curable because latent bacilli are resistant to the first line drug Isoniazid [32]. 
4.  The enzyme EgtB is not a good drug target in ERG biosynthesis as targeting that 
enzyme may induce resistance instead of susceptibility in the mycobacteria 
5. The enzyme EgtA and EgtD could be a good drug targets if effects other than 
inhibition of ERG production are taken into account. 
6. The enzyme EgtC is compensated for by another enzyme therefore may not be a good 
drug target since mutant deficient in EgtC has lost only ~ 30% of ERG 
7. The proteins MT1289 and MT1953 are involved in the metabolism of ERG, but their 
specific function is yet unknown 
8. The enzyme EgtE is not essential for ERG biosynthesis as deleting this enzyme 
causes an increased production of ERG. 
9. Mycothiol and ERG compensate each other to protect M. tuberculosis since mutants 
deficient in one produce more of the other. 
However, more studies need to be done to investigate the role of the ERG in mycobacteria in 
order to validate its biosynthesis as a potential TB drug target. 








This study opens a new avenue of research for a new drug target against TB. Ergothioneine 
biosynthesis could be a new drug target against MDR, XDR, TDR and latent TB. This study 
contributes to the global fight against TB. 
5.2 Future studies: Quantification of ERG in the ∆iscS  (Rv3025c) mutant 
Since the ∆egtE mutant produces more ERG relative than the wild type, it is important to 
investigate which enzyme alternatively catalyses the last step of ERG biosynthesis. We will 
attempt to do that by quantifying ERG in the ∆iscS mutant which is known to be sensitive to 
oxidative stress. If data indicate that the ∆iscS mutant is ERG-deficient or has a decreased 
level of ERG, then we will have to investigate the expression level or protein level of IscS 
and Rv1464 in the ∆egtE mutants. 
5.3 Future studies: Investigation of the role of ERG during dormancy  
In view of the data that indicate that ERG is essential to mycobacteria when their metabolism 
shuts down, it is very important to investigate the role of ERG during dormancy. In this study 
we will use published models of dormancy to evaluate the role of ERG. Mutants will be 
cultured in conditions known to induce dormancy; low oxygen (5%), high CO2 (10%), low 
nutrient (10% Dubos medium) and acidic pH (5.0) [234]. Viability of the mutants relative to 
the wild type will be evaluated over time with and without treatment with current anti-
tuberculosis drugs. 
5.4 Future studies: Generation and characterization of ∆egtA-mshA and 
∆egtD-mshA M. tuberculosis  CDC1551 mutants 
Since we were not able to conclude that ERG protects M. tuberculosis from oxidative stress 
because of the protective effect of GGC in the ∆egtB-mshA mutant We have transformed the 
∆egtA and ∆egtD mutants with the deletion construct of mshA, that will enable us to generate 
double mutants via homologous recombination. We will further investigate the anti-oxidative 
role of ERG in these mutants. Their susceptibility to current anti-tuberculosis drugs, oxidative 
stress, nitrosative stress and acidic stress will be investigated. Then, the survival of the most 
susceptible double mutant will be investigated ex-vivo (macrophage infection experiment) 
and in-vivo (mouse model of infection). 
5.5 Future studies: Cytokine expression profile determination upon 
infection with ERG-deficient mutants 
Since it is known that ERG modulates the immune response and that the CDC1551 and 
H37Rv modulate the immune response differently during infection, it will be interesting to 
compare the cytokine expression profile of those strains with and without ERG during 








infection. In other words compare the cytokine expression profile of the ERG-deficient strain 
(∆egtD in CDC1511 versus ∆egtD in H37Rv generated in this study) and of the wild type 
strains (CDC1551 versus H37Rv). It was worth noting that the protein EgtD is negatively 
regulated by phosphorylation with PknD which is a protein kinase. Since it is knoe that 
protein kinases are involved in the regulation of stress responses and pathogenicity, results 
from this experiment may indicate the role of ERG in the pathogenesis of tuberculosis [214]. 
5.6 Future studies: Investigation of ERG transporter 
In this study, we have quantified ERG in potential mutants of ERG transporter; results 
obtained in this study did not allow us to deduce the ERG transporter. Therefore, more 
investigations are needed. The second attempt will be to use commercially available 
antibodies directed against eukaryote ERG transporter OCTN1 to identify ERG transporter in 
M. tuberculosis. 
5.7 Future studies: Investigation of ERG import 
 e have shown that ERG is secreted, but we don’t know if it is imported as was seen with 
MSH. This study will aim to supplement an ERG-deficient mutant culture with various 
concentrations of ERG and quantify IE and EE at various time points post supplementation. 
Ribonucleic acid (RNA) will be extracted at these time points and the expression profile of 
this strain will be determined by RNA-sequencing. If a potential ERG importer is identified, 
mutant deficient in this will be generated and using 
14
C labelled ERG we will validate ERG 
importer by an uptake experiment. 
5.8 Future studies: Investigation of the role of EgtE in cellular 
aggregation 
We have observed in this study that the ∆egtE CDC1551 mutant do not form visual 
aggregates as opposed to other strains at stationary phase. To further investigate this 
observation, cells were spotted on solid culture to compare the granularity partern of the 
mutant to the wild type. Secondly, the membrane structure the mutant is compared to the wild 
by electron microscopy. Thirdly, the biofilm formation patern of the mutant is compared to 
the wild type. Fourthly, the mycolic acid content of the membrane of the mutant is compared 
to the wild type. Lastly, the mutant will be grown in the detergent taloxypol to investigate if 
the absence of aggregation is observed using a dfferent detergent. 
5.9 Future studies: Deletion of egtA , egtC and egtD in H37Rv and 
characterization of the mutants  








In this study, we generated an ∆egB and ∆egtE mutant in H37Rv, to further investigate the 
role of each enzyme in ERG biosynthesis in H37Rv, egtA, egtC and egtD will be deleted 
individually and the resulting mutants will be characterized. Results obtained will validate 
what was obtained in CDC1551 or will enable us to determine the physiological differences 
between CDC1551 and H37Rv. 
5.10 Future studies: Generation of ∆mshA,  ∆egtA-mshA,  ∆egtB-mshA, 
∆egtC–mshA and ∆egtD-mshA in H37Rv and characterization of the 
mutants 
This study will also enable us to validate results obtained in case of CDC1551 in this study. 
5.11 Future studies: Evaluation of total thiols content of ERG single and 
ERG/MSH double deficient mutants  
It was previously stated that MSH is the major thiol when the cell lysate of MSH-deficient 
mutants were evaluated for total thiols using the Ellman’s reagent by measuring 
spectrophotometrically at 412 nm [102]. However, it is more likely that ERG measurement 
was missed in that assay, since ERG due its unique structure, does not react positively to 
many thiol assays [184]. So it will be important to know the total thiol content of the 
extracellular medium and cell lysate of the ERG-deficient mutants as well as the ERG/MSH-
deficient mutant. A suitable assay should be carefully designed. 
5.12 Future studies: Measurement of the oxidative stress level of ERG 
single and ERG/MSH double deficient mutants by flow c ytometry 
It was shown that mycobacteria ROS level could be measured by flow cytometry when 
stained with dihydroethidium [235]. It will be interesting to investigate the ROS level in the 
most susceptible ERG/MSH-deficient mutant and in the ERG and MSH-deficient single 
mutants in order to shed more light on the role of ERG and MSH in M. tuberculosis. 
5.13 Future studies: Investigation of the susceptibility of ERG and 
ERG/MSH deficient mutants to vitamin C  
It was previously shown that vitamin C has a sterilizing effect and functions as a pro-oxidant 
or anti-oxidant depending on the culture medium.  It was shown that when a MSH-deficient 
mutant was treated with 4mM vitamin C, its viability decreased dramatically over time [235]. 
So, it will be interesting to know the effect of vitamin C on the ERG-deficient mutants and 
the ERG/MSH double mutant. The MIC of the mutants to vitamin C will also be investigated. 
 
 










Appendix: Additional information and references 
ADDITIONAL INFORMATION 
 RESTRICTION ENZYME DIGESTION, AGAROSE GEL ELECTROPHORESIS AND LIGATION 
The PCR product was run on a 1% agarose gel. The gel was made as follows: 1-3 gram of 
SeaKem® LE Agarose (Whitehead Scientific) was added in ~100-300ml 1X TEA buffer 
(Buffer of Tris Base, acetic acid and EDTA at a pH of 8). This was boiled in a microwave, 
allowed to cool and poured in an electrophoresis tray. Then, an appropriate amount of 
fluorescent DNA stain (Novel juice, BiochomBiotec) was added to each sample or the more 
efficient GR green (Inqaba Biotec) was added directly into the gel (1ul per 100 ml of agarose 
gel) and the ladder (O gene ruler 1kb DNA, Inqaba Biotec). This was run at a voltage of 100-
150 volts depending on the gel tray size in 1X TAE buffer. The gel was visualised in a dark 
room under UV irradiation or using the fluorescence detection light box. The band of interest 
was excised from the gel using a scalpel surgical blade. This gel piece was placed in a 1.5-
2ml tube and a specific volume of DNA binding solution was added. The gel was allowed to 
dissolve at 55-60
◦
C. The higher the volume of the DNA binding solution the quicker the gel 
would dissolve. The dissolved gel solution was transferred into a column and the column was 
washed twice with a wash solution and the DNA was finally eluted with a low salt solution or 
nuclease free water. This was done according to the manufacturer instructions on the kit I 
used (GeneJet Gel extraction kit (Therrmo Scienitific) or Zymoclean Gel DNA recovery Kit 
(Zymoresearch). 
The concentration of DNA was estimated using a spectrophotometer (Thermo Scientific) by 
measuring the absorbance at 260nm and/or by visual comparison of the sample band intensity 
on the gel to the band intensity of a ladder of known concentration. 
The extracted DNA fragment was then ligated to PgemTeasy. Ligation throughout this study 
was optimised to the following protocol: 
Using the Rapid DNA ligation kit, a specific amount of Insert DNA and the vector (3:1 ratio) 
were added into a reaction containing 2.5-5% polyethylglycol (PEG), 1X ligation buffer and 
1-2ul of ligase. This was left at room temperature or at 22
◦
C for 10-45 mins depending on 
how big the insert and the vector are. Then the ligation reaction mix was purified using the 
gel recovery kit of Zymoresearch or Thermo Scientific. Five microliter of the ligation mixture 








was used to transform 50µl of Escherichia coli electrical competent cells using a gene pulsar 
II (Biorad) with the following settings: Resistance of 200Ω, Voltage of 2.5V, capacitance 
25µF or 100-300µl of chemical competent E.coli cells by heat shock. If E.coli chemical 
competent cells were used, purification of the ligation product was not necessary, half or the 
entire reaction was added into the competent cells and these were incubated on ice for 30 
mins then heat shocked for 5 mins at 45 degrees and cool immediately for 1 mins on ice. 
After electroporation, the cells were quickly re-suspended in 1ml of LB- broth media (Sigma 
Aldrich) and incubated for an hour at 37
◦
C and plated on LB-agar solid culture containing the 
specific selective antibiotic and incubated overnight. Electrical E. coli competent cells were 
obtained as follow: E.coli was grown to and OD600 of 0.8, then it was washed several times 
with ice cold 10% glycerol to remove completely any salt that may interfere with 
electroporation. Then, it was re-suspended in 10% glycerol, snapped freeze in liquid nitrogen 
and stored at -80
◦
C. 
Chemical competent cells were obtained as follows: 
Exponentially growing E.coli cultures were peletted are re-suspended in 100mM MgCl2 and 
incubated on ice for 20-30mins and then these were pelleted again and re-suspended in 
100mM Cacl2-15% glycerol snapped free in liquid nitrogen and store at -80
◦
C. 
Colony forming units were then picked from the plate that were incubated overnight and were 
used to inoculate cultures from which plasmids were extracted and screened by restriction 
enzyme digestion (RED). Expected bands are determined using the program known as 
GENtle. The desired fragments were excised from Pgem Teasy by RED, using the enzymes 
that correspond to the restriction sites (RS) introduced into the primers used to amplify the 
inserts. The excised fragments were ligated to a subsequent vector that was digested with the 
same enzyme to ensure compatibility during ligation. 
Similar procedures were followed to design every construct in this study, and the final 
desired construct was used to transform the mycobacteria. 
 EXPERIMENTAL PROCEDURE TO OBTAIN DELETION MUTANTS 
Once the deletion constructs were designed, they were used to delete the gene of interest as 
follows: 
Mycobacteria were rendered competent and were transformed with 4-6µg of the purified 
construct. M. smegmatis was rendered competent as previously described with E.coli, while 
M. tuberculosis was rendered competent by washing the exponential culture in 10% glycerol 
containing 0.05% Tween 80. As opposed to M. smegmatis and E.coli, M. tuberculosis was 
rendered competent at 37°C not 4°C. Competent mycobacteria were electroporated directly 








and were snap freezed as in the case of E.coli, neither were ther stored. They were prepared 
fresh for every electroporation 
Mycobacteria were electroporated using the following settings: Resistance of 1000Ω, Voltage 
of 2.5V, capacitance 25µF. The electroporated cells were re-suspended in 7H9 and incubated 
overnight at 37°C. These were plated on 7H11 containing kanamycin at concentration 50 
µg/ml and X-gal (~0.08mg/ml) and incubated for 2 to 4 weeks protected from light. 
Blue colonies (SCO) were picked, and a few were streaked on plates without antibiotics, and 
others were inoculated in liquid cultures containing kanamycin. These were incubated for 1 to 
2 weeks. A loop full of cells was scrapped off the plate and re-suspended in 7H9 and 
clumping was disrupted by vortexing and/or triturating. Then this was serially diluted and 
plated on 7H11 plates containing 5% sucrose and X-gal. Three to four weeks later, white 
colonies were picked and suspended into 20 to 100µl (depending on the size of the colony) of 
sterile distilled water. Then 2-5µl of suspension was spotted on kanamycin plates and sucrose 
plates separately. The rest was boiled at 100 degree for 20 mins to 1 hour. The boiled culture 
was used as template for the screening PCR. Colonies were confirmed to be mutants when 
the PCR result indicated deletion and when the corresponding colony could not grow on 
kanamycin plates but grew on sucrose plates. SCO blue colonies that were inoculated in 
kanamycin media were either kept as back up stocks or were used to inoculate another liquid 
culture without kanamycin. This culture was allowed to grow for 1-2 weeks, and the culture 
was pelleted, re-suspended in a smaller volume and serially diluted and plated on sucrose 














FigureS 1Gene deletion process 
Kan: kanamycin, X-gal: 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, aph: kanamycin resistance gene, 
sacB: code for levan sucrase, Lac-z: gene coding for the β-galactosidase which break down X-gal to yield a blue 
product; bla: ampicillin resistance gene; US: upstream, DS: downstream, WT: wild type, SCO: single cross 









First homologous event give 
rise to SCO colonies: kan
resistant, blue on X-gal and 
sucrose sensitive, giving  2 
specific products upon PCR 
screening.
Second  homologous event give 
rise  either to WT or to DCO 
colonies (mutants): kan sensitive, 
sucrose resistant, white on X-gal, 
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